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Atherosclerosis is a chronic inflammatory disease, characterised by infiltration of 
leukocytes and accumulation of fatty deposits in the artery wall.  Early events in this disease 
process include recruitment of platelets to the artery wall, which in turn aid in leukocyte 
recruitment.  However, upon activation platelets release microvesicles (PMV), we are interested 
in whether PMV have a role in enhancing leukocyte recruitment. 
We demonstrated using whole blood that upon activation, platelets form aggregates 
with monocytes and neutrophils.  The data suggests that upon platelet activation, PMV may be 
generated and subsequently may have a role in heterotypic aggregate formation observed.  
Interestingly, lymphocytes did not form aggregates with platelets (or PMV) as readily.  We 
showed that blocking P-selectin leads to a significant reduction in heterotypic aggregate 
formation.  We also demonstrated the presence of P-selectin glycoprotein ligand-1 (PSGL1), the 
ligand with the highest binding affinity for P-selectin, on monocytes and neutrophils.   
Monocytes preferentially bound platelets or PMV.  However, we found no significant 
increase in recruitment of these heterotypic aggregates to von Willebrand factor, under 
conditions of low shear stress compared to monocytes alone.  These heterotypic aggregates 
provide a mechanism for cross-talk between cell types and have a potential role in 
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1.1.0 The blood vasculature 
1.1.1 Endothelial cells 
The lumens of all of the blood vessels of the vasculature are lined with a monolayer of 
endothelial cells (EC), which are in constant contact with the blood.  Endothelial cells are joined 
by tight and adherens junctions and are supported by a subendothelial protein matrix, produced 
by EC themselves, as well as other cells such as smooth muscles cells and pericytes (Figure 1-1) 
(Michiels, 2003).  The subendothelial matrix consists of molecules such as collagen III, IV and V, 
laminins, heparan sulphate, proteoglycans and fibronectin (Eldor et al., 1985).  It provides a 
surface for anchorage of EC as well as their proliferation and migration, should the monolayer be 
damaged and an angiogenic response be required (Michiels, 2003).  Indeed, fibronectin has also 
been shown to play a role in EC migration through an integrin dependent mechanism (Roy et al., 
2003).  EC also regulate the haemostatic process as well as playing an important role in the 
inflammatory response.  These aspects of EC function will be discussed in more detail later.   
The EC of veins and arteries form a continuous and poorly permeable barrier, which 
guards against loss of the cellular and fluid constituents of the blood into the tissues.  However, 
blood is supplied to tissues and organs through capillary beds and the EC lining capillaries need 
to allow for the passage of nutrients from the blood into the surrounding tissue and for the 
removal of waste products from the tissue.  In some tissues where specialised functions occur 
the EC and the subendothelial basement membrane have become specially adapted.  For 
example, glomerular endothelial cells (GEnC) of the kidney are fenestrated (60-80nm wide 
pores), which allows for the efficient passage of solutes and water out of the blood and into the 
Bowman’s capsule (Satchell, 2004).  Water and some salts are actively reabsorbed at distal sites, 
while waste metabolites are excreted from the body in the urine.  The subendothelial matrix 
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below the glomerular EC is highly negatively charged this, coupled with the small size of the 
fenestrations, prevents large proteins passing through (Satchell et al., 2006).  The liver sinusoids, 
which also require passage of solutes and large macromolecules such as lipoproteins, have 
discontinuous, fenestrated EC which support the transport of these molecules (Braet and Wisse, 
2002). 
 
Figure 1-1: Endothelium lining the blood vasculature 
Endothelial cells lining the blood vessel wall are supported by their own extracellular matrix, 
which forms above a layer of smooth muscle cells.  The endothelial cells are held together to 
make a poorly permeable barrier through tight junctions made of claudin, occludin, or junction 
adhesion molecules (JAMs), (including JAM-A, JAM-B and JAM-C), as well as adherens junctions.  
There are also gap junctions formed from connexin which, allow the passage of nutrients into 
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1.2.0 Blood  
Blood has two major components.  The first is cellular in nature and includes specialised 
cells of the immune and haemostatic systems as well as erythrocytes.  These are transported in 
the second, the blood plasma.  Plasma is a complex mixture of solutes including proteins such as 
albumin and clotting factors, metabolites such as glucose and waste products, carbon dioxide 
(CO2), urea, lactic acid and lipids, which are solubilised by association with lipoproteins.   
1.2.1 Lineage and development of blood cells 
The cells of the blood; leukocytes, erythrocytes and platelets develop in the bone 
marrow through the process of haematopoesis.  This leads to the production of 1011-1012 new 
blood cells in a healthy adult every day.  Haemopoietic stem cells are able to differentiate into 
multipotent progenitor cells, which in turn differentiate to produce either common lymphoid 
progenitor cells or common myeloid progenitor cells through the process of mitosis (Figure 1-2) 
(Beerman et al., 2010).  Cell fate is determined by the haemopoietic microenvironment, the 
presence of glycoprotein growth factors (colony stimulating factors) such as 
granulocyte/macrophage cell stimulating factor (GM-CSF), granulocyte cell stimulating factor (G-
CSF) and macrophage stimulating factor (M-CSF), which are able to initiate signal transduction 
pathways to alter transcription (Krause, 2002).  Common myeloid progenitor cells are able to 
differentiate to form erythrocytes, platelets and cells of the innate immune system (Figure 1-2) 
(Chotinantakul and Leeanansaksiri, 2012).  Each of these cells has its own characteristic 
appearance, and specialised function.  




Figure 1-2: Blood cell development 
Figure 1-2 demonstrates how self renewing haemopoietic stem cells found within the bone 
marrow are able to differentiate in response to the haemopoietic microenvironment, to form 
blood cells through the process of haematopoesis.  Cells produced from common myeloid 
progenitor cells platelets, erythrocytes, monocytes, neutrophils, basophils, eosinophils and also 
a subset of cells produced from common lymphoid progenitor cells -natural killer cells mature in 
the bone marrow and then are released into the blood stream.  Pro T-cells and Pro-B cells are 
released into the blood where they travel to the thymus and spleen respectively to differentiate 
into mature T- and B-lymphocytes.  Monocytes are capable of migrating into tissues, where they 
further differentiate to form macrophages and dendritic cells.  (Image adapted from Stirewalt 
and Radich, 2003.) 
 
1.2.2 Erythrocytes 
 Erythrocytes or red blood cells (RBC) are the largest population of blood cells 
constituting ≈40% of the blood volume, meaning a healthy haematocrit is considered to be 
between 0.35 and 0.4 (World Health Organisation WHO).  They are produced in the red bone 
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progenitor cells (reticulocytes), which are released into the blood to further differentiate to form 
RBC.  Their main function is to transport oxygen to tissues and organs and CO2 from tissues to 
the lungs.  RBC are approximately 4μm in diameter, anucleate, highly deformable and shaped 
like biconcave discs, characteristics which aid in their ability to travel through small capillaries 
thereby giving easy access to tissues and organs.  They contain haemoglobin, a molecule, which 
is able to bind oxygen in regions of high concentration (the lungs) and release it in regions of low 
concentration (metabolising tissues) (Clark et al., 1985).    
1.2.3 Granulocytes 
Granulocyte populations are constituted of neutrophils, basophils and eosinophils.  As 
the name suggests, these cells contain granules which give them a distinct staining phenotype. 
Eosinophils and basophils are both present in low numbers (i.e. constituting ≈1% of the total 
leukocyte population in blood).  They both have important roles in immunity against 
multicellular parasites, but also appear to be important in allergic responses (Chirumbolo, 2012; 
Rosenberg et al., 2013).  Eosinophils have a short half life and were thought to have evolved to 
protect the host from parasitic infections such as helminths, but they may also have a role in 
protecting the host from infections which occur due to mRNA viruses (Rosenberg et al., 2013).  
There is also some debate in the literature as to whether eosinophils are able to act as antigen 
presenting cells, allowing them to play a role in activating the adaptive immune system 
(Rothenberg and Hogan, 2006). 
The most common leukocyte is the neutrophil.  These are short lived cells with an 
average lifespan in the blood, of 5-7 hours (Summers et al., 2010).  They are ‘the first 
responders’ to an infection and to inflammatory signals (Witko-Sarsat et al., 2000).  They contain 
three types of granules, azurophilic (or primary) granules, specific (or secondary) granules and 
Chapter-1  General Introduction 
7 
 
tertiary granules, which contain many cytotoxic and bactericidal components (Table 1-1).  They 
are most effective at destroying bacterial and fungal cells.  When neutrophils come in to contact 
with bacterial or fungal cells they become activated through pattern recognition receptors (PRR) 
interaction with pathogen associated molecular patterns (PAMPS).  Once activated, neutrophils 
phagocytose the pathogen.  This process involves the pathogen being engulfed and taken up 
inside a phagocytotic vacuole.  Once inside the vacuole the azurophilic and specific granules fuse 
with the phagocytotic vacuole and degranulate at roughly the same time, followed later by the 
tertiary granules (Segal, 2005).  This leads to the pH inside the vacuole being lowered giving 
optimal conditions for enzymes (such as serine protease, also released from the granules) to 
degrade the pathogen (Segal, 2005).  The release of nitric oxide and other oxidising agents also 
help in destroying the pathogen (Witko-Sarsat et al., 2000).   
Another way in which neutrophils kill pathogens is through the formation of neutrophil 
extracellular traps (NETs).  NETs are composed mainly of DNA and histones as well as some of 
the contents from the azurophilic, specific and tertiary granules (Carestia et al., 2013).  Histones 
themselves have been shown to have antimicrobial properties (Huang et al., 2011).  This means 



















Table 1-1: Contents of Neutrophil Granules 
Table 1-1 shows neutrophil granules and the contents of each (Eyles et al., 2006).  
Myeloperoxidase produces hypochlorous acid lowering the pH.  Defensins, serine proteases, 
collagenase, and gelatinase damage bacteria or fungi cell membranes and walls, some are even 
effective against enveloped viruses, these enzymes are most effective at low pH. Lactoferrin 
targets DNA/RNA and polysaccharide, while MAC-1 and fMLP-R are part of the complement 
cascade.  Lysosmes contain hydrolytic enzymes which also aid in destroying pathogens. 
 
1.2.4 Monocytes 
Monocytes play a role in both the innate and adaptive immune responses.  They are the 
largest of the leukocytes and possess a distinctive kidney shaped or horseshoe shaped nucleus.  
Monocytes account for between 5-8% of circulating leukocytes (Ghattas et al., 2013).  
Monocytes develop from the haemopoietic stem cell precursor known as monoblasts, these 
later develop into promonocytes and finally monocytes.  Monocytes migrate from the bone 
marrow and enter the blood stream using interactions between chemokine (CC motif) ligand 2 
(CCL2), expressed by the bone marrow and monocyte chemokine (CC motif) receptor 2 (CCR2) 
(Serbina and Pamer, 2006).  Once present in the blood stream they circulate for between 1-3 
days (Whitelaw and Bell, 1966).  Unlike other leukocytes they can migrate into tissues in the 
absence of inflammation to further differentiate into either macrophages (innate immune cells) 
Azurophilic granules Myeloperoxidase 
 Defensins 
 Serine protease 
 Lysosomes 
Specific granules Lactoferrin 
 Lysosome 
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or dendritic cells (DC) (adaptive immune cells) (Serbina and Jia, 2008).  As part of the innate 
immune system, the main function of monocyte derived macrophages is to protect the host 
from invading pathogens.  This is achieved through phagocytosis of exogenous bacteria, fungi 
and viruses.  Macrophages are also important regulators of the inflammatory response, being a 
major source of inflammatory cytokines (Table 1-2) (Murray and Wynn, 2011).  Monocytes that 
differentiate into DC are professional antigen presenting cells and are involved in cross talk with 
helper T-cells, which leads to activation of the acquired immune response (Randolph et al., 
1999).  This aspect of their function is discussed in greater detail later. 
Inflammatory cytokines TNFα 
 TGFβ 
 IL-6 




Anti-inflammatory cytokines IL-10 
 
Table 1-2: Cytokines (including chemokines) produced by macrophages 
Table 1-2 shows some of the cytokines (including chemokines) produced by macrophages during 
the inflammatory response (Yoshida and Tuder, 2007).  (Tumour necrosis factor-α, TNFα, 
transforming growth factor-β, TGFβ, IL, interlukin and CXCL, chemokine CXC motif ligand.) 
 
Monocytes are not a homogenous population, to date three subpopulations have been 
identified; these include the ‘classical monocytes’ (or mon1),  ‘intermediate monocytes’ (mon2) 
or  ‘non classical monocytes’ (mon3) (Figure 1-3) (Shantsila et al., 2011).  The largest of the 
monocyte populations (~90%)  is the classical monocytes which can be identified by the 
following markers CD14+CD16-CCR2+ (Figure 1-3) (Shantsila et al., 2011).  Other markers 
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expressed by this subset include expression of Leucocyte (L)-selectin (Cluster of differentiation 
62L, CD62L), CD64 and low level expression of vascular cell adhesion molecule (VCAM) receptor 
and fractalkine receptor; CX3CR1 (Figure1-3) (Strauss-Ayali et al., 2007; Geissmann et al., 2003; 
Ghattas et al., 2013).  This subset produce high levels of CCL2, interlukin-10 (IL-10), CXCL8, 
reactive oxygen species (ROS) and IL-6 (Woollard, 2013).  Intermediate monocytes are the most 
recent subset to be identified these express CD14+, CD16+ (low) and CCR2+ (Figure 1-3).  They are 
the smallest population of monocytes.  This subset express the highest levels of angiopoietin 
receptor (Tie2) (Strauss-Ayali et al., 2007; Ghattas et al., 2013; Jaipersad et al., 2014).  They are 
known to secrete high levels of tumour necrosis factor α (TNFα), IL-1β and IL-6 (Woollard, 2013). 
Non classical monocytes can be identified by their expression of CD14+ (low), CD16+ and 
CCR2-.  They express the highest amount of CD16, CX3CR1 and VCAM, however they express no 
L-selectin (Strauss-Ayali et al., 2007; Ghattas et al., 2013; Shantsila et al., 2011).  The subtle 
variation of expression of different surface markers between monocyte subsets leads to 
differences in their behaviour.  Ly6Chi (equivalent mouse population of Mon1) with higher CCR2 
expression are known to arrive earlier in the inflammatory process, followed later by Ly6Clo 
(equivalent mouse population of Mon3), which are more responsive to (CX3CL1) fractalkine 
(Nahrendorf et al., 2007).  The ability of monocytes to respond to and release cytokines and 
chemokines during the inflammatory response enables them to fulfil their role, in protecting the 
host from invading pathogens.  




Figure 1-3: Monocyte Subsets 
Figure 1-3 demonstrates the differences in receptor expression by mon1 (classical), mon2 
(intermediate) and mon3 (non-classical) monocytes (Geissmann et al., 2003; Ghattas et al., 2013; 
Shantsila et al., 2011; Strauss-Ayali et al., 2007). 
 
1.2.5 Lymphocytes and the acquired immune system 
Lymphoid stem cells are able to differentiate to form either lymphocytes or natural killer 
cells (Chotinantakul and Leeanansaksiri, 2012) (Figure 1-1).  T- and B-cells constitute the effector 
cells of the acquired immune system and are able to recognise and mount an immune response 
against specific pathogens (or other antigens).  This is due to a large repertoire of receptors, 
which mediate recognition of antigens (Ogle, B. M., Cascalho Marilia, Joao Cristina, Taylor 
William, 2003).  They also confer lasting immunity to the host by producing memory cells, giving 
a quicker response if a specific pathogen invades again.   
Diversity of T-cell receptors (TCR) and immunoglobulins (Ig) is achieved through genomic 
rearrangements of the variable (v) joining (J) and diversity (D) chains (Boyd et al., 2013).  Once 
formed these receptors go through a negative selection process to remove any receptors that 
have a high affinity for self antigens (Boyd et al., 2013).  T-cells leave the bone marrow and travel 
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distinguished through their expression of either CD4+ (helper T-cells) or CD8+ (cytotoxic T cells) 
(Janssen et al., 2003).   
All cells of the body express major histocompatibitly complex (MHC) class I receptors, 
which if the cell becomes infected (especially by a virus), can be used to present antigens to 
immune cells  (Figure 1-4) (Greene et al., 2011).  A specific CD8 + TCR can recognise antigen 
peptide displayed by MHC class I, leading to T-cell activation and destruction of the infected cell 
(Figure 1-4) (Masopust et al., 2007). 
 
 
Figure 1-4: MHC Class I signalling to CD8+ cytotoxic T-cells 
Viral proteins of an infected cell are processed by the endoplasmic reticulum and become 
associated with MCH class I receptors, these are trafficked to the surface of the cell via the golgi 
body and expressed on the cell surface.  The T-cell receptor of a specific clone of CD8+ cytotoxic 
T-cells can bind to the MCH class I receptor, which is associated with viral peptide.  This then 
signals to the cell to undergo apoptosis. (Figure adapted from Vyas et al., 2008.) 
 
Helper T-cells provide the mechanism for cross talk between the innate and the acquired 
immune system.  Phagocytotic cells of the innate immune system, macrophages or dendritic 
T cell receptor
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cells are antigen presenting cells, which express MHC class II receptors (Geissmann et al., 2008).  
After engulfing and destroying an invading pathogen an antigen (usually a short peptide) is 
expressed in association with the MHC class II receptor.  The TCR on CD4+ T-cell, which is specific 
for a given antigen, for each ‘clone’ of T-cells, recognises and binds to the antigen (Figure 1-5).  
This is accompanied by simultaneous binding of the CD80 or CD86 (antigen presenting cell 
receptors) to the CD28 receptor (expressed on T-cells) leading to the activation of the CD4+ T-cell 
and its differentiation into an effector cell (Figure 1-5) (Luckheeram et al., 2012).  CD4+ effector 
cells secrete IL-2, which act as autocrine signalling in a positive feedback loop, this is effective in 
areas where these cells are highly concentrated, such as the lymph nodes (Sojka et al., 2004).   
The effector cells of CD4+ can be either of two subclasses TH1 or TH2 (Luckheeram et al., 
2012).  TH1 cells mainly secrete interferon γ (IFN-γ) and TNFα.  TNFα will activate surrounding EC 
by triggering the inflammatory response, leading to increased leukocyte recruitment (this will be 
discussed in more detail later).  Binding of TH1, CD40 ligand (CD40L) (also known as CD154) to 
CD40 on the macrophage or secretion of IFN-γ by the TH1 and its interaction with the 
macrophage; are both mechanisms which promote macrophage activation (Mosser, 2003).  TH1 
cells are also able to aid in activation of CD8+ T cells leading to a cytotoxic T cell response (Huang 
et al., 2007).   
TH2 will produce IL-4, IL-5, IL-10 and IL-13 these are responsible for the activation of B-
cell lymphocytes and the humoral response (Mosmann and Sad, 1996).  B-cells reach maximal 
activation through a two step process; the first step involves the B-cell binding specifically 
recognised antigen to its antigen specific B-cell receptor (BCR) (Figure 1-5) (Linsley et al., 1991).  
The second step involves an effector CD4+ (either TH1 or TH2), which specifically recognises the 
same antigen. The effector CD4+ binds its CD40L to the B-cell CD40 receptor leading to B-cell 
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activation (Figure 1-5) (Mosmann and Sad, 1996).  Upon activation a naive B-cells will form a 
plasma cell, which is short lived but able to produce large quantities of antibodies (IgA, IgE, IgD, 
IgG or IgM) or a memory B-cell (Tobón et al., 2013).  
 
Figure 1-5: CD4+ helper T cells activate B cells  
Antigen presenting cells (such as a macrophages) engulf and destroy invading pathogens, they 
then display antigen via their MHC class II receptor.  A specific CD4+ helper T-cell receptor, which 
recognises the antigen, binds to the antigen and MHC class II.  The T-cell CD28 simultaneously 
binds to the CD80/CD86 expressed by the antigen presenting cell.  This leads to activation of the 
CD4+ T cell, which now becomes an effector cell.  The B-cell has two receptors, which will 
recognise the same specific antigen; B-cell receptor and MHC class II receptor. Antigen binding 
to the B-cell receptor leads to downstream signalling and partial B-cell activation.  The effector 
T-cell receptor interacts with B-cell, MHC class II, bound to antigen.  These interactions coupled 
with the interaction between T-cell CD40L and B-cell CD40 leads to full B-cell activation.  Active 
B-cells can now differentiate into either plasma cells, which, secrete large quantities of antibody, 
or memory B cells.  (Image adapted from King, 2009.) 
 
B-cells are produced in the bone marrow but reach maturity in the spleen (Tobón et al., 
2013).  They can be identified through the presence of a BCR, which like TCR goes through a 
developmental process which includes VJD rearrangement (Tobón et al., 2013).  Any B-cells with 
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can only be achieved through interactions with CD4+ cells (Figure 1-5); there are other routes 
through which partial B-cell activation can be achieved, this however, will not result in the 
production of long lived memory B-cells (Tobón et al., 2013).  B-cell activation can be achieved 
through BCR binding to antigen, this can be internalised and processed and later expressed on 
the MHC class II receptor on the B-cell surface (Wang and Zheng, 2013).  However B-cells also 
express toll like receptors (TLRs) including TLR9, these are able to non specifically recognise 
invading pathogens, resulting in partial B-cell activation (Wang and Zheng, 2013). 
1.2.6 Platelets 
Platelets are anucleate cells and the smallest of all the blood cells being only 3μM in 
diameter (or smaller) (Rivera et al., 2009).  Platelets are derived from bone marrow resident 
progenitor cells called megakaryocytes and are shed into the blood from proplatelets, 
membrane processes which are extruded across the EC of the bone marrow sinusoids 
(Chotinantakul and Leeanansaksiri, 2012).  Platelets have an extensive cytoskeleton and dense 
tubular system.  They posses glycogen granules, a small number of mitochondria and dense (δ) 
and alpha (α) storage granules (Rivera et al., 2009).  δ granules contain nucleotides (mainly ADP 
and ATP), serotonin, histamine, pyrophosphate and calcium (McNicol and Israels, 1999), while α 
granules contain molecules needed for both autocrine and paracrine signalling events during 
platelet activation such as; von Willebrand factor (vWf), fibrinogen, Platelet (P)-selectin, platelet 
endothelial cell adhesion molecule (PECAM-1 or CD31), CD40L, platelet factor 4 (CXCL4), β-
thromboglobulin, thrombospondin, platelet derived growth factor (PDGF), clotting factor V and 
αIIbβ3 (Blair and Flaumenhaft, 2009; Rivera et al., 2009).  The major role of platelets is regulation 
of haemostasis and thrombosis (Huo and Ley, 2004).  Platelets are present in the blood stream in 
an inactive state, but can be quickly activated to form a thrombus upon vascular injury.  Platelet 
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activation and thrombosis is achieved through the interaction of platelet receptors with 
components of the exposed subendothelial matrix; molecules such as collagen, thrombospondin, 
laminins and fibronectin (Nieswandt et al., 2011).  This is an example of cross-talk between 
platelets, EC and the subendothelial matrix.  
The role platelets have in clot formation depends upon where the injury occurs within 
the blood circulation system.  Venous clots are dependent on activation of the coagulation 
cascade (Figure 1-6).  The coagulation cascade is triggered through two pathways; the extrinsic 
(or tissue factor - TF) pathway, which starts when TF is released from damaged EC, or activated 
monocytes or macrophages (Figure 1-6) (Levi et al., 2004).  The lesser pathway, the contact 
activation pathway, begins with the exposure of collagen followed by subsequent activation of 
FXII (Figure 1-6) (Davie et al., 1991).  Activation of the coagulation cascade, through either 
pathway results in activation of serine protease enzymes from their zymogen form (Figure 1-6) 
(Levi et al., 2004).  One by-product of this cascade is thrombin (Figure 1-6) (Coughlin, 2000).  The 
end product of this cascade is fibrin, which platelets use for crosslinking to form a stable clot 
(Figure 1-6) (Schulz et al., 2013). 




Figure 1-6: The coagulation cascade 
Schematic of the coagulation cascade; contact activation pathway is triggered upon the exposure 
of collagen in the subendothelial matrix, this activates the serine protease factor XII (FXII) to its 
active form FXIIa.  The extrinsic (or tissue factor -TF) pathway, starts when tissue factor cleaves 
FVII into its active form FVIIa.  Activation of both pathways leads to the conversion of zymogens 
into their active serine protease form, resulting in thrombin generation and eventual fibrin 
deposition. Antithrombin, protein C and tissue factor pathway inhibitor (TFPI) all regulate the 
coagulation cascade by inhibiting zymogen activation.  
 
Thrombin is a potent platelet agonist which stimulates platelets through cleavage of the 
N terminus of protease activated receptor 1 (PAR1) and PAR4 the new terminus acts as a ligand 
for its own receptor (Coughlin, 2000).  Signalling of thrombin through PAR1 and PAR4 expressed 
on the platelet surface leads to irreversible platelet activation inducing shape change, release of 
platelet granules, P-selectin expression and activation of αIIbβ3 integrin (Figure 1-8) (Coughlin, 
2000). 
However, arteries are subject to a high shear rate, which limits fibrin deposition and 
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2002).  Under these conditions platelets have a more crucial role in thrombus formation.  Upon 
vascular injury collagen I, III and VI of the subendothelial matrix are exposed.  EC are activated 
and release von Willebrand factor (vWf) from internal stores (Weibel Palade bodies) (Tull et al., 
2006).  Von Willebrand factor is a large molecular weight molecule, which can be cleaved into a 
smaller soluble form (Kanaji et al., 2012).  Von Willebrand factor can either be expressed on the 
surface of damaged EC or captured by the exposed collagen, which has a high binding affinity for 
soluble vWf (Figure 1-7) (Kanaji et al., 2012).  The platelet receptor Glycoprotein Ib-IX-V (GPIb 
also known as CD42b) has a high affinity for the cleaved form of vWf (Kanaji et al., 2012).  The 
interaction between CD42b and vWf allows platelets to be captured to the vessel wall, however, 
the short lived nature of these interactions results in a platelet rolling phenotype being observed 
(Figure 1-7)  (Nieswandt et al., 2011).  These short lived interactions result in transient calcium 
Ca2+ release, and a reversible form of platelet activation (Nieswandt et al., 2011). 
Rolling platelets will eventually come into contact with collagen (Figure 1-7).  Collagen is 
able to activate platelets through interactions with the GPVI receptor (Gibbins et al., 1997).  This 
leads to downstream signalling events through Src family kinase (SFK) and phospholipase C-γ2 
(PLC-γ2) (Figure 1-8) (Yanaga et al., 1995; Blake et al., 1994).  This results in an increase in 
intracellular Ca2+ levels, platelet shape change through rearrangement of the actin cytoskeleton 
and degranulation (Nieswandt and Watson, 2003).  Collagen is one of the most effective platelet 








Figure 1-7: Platelet capture upon endothelium damage 
Soluble von Willebrand factor (vWf) is captured by collagen in the subendothelial matrix.  The 
platelet receptor CD42b is able to form short lived interactions with vWf, allowing platelets to 
roll along the vWf matrix.  Eventually either 1) platelet receptor GPVI will come into contact with 
collagen and firm platelet adhesion will occur.  Or 2) paracrine signalling through 
ADP/thromboxane will result in conformational shape change of αIIbβ3 integrin, allowing the 
platelet to firmly adhere to vWf using this receptor.   
 
Platelet degranulation will result in the release of ADP from δ granules, this is part of a 
positive feedback loop for platelet activation resulting in signalling through an autocrine or 
paracrine fashion (Figure 1-7).  ADP stimulates platelet activation through the P2Y1 and P2Y12 
receptors (Figure 1-8) (Jin and Kunapuli, 1998).  Signalling through P2Y1 results in reversible Ca2+ 
mediated platelet shape change through cytoskeletal rearrangement and formation of filopodia 
and lamellipodia, increasing their surface area (Figure 1-8), whilst signalling through P2Y12 
involves inhibition of adenylyl cyclase resulting in irreversible activation (Figure 1-8) (Jin and 
Kunapuli, 1998).  Signalling through both receptors is required to achieve full platelet activation 
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bleeding disorder, showing the importance of platelet activation through this pathway 
(Hollopeter et al., 2001). 
Upon activation platelets synthesis thromboxane (TxA2) from arachidonic acid (AA) 
through a Cyclooxygenase-1 (COX-1) dependent pathway (Liu et al., 2012). TxA2 also has a role 
in a positive feedback loop and signals through the thromboxane A2 receptor (TP) with 
downstream signalling including activation of PLC-β resulting in an increase in Ca2+ (Figure 1-8), 
(Offermanns et al., 1994, 1997). 
 More recently other platelet receptors have been identified which may have a 
role in platelet activation.  C-type lectin receptor (CLEC-2) has been found to be expressed by 
platelets and subpopulations of haemopoetic cells (Hughes et al., 2010).  Its only known 
endogenous ligand to date is podoplanin, which is expressed by kidney podocytes, lung type I 
alveolar cells and lymphatic endothelial cells (Hughes et al., 2010). The interaction between 
CLEC-2 and podoplanin is thought to play a key role in lymphatic angiogenesis (Suzuki-Inoue et 
al., 2006).  Activation through this receptor can also occur upon binding of rhodocytin from the 
Malayan pit viper Calloselasma rhodostoma, a commonly used agent for activating platelets 
through this signalling pathway (Suzuki-Inoue et al., 2006).  Like GPVI, CLEC-2 also signals 
through the SFK; spleen tyrosine kinase (SYK) (Figure 1-8) (Hughes et al., 2010; Suzuki-Inoue et 
al., 2006).  
Other molecules, which are known to activate platelets are histones and oxidised low-
density lipoprotein (oxLDL).  Histones have been shown to activate platelets, with histone 4 (H4) 
being the most potent platelet activator (Semeraro et al., 2011).  It was first thought histones 
activated platelets through a charge based interaction.  However, it has now been demonstrated 
that histones H3 and H4 stimulate platelets at least in part, through the TLR-2 and TLR-4 
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receptors (Fuchs et al., 2011; Semeraro et al., 2011).  Oxidised LDL plays a significant role in the 
development of atherosclerosis.  It is thought to be a potential platelet activator acting through 
lectin like oxidized receptor 1 (LOX-1) or CD36, scavenger receptors expressed on the platelet 
cell surface  (Korporaal et al., 2007; Chen et al., 2001; Zhao et al., 1995). 
Upon platelet activation αIIbβ3 undergoes a conformational shape change, when this 
occurs it is able to bind to vWf and fibrinogen.  Binding of αIIbβ3 to vWf on the subendothelial 
matrix will result in firm adhesion (Figure 1-7). Platelet crosslinking through αIIbβ3, vWf and 
fibrinogen will allow stable clot formation to occur (Peterson et al., 1987; Rivera et al., 2009).  
The developing clot provides a procoagulant surface allowing for the production of more fibrin 
from fibrinogen via the action of thrombin (Falati et al., 2002).  P-selectin will also be released 
from α granules and expressed on the platelet surface, this can be important for interactions 
with platelets and leukocytes (Kuckleburg et al., 2011). It is often used as a measurement of 
platelet activation.  
 




Figure 1-8: Platelet activation 
Platelet receptors include G-protein coupled receptors P2Y1, P2Y12, (Protease activating 
receptor 1 and 4) PAR1 and PAR4 and prostanoid TP receptor (TP).  Activation through ADP 
occurs first through the P2Y1 receptor, resulting in reversible shape change and an increase in 
cytosolic Ca2+.  For full platelet activation signalling must also occur through P2Y12, which leads 
to inhibition of adenylyl cyclase and a decrease in cAMP production and a subsequent 
conformational change of the αIIbβ3 integrin into its active form.  Signalling through the 
thromboxane receptor (TP) occurs in a PLCβ dependent manner leading to a rise in cytosolic Ca2+ 
and shape change, degranulation and αIIbβ3 integrin activation.  Activation by thrombin occurs 
through the PAR1 and PAR4 receptors also in a PLCβ dependent manner leading to irreversible 
platelet activation.  The integrin receptor GPVI and the C-type lectin domain 2, (CLEC-2) 
receptor, both signal through a Src family kinase dependent pathway, resulting in full platelet 
activation upon collagen or podoplanin binding to its receptor.  (Figure adapted from Pignone 
and Williams, 2010). 
 
Mechanisms need to be in place to make sure that clot formation is a localised process 
and that unwanted thrombus formation does not take place in the circulation.  This is mainly 
achieved through crosstalk between platelets and EC.  But it is also aided by Soluble vWf having 
a much lower affinity for CD42b (Kanaji et al., 2012).  One mechanism for preventing platelet 
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arginine through a Ca2+ dependent pathway producing NO (Chou et al., 2008).  Prostacyclin 
(prostaglandin-I2; PGI2) is also synthesised from arachidonic acid (AA) through COX-1, and 
prostacyclin synthase (McAdam et al., 1999).  Prostacyclin and NO are able to increase the 
concentration of cyclic nucleotides (cAMP and cGMP) within the platelet (Mellion et al., 1981; 
Best et al., 1977).  This leads to phosphorylation of protein kinase A (PKA) and a decrease in 
intracellular Ca2+.  Thus, cyclic nucleotides inhibit all of the known activatory pathways in 
platelets including the Ca2+ sensitive conformational changes of α IIbβ3, thereby preventing 
inappropriate thrombus formation. (Gkaliagkousi et al. 2007  Antl et al. (2007).  EC also express  
CD39 an integral membrane protein, which metabolises ADP into AMP thereby preventing 
activation of platelets through the P2Y1 and P2Y12 receptors (Marcus et al., 1997).   
1.2.7 Platelet microvesicles 
Microvesicles are cell derived lipid vesicles shed from the plasma membrane of cells. 
They are 0.1-1µm in size and have a lipid membrane, but lack a nucleus or synthetic capacity 
(Hargett and Bauer, 2013).  However, microvesicles are thought to contain proteins, mRNA and 
micro-RNA (miRNA) and could play an important role in cell signalling if this cargo was 
transferred to recipient cells (Garzetti et al., 2013; Hunter et al., 2008; Mause et al., 2005).  
Several cell types are known to be able to generate microvesicles upon activation and during 
apoptosis, including EC, epithelial cells, leukocytes, erythrocytes, megakaryocytes and platelets 
(Hargett and Bauer, 2013).  Microvesicles are released by budding directly from the plasma 
membrane (Figure 1-9).  Therefore, they should not contain any internal protein markers, unlike 
exosomes, which originate from multivesicular endosomes inside the cell and are trafficked to 
the plasma membrane and released (Figure 1-9) (Bobrie et al., 2011).  Exosomes are 40-100nm 
in size and although purifying methods (such as ultracentrifugation) are used to separate plasma 
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membrane derived microvesicles from exosomes, these methods are still not fully effective and 
require further development. 
 
 
Figure 1-9: Platelet microvesicle production 
Platelet microvesicles are released from the cell surface, whereas, exosomes originate in 
multivesicular endosomes, which fuse with the plasma membrane allowing for exosome release.  
Platelet microvesicles are believed to be taken up by recipient cells, through 1) fusion with the 
plasma membrane or 2) through receptor mediated endocytosis. 
 
Microvesicles express markers from the parent cell.  Thus, platelet microvesicles (PMV) 
are known to express CD42b, CD41 and CD62P (Flaumenhaft et al., 2009).  However 
microvesicles shed from megakaryocytes also express CD42b and CD41 (Flaumenhaft et al., 
2009).  These two populations have not been systematically separated in most studies of 
microvesicles in patient plasma.  Shai et al (2012) showed, there may be differences in the 
overall number and the proteome of PMV, depending on the route of platelet stimulation.  
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proteins compared to PMV produced by platelets subjected to high shear stress (Shai et al., 
2012). 
Although PMV are produced in healthy individuals elevated levels have been observed in 
cases of inflammatory diseases such as rheumatoid arthritis (RA), systemic lupus erythematosus 
(SLE) and atherosclerosis (Beyer and Pisetsky, 2010).  Nomura et al, (1995) demonstrated 
diabetes mellitus (DM) patients with high LDL or triglyceride levels have increased plasma levels 
of microvesicles.  It has also been demonstrated that PMV and endothelial microvesicles are 
increased within 1 day of onset of acute coronary syndrome (ACS) (Biasucci et al., 2012).  The 
elevated levels of microvesicles detected in disease states suggest that microvesicles may play a 
role in disease progression, although this hypothesis has not been tested in atherosclerosis. 
Microvesicles have been shown to regulate thrombosis, coagulation, angiogenesis and 
inflammation (Yang et al., 2012; Hargett and Bauer, 2013).  Scholz et al, (2002) demonstrated 
that platelets could transfer TF to monocytes via PMV, indicating a role for PMV in initiating 
coagulation.  This is further confirmed by the observation that patients with Scott syndrome are 
deficient in PMV production and as a consequence suffer from impaired coagulation response 
(Simss et al., 1989).  A role for PMV in inflammation has been shown by their ability to deliver 
RANTES (CCL5) to endothelial cells and promote monocyte recruitment, this could potentially 
have major implications in inflammatory diseases such as atherosclerosis, where the recruitment 
of monocytes is a major contributor to the cellular pathology of the disease (Mause et al., 2005). 
Although it is widely agreed that microvesicles have a role in regulating the function of 
target cells both in health and disease, there is some debate in the literature as to how vesicles 
deliver their molecular cargo (e.g. proteins and microRNA, miRNA) to other cells.  Del Conde et 
al, (2005) believe that vesicle membranes simply fuse with the plasma membrane of the cell and 
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release their contents (Figure 1-9).  Whereas others believe MV are taken up through receptor 
mediated endocytosis (Figure 1-9) (Yang et al., 2012).  Of course, both options may operate 
simultaneously.  
1.2.8 The innate immune system 
The body needs to defend itself from invading pathogens such as bacteria, fungi and 
viruses to prevent infection from occurring.  The first line of defence is the presence of physical 
barriers such as specialized epithelium which forms the skin and lines orifices such as the nose, 
throat and GI tract (Sun et al., 2012; Shaykhiev and Crystal, 2013).  The epithelium lining the 
nose and throat is created by a monolayer of specialized epithelial cells connected by 
impermeable tight junctions, some of these cells are mucous producing or have cilia which help 
to prevent pathogens adhering and thus, protect the lungs from infection (Shaykhiev and Crystal, 
2013).  Damage to the epithelium will allow pathogens to penetrate.  When this occurs, the next 
line of the body’s defence is the leukocytes, which constitute the innate immune system 
(Geremia et al., 2014).  Leukocytes of the innate immune system, appear to be evolutionary 
conserved between a wide range of species separated by significant periods of evolutionary time 
(Beutler, 2004).  Innate immune cells recognise and destroy invading pathogens in a non-specific 
manner, which does not confer any lasting protection to the host (Geremia et al., 2014).   
Leukocytes of the innate immune system express PRRs which are able to recognise 
essential, highly conserved molecular patterns expressed by pathogens (but not by the host 
cells), known as PAMPS (Uematsu and Akira, 2006).  Pattern recognition receptors include TLRs, 
which are type I integral membrane glycoproteins, containing 19-25 extracellular leucine rich 
repeats (LRR) motifs.  10 different TLRs have been identified in humans (Table 1-3) (Lu et al., 
2013).  Each TLR has a small repertoire of molecular patterns it can recognise. For example TLR1, 
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TLR2 and TLR6 are able to target lipids, whereas TLR 7, TLR8 and TLR9 are able to target DNA 
(Table 1-3) (Akira et al., 2006).  Other PRRs include nucleotide binding oligomerization domain 
like receptors (NLRs) 22 of which have been identified in humans (Chaput et al., 2013).  NLRs are 
intracytoplasmic receptors, able to bind to PAMPS on phagocytosed pathogens (Uematsu and 
Akira, 2006).  Stimulation of NLRS and TLRs leads to the release of cytokines and chemokines 
through a downstream signalling cascade (Akira et al., 2006; Geremia et al., 2014) and are thus 
important and early initiators of the inflammatory response.  
In the event of an infection the body needs to signal to circulating cells of the innate 
immune system, so that they accumulate at the site of infection.  This is done through the 
release of chemical signals known as cytokines and chemokines (a family of chemotactic-
cytokines). These are released as part of a carefully controlled process, known as the 
inflammatory response, which will be discussed in more detail below.  However, at a basic level, 
cells of the innate immune system are able to migrate towards these signals within a matter of 
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Table 1-3: Table of toll like receptors (TLRs) expressed by leukocytes 
Table 1-3: shows the TLRs expressed on leukocyte subsets of the innate and acquired immune 
system and their known target pathogen associated molecular patterns (PAMPs). 
(Table adapted from Waltenbaugh C, Doan T, Melvold R, 2008.) 
 
1.3.0 Inflammation 
Inflammation is the response of the vasculature to trauma.  There are four classic signs 
of inflammation, redness, swelling, heat and pain.  Vasodilatation of the blood vessels 
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surrounding the site allows an increase in blood flow which accounts for the redness and heat.  
The swelling and pain is caused by an increase in the permeability of the surrounding blood 
vessel walls, allowing excess blood plasma to enter the tissue, this is accompanied by leukocyte 
infiltration. 
Leukocyte infiltration has many roles such as preventing infection, aiding in tissue 
remodelling and also providing signals to resolve the inflammatory process.  Inflammation 
should be an acute response, which ceases as tissue homeostasis is restored, preventing any 
further infiltration by leukocytes.  When inflammation does not resolve, there is continuous 
infiltration of the tissue by leukocytes resulting in pathological tissue remodelling, which is 
observed in chronic inflammatory diseases such as atherosclerosis. 
1.3.1 The leukocyte adhesion cascade  
Upon damage to the endothelium leukocytes need to be captured to the site of 
inflammation, this is achieved through a complex signalling cascade, known as the leukocyte 
adhesion cascade.  Upon tissue injury cytokines (e.g. TNF-α, IL1-β and IFN-γ) are released from 
surrounding tissues, macrophages and mast cells to activate EC and trigger the start of the 
leukocyte adhesion cascade (Ley et al., 2007). 
There are 3 main steps to leukocyte recruitment, the first includes capture and rolling, 
which is a selectin or vascular cell adhesion molecule-1 (VCAM-1 or CD106) mediated event 
(Figure 1-10) (Tedder et al., 1995).  The second step is activation of leukocytes and EC by 
chemokines (Figure 1-10).  Chemokine signalling leads to up regulation of integrin receptors for 
EC-borne adhesion molecules such as intracellular adhesion molecule-1 (ICAM-1 or CD54) and 
VCAM-1 and leukocyte β1 and/or β2 integrins (Figure 1-10) (Ley et al., 2007).  Interaction 
between leukocyte integrins and EC adhesion molecules results in leukocyte movement being 
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arrested and leukocytes becoming firmly adherent (Figure 1-10) (Ley et al., 2007).  Firmly 
adherent leukocytes are ready to transmigrate across the EC barrier and enter the vessel wall 
(Figure 1-10).  
 
 
Figure 1-10: Leukocyte adhesion cascade 
1) Leukocytes are captured by the vessel wall through short lived selectin based interactions, 
which result in leukocyte rolling.  2) Chemokines released from surrounding activated cells 
activate both leukocytes and EC resulting in leukocyte β1/β2 integrin expression and EC ICAM-1 
and VCAM-1 receptor expression.  Interaction of these leukocyte receptors with the EC receptors 
results in firm adhesion of leukocytes to EC.  3) Activated, adherent leukocytes are now ready to 
transmigrate through either the transcellular or paracellular route.  (Image adapted from (Ley et 
al., 2007). 
 
1.3.2 Capture and rolling 
The process of margination allows leukocytes to come into contact with the 
endothelium.  This is a physical characteristic of flowing blood, where the low shear environment 
in the central flow encourages red cell aggregation.  These aggregated red cells behave like large 
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occur with EC (Schmid-Schönbein et al., 1980; Abbitt and Nash, 2003).  This process mainly 
occurs in post capillary venules, due to the permissive fluid dynamics in this vascular bed. 
Once in close proximity to the vessel wall, capture of leukocytes to the activated EC is 
mediated by selectins.  There are 3 different classes of selectins, endothelial (E)-selectin, Platelet 
(P)-selectin and leukocyte (L)-selectin (Figure 1-11) (Carlos and Harlan, 1994).  The extracellular 
regions of selectins are highly conserved and consist of an amino terminal, a Ca2+ dependent 
lectin domain and 2-9 short consensus repeats (Figure 1-11) (Carlos and Harlan, 1994).   
 
 
Figure 1-11: Selectins 
The smallest selectin is leukocyte (L)-selectin has only 2 consensus repeats, endothelial (E)-
selectin contains 6 consensus repeats and the largest selectin; platelet (P)-selectin contains 9 
consensus repeats.  (Figure adapted  from Hanley et al., 2004.) 
 
Under normal circumstances EC do not express selectins, however, in response to 
cytokine signals of inflammation activated EC display E-selectin and P-selectin on their surface 
(Figure 1-12) (Ley et al., 2007).  HUVEC stimulated in vitro with TNFα has been shown to have 
maximum expression of E-selectin after 4-6hrs but this decreases back to baseline within 24-
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however it  is trafficked to the surface upon EC activation (McEver et al., 1989).  Another source 
of P-Selectin is platelets, where it was first identified and gets its name.  P-selectin is stored 
within the α-granules of platelets and is released upon activation (Rivera et al., 2009).  It is 
therefore possible for activated platelets, adherent to the EC surface to deliver P-selectin here 
and aid in leukocyte recruitment (Pitchford S.C et al., 2005). 
L-selectin is constitutively expressed by all leukocytes except a subset of memory T cells 
and NK cells (Tedder et al., 1995a).  Expression of L-selectin may be highly concentrated in 
certain regions such as on the microvilli projections of unstimulated neutrophils, allowing for 
early contact with EC-borne  selectin ligands (Tedder et al., 1995a).  A decrease in leukocyte 
infiltration was seen under inflammatory conditions in mice deficient in L-selectin, 
demonstrating the importance of its role in the inflammatory response (Tedder et al., 1995b).  
Leukocytes also express P-selectin glycoprotein ligand 1 (PSGL-1), which after undergoing post 
translational glycosylation is known to bind to all selectins allowing leukocyte-endothelial, 
leukocyte-platelet and leukocyte-leukocyte interactions to occur (Figure 1-12) (Hanley et al., 
2004).  It should be noted however that PSGL-1 is the highest affinity ligand for P-selectin and 
these molecules will bind preferentially (Mehta, P. Cummings, 1998). 
Selectin mediated interactions are weak and continually break and reform, often the 
new bonds form before the old ones are broken (Figure 1-12) (Alón et al., 1995).  This results in 
the phenomenon of leukocytes rolling along the endothelium in the direction of flowing blood 
(Figure 1-12) (Alón et al., 1995; Ley et al., 2007).  L-selectin interactions require shear stress to 
form, if the shear stress is too low then leukocyte capture and rolling is not supported (Marshall 
et al., 2003; Finger et al., 1996).  L-selectin interactions requiring shear stress to form, helps to 
prevent leukocyte aggregation from occurring in areas of low shear stress (Cines et al., 1998).   
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There are reports that interactions through selectins cause further activation of EC and 
allow them to express integrin receptors on their surface, while simultaneously causing partial 
activation of leukocyte integrins (Zarbock et al., 2007a).  It has been shown that integrins may 
also play a role in leukocyte capture and slow the rolling process, before leukocyte firm adhesion 
takes place (Dunne et al., 2002).  Mice deficient in macrophage antigen-1 (MAC-1 or 
CD11b/CD18 αM integrin/β2 integrin) or lymphocyte function associated antigen-1 (LFA-1 or 
CD11a/CD18 or αL integrin/ β2 integrin) had significantly increased leukocyte rolling velocities 
(Dunne et al., 2002).  Huo et al. (2000) demonstrated monocyte very late antigen 4 (VLA-4) 
interaction with VCAM-1 allowed slow rolling to occur, blocking this interaction significantly 
increased rolling velocities.   
 
Figure 1-12: Leukocyte capture and rolling 
During the inflammatory response activated cells, such as macrophages secrete TNFα, this will 
activate surrounding endothelial (EC) cells, resulting in their surface expression of platelet (P)-
selectin and endothelial (E)-selectin.   Leukocytes in the flowing blood are forced to the 
endothelial cell wall due to the process of margination.  Constitutively expressed leukocyte (L)-
selectin and PSGL-1 are able to interact with surface expressed EC selectins.  The bonds which 
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1.3.3 Activation and firm adhesion 
Activated EC produce chemokines, chemokines belong to 4 subfamilies CXC, CC, CX3C 
and XC, which have been classified depending on the position of cystine residues (Zlotnik and 
Yoshie, 2012).  Chemokines bind to glycosaminoglycans (GAGS) on the EC surface, which is 
thought to aid in prolonging their stability by preventing their degradation (Johnson et al., 2005).  
Some chemokines have been reported to activate EC leading to upregulation of surface 
expression of Ig superfamily members such as ICAM-1 and VCAM-1, which act as integrin 
receptors for leukocyte β2 and β1 integrins, respectively (Figure 1-13).  Lymphocytes are known 
to be high in β2 integrin expression, in contrast to monocytes, which are high in β1 expression 
(Chan et al., 2001). 
Chemokines activate leukocytes causing a conformational change to occur to 
constitutively expressed integrins, through a complex signalling cascade involving G-protein 
coupled receptors (GPCRs) (Figure 1-13).  Binding of a chemokine to its receptor expressed on 
the leukocyte is referred to as outside-in signalling, this induces a conformational change to 
occur to the integrin receptor resulting in opening of the ligand binding pockets (Chigaev et al., 
2003; Nahrendorf et al., 2007; Ley et al., 2007).  In contrast inside-out signalling occurs 
downstream of ligand binding to activate integrins and aids in stabilisation (Constantin et al., 
2000).  These two signalling pathways are able to occur simultaneously leading to leukocyte firm 
adhesion and activation (Constantin et al., 2000).  
 




Figure 1-13: Leukocyte activation and firm adhesion 
Endothelial cells and leukocytes become activated by the binding of chemokine ligands to their 
relevant receptors.  This results in EC expression of Ig superfamily members ICAM-1 and VCAM-
1, which are able to interact with LFA-1/MAC-1 or VLA4 respectively, resulting in firm stationary 
adhesion of the leukocyte.  
 
Each chemokine is only able to bind to certain chemokine receptors (Table 1-4 and Table 
1-5).  This allows for some discrimination between recruitment of leukocyte subsets, as each will 
respond to different chemotactic signals.  Chan et al, (2001) showed that monocyte VLA-4 
affinity for VCAM-1 was increased in response to CXCL12.  CXCL12 is a ligand known to bind to 
the chemokine receptors CXCR4 which is expressed by monocytes (Table 1-5) (Zlotnik and 
Yoshie, 2012).  The largest monocyte subset (CD14+CD16-), are known to express high levels of 
CCR2 (Table 1-5).  This has a high affinity for monocyte chemotactic protein-1 (MCP-1 or CCL2) 
which is produced by EC and indeed by monocytes themselves in response to TNFα, 
lipopolysaccharide (LPS) and IL-1 (Table 1-4).  The ability of the classical CD14+CD16- monocyte 
subset to respond to CCL2, one of the most abundant inflammatory chemokines makes them the 
most prevalent monocyte subset at the site of inflammation, earning them the reputation of 
being the most proinflammatory of the monocyte subsets (Strauss-Ayali et al., 2007).  Non-
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CXC3R1 (fractalkine receptor) meaning they are highly responsive to fractalkine and migrate 
towards this (Geissmann et al., 2003).  As fractalkine is released downstream of CCR2 this means 
this monocyte subset arrive later than the classical subset (Nahrendorf et al., 2007). 
Platelets are also thought to aid in monocyte recruitment to endothelium during the 
inflammatory response.  Upon activation platelets will release the contents of their α granules, 
including the chemokines CXCL4 (platelet factor 4), CXCL7 and CCL5 (RANTES) (Table  1-4) 
(Zlotnik and Yoshie, 2012).  CCL5 is known to bind to the receptors CCR1 and CCR5 and has been 
demonstrated to have an active role in inducing monocyte arrest on inflamed endothelium (von 
Hundelshausen et al., 2005, 2001).  Evidence is beginning to emerge which suggests that CXCL4 
binds to CXCR3b expressed by endothelial cells (Kuckleburg et al., 2011).  This interaction, 
combined with the interaction of CCL5, may enhance monocyte adhesion and transmigration 
(Kuckleburg et al., 2011).  However CXCL4 signalling alone has no effect on monocyte 
recruitment (Kuckleburg et al., 2011).  This demonstrates a role for crosstalk between platelets 
and monocytes in monocyte recruitment to EC.  Once firmly adherent, monocytes are now ready 
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CXC subfamily    
CXCL1 GROα Epithelial cells 
Endothelial cells 
CXCR2 
CXCL2 GROβ Monocytes 
Macrophages 
CXCR2 
CXCL3 GROγ Epithelial cells CXCR2 
CXCL4 Platelet factor 4 (PF4) Platelets CXCR3b 
CXCL5 Epithelial-derived neutrophil-activating peptide 
78 (ENA-78) 
Endothelial cells CXCR2 
CXCL6 Granulocyte chemotactic protein 2 (GCP2) Endothelial Cells CXCR1 
CXCR2 
CXCL7 Neutrophil-activating peptide-2 (NAP-2) Platelets CXCR1 
CXCR2 





CXCL9 Monokine Induced by Gamma interferon (MIG) Epithelial cells CXCR3 




CXCL11 Interferon-inducible T-cell alpha chemoattractant 
(I-TAC) 
Epithelial cells CXCR3 
CXCR7 




CC subfamily    









CCL3 Macrophage inflammatory protein 1α (MIP1-α) Monocytes 
Lymphocytes 
CCR1 CCR5 
CCL4 MIP-1β Monocytes 
Lymphocytes 
CCR5 
CCL5 Regulated on activation, normal T cell expressed 
and secreted (RANTES) 
Platelets CCR1 CCR3 
CCR5 
CCL7 MCP-3 Fibroblasts CCR1 CCR2 
CCR3 
CCL8 MCP-2 Endothelial cells CCR1 CCR2 
CCR5 
CCL13 MCP-4 Fibroblasts CCR2 CCR3 
XC subfamily    
XCL1  Lymphocytes XCR1 
CX3C subfamily    
CX3CL1 Fractalkine Endothelial cells CX3CR1 
Table 1-4: Chemokine ligands 
Table 1-4 shows chemokines and their alternative names, some examples of cell types which are 
known to express them and their relevant receptors.  (Table adapted from Zlotnik and Yoshie, 
2012). 
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Chemokine Receptor Alternative name Cells expressing 
receptor  
Chemokine ligand 
CXCR subfamily    
CXCR1 Interlukin-8 receptor A 
(IL8RA) 
Neutrophils CXCL6 CXCL7 CXCL8 
CXCR2 IL8RB Neutrophils CXCL1 CXCL2 CXCL3 
CXCL5 CXCL6 CXCL7  
CXCL8 
CXCR3 G protein coupled 
receptor-9 (GPCR-9) 
Lymphocytes CXCL4 CXCL9 CXCL10 
CXCL11  
CXCR3b  Endothelial cells CXCL4 
CXCR4  Monocytes CXCL12 
CXCR7   Monocytes CXCL12 





CCL3 CCL5 CCL7 CCL8 
CCL13  
CCR2 CC-CKR-2 Monocytes CCL2 CCL7 CCL8 
CCL13 
CCR3 CC-CKR-3 Basophils 
Eosinophils 
CCL5 CCL7 CCL11 
CCL13 
CCR5 CC-CKR-5 Monocytes 
Lymphocytes  
Dendritic cells 
CCL3 CCL4 CCL5 CCL8 
CCL11 
XCR subfamily    
XCR1 GPCR-5 Dendritic cells XCL1 XCL2 
CX3CR1 subfamily    
CX3CR1 Fractalkine receptor Monocytes 
Lymphocytes 
CX3CL1 
Table 1-5: Chemokine receptors 
Table 1-5: shows chemokine receptors and their alternative names an example of the cells which 
are known to express them and the relevant chemokine receptors.  (Table adapted from Zlotnik 
and Yoshie, 2012). 
 
1.3.4 Leukocyte transmigration   
Once a leukocyte has been activated and stationary adhesion to the EC has occurred, it 
can transmigrate across the vessel wall and enter the surrounding tissue (Figure 1-14).  This 
occurs through a process known as diapedesis, where activated leukocytes transmigrate across 
the EC barrier (~2-5mins), the EC basement membrane (~5-15mins) and finally across the 
surrounding pericytes, leaving the vessel and entering the surrounding tissue (Ley et al., 2007).  
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There are two main routes, which activated leukocytes may take to cross the EC barrier, either 
transmigrating through the EC junctions (paracellular) or through the EC themselves 
(transcellular) (Muller, 2011).  The most common route of diapedesis is the paracellular route 
and many of the molecules which form the tight and adherens junctions of the endothelium play 
a role in leukocyte transmigration (Figure 1-14) (Muller, 2011). 
However the first step in initiating paracellular transmigration starts with the clustering 
of VCAM-1 and ICAM-1 at the site of diapedesis (Matheny et al., 2000; Shaw et al., 2004).  
Interaction of these molecules with the EC cytoskeleton leads to an increase in cytosolic Ca2+ 
levels and rearrangement of the actin cytoskeleton, resulting in EC contraction (Cook-Mills et al. 
2004; Etienne-Manneville et al. 2000; Matheny et al. 2000).  This is thought to be one of the first 
steps in the leukocyte transmigration process.  However this may not be the only role for these 
Ig super family molecules; both play a role in redistributing vascular endothelial-cadherin (VE-
cadherin), a molecule which inhibits leukocyte diapedesis (Turowski et al., 2008; van Wetering et 
al., 2003). 
VE-cadherin is a molecule which forms homophilic interactions in order to stabilise 
adherens junctions, it associates with β-catenin and α-catenin (Schulte et al., 2011).  
Phosphorylation of β-catenin through ICAM-1 signalling allows the homophilic interaction 
between VE-cadherin to be broken, allowing disassembly of the junction (Turowski et al., 2008).  
VE-cadherin-α-cadherin knock in mice, (which could not be phosphorylated at the β-catenin 
site,) showed stabilised VE-cadherin interactions and decreased transmigration during the 
inflammatory response (Schulte et al., 2011). 
Other EC adhesion molecules, which under homeostatic conditions interact to maintain 
cell junction integrity have been shown to interact with leukocytes and aid in their 
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transmigration under inflammatory conditions (Muller, 2011).  Junctional adhesion Molecules 
(JAMs) such as JAM-A, which is capable of homophilic adhesion or can form heterophilic bonds 
with JAM-C, or JAM-B, also aid in maintaining EC junctions (Chavakis et al., 2004; Ostermann et 
al., 2002).  However, under inflammatory conditions JAM-A has been observed to interact with 
LFA-1 but not MAC-1 on leukocytes and aid in transmigration (Figure 1-14), (Ostermann et al., 
2002).  In vivo studies have revealed that JAM-A knockout mice show significantly reduced 
neutrophil transmigration (Woodfin et al., 2009).  Likewise JAM-C has been found to interact 
with MAC-1 and also aid in leukocyte transmigration (Figure 1-14) (Chavakis et al., 2004).  
Chavakis et al, (2004) showed that by inhibiting JAM-C interaction with MAC-1, neutrophil 
transmigration was significantly reduced.  Evidence suggests that a molecule closely related to 
JAMS, which consists of a longer cytoplasmic domain, endothelial cell selective adhesion 
molecule (ESAM) also aids in leukocyte transmigration (Wegmann et al., 2006), however, its 
leukocyte ligand is yet to be identified (Wegmann et al., 2006). 
Platelet endothelial cell adhesion molecule-1 also an Ig superfamily member expressed 
by EC, leukocytes and platelets has been shown to be required for paracellular leukocyte 
migration (Figure 1-14) (Muller et al., 1993).  Muller et al, (1993) demonstrated that PECAM-1 
blocking antibodies prevented monocyte transmigration in vitro.  Other molecules shown to 
have a role in transmigration include ICAM-2, CD99 and CD99Like2 (CD99L2) (Issekutz et al., 
1999; Schenkel et al., 2002; Bixel et al., 2007).  CD99 forms homophilic interactions between 
adjacent EC.  However, under inflammatory conditions endothelial cell CD99 is able to form 
interactions with CD99 expressed on monocytes and neutrophils (Schenkel et al., 2002; Lou et 
al., 2007).  Woodfin et al, (2009) amongst others have suggested that the interactions involved in 
transmigration may occur in a specific order.  It was observed that leukocyte transmigration 
through EC was halted at specific points in ICAM-2-/-, JAM-A-/- and PECAM-1-/- knock-out mice, 
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with the leukocyte migrating further through the EC barrier in each respective knock out mouse 
(Woodfin et al., 2009). 
 
Figure 1-14: Leukocyte transmigration 
Transmigrating leukocytes may use junctional adhesion molecules such as ICAM-2, JAM-A, JAM-
C, PECAM-1 and CD99 to aid in their movement across the EC barrier.  This is through interaction 
with molecules such as LFA-1, MAC-1 and PECAM-1 and CD99 expressed by leukocytes.  (Figure 
adapted from (Ley et al., 2007)  
 
The transcellular route of transmigration is used by 5-20% of leukocytes, it is a rapid 
response which can occur in ~1min (Ley et al., 2007). Many of the same molecules, which are 
responsible for paracellular migration have been implicated to play a role in this pathway, 
including ICAM-1, PECAM-1, CD99 (Mamdouh et al., 2009).  ICAM-1 has been shown to cluster at 
the site of transmigration and throughout the channel the leukocyte passes through (Shaw et al., 
2004).  It is not entirely clear why cells, which are captured and activated through the same 













Atherosclerosis, a chronic inflammatory disease, is one of the leading causes of morbidity 
and mortality in the western world (Dahlöf, 2010).  The risk factors for this disease include aging, 
smoking, hypertension, elevated circulating levels of cholesterol and triglycerides and diabetes 
mellitus (as well as many other chronic inflammatory or auto-immune conditions) (Favero et al., 
2014).  Atherosclerosis involves the accumulation of fatty deposits in the wall of large and 
medium sized arteries (Ross, 1999).  The disease is initiated by endothelial dysfunction, which 
usually occurs at predilection sites where laminar blood flow is disturbed and the endothelium is 
under increased stress (Figure 1-15), (Moore and Tabas, 2011).  Damage or at least a change in 
phenotype, which compromises barrier function leads to accumulation of low density 
lipoproteins and associated lipids in the intimal layer of the artery (Figure 1-15).  Oxidation of 
LDL occurs in situ, rendering it inflammatory in nature and driving the process of monocyte 
recruitment to the vessel wall (Figure 1-15).  The earliest stage of atheroma formation is called 
the fatty streak (Eriksson et al., 2001).  Over time more lipid accumulation and further leukocyte 
infiltration leads to the formation of a plaque, with a lipid core, at which point smooth muscle 
cells infiltrate the plaque forming a protective fibrous cap (Figure 1-15), (Libby, 2012).  
Eventually the lipid core can become necrotic and the fibrous cap thinned (Figure 1-15), (Moore 
and Tabas, 2011).  This is now termed an unstable plaque, with an associated  risk of rupturing 
(Figure 1-15), (Moore and Tabas, 2011).  If the plaque ruptures a platelet thrombus will form at 
the site (Figure 1-15), (Cosemans et al., 2013).  The mural thrombus, or embolizing fragments 
have the potential to  block blood flow to the heart or brain, causing either a heart attack or 
stroke (Cosemans et al., 2013). 




Figure 1-15: Atherosclerotic plaque formation 
A) Healthy endothelium; endothelial cells and their basement membrane are found above the 
tunica intima, here resident Smooth muscle cells (SMC) can be found.  Below the intimal layer is 
the medial layer, this contains the majority of the SMC in their own matrix.  The outer layer, the 
adventitia contains mast cells and nerve endings.  B) Phenotypic changes to endothelial cells (EC) 
results in recruitment of monocytes from the blood, this is accompanied by uptake of LDL, these 
accumulate in the intimal layer.  LDL is oxidised in situ, its proinflammatory nature drives 
recruitment of monocytes.  Monocytes differentiate to become macrophages and uptake oxLDL, 
resulting in the formation of foam cells.  As the disease progresses monocytes will recruit T-cells 
through interactions with MHC-II receptors.  C) As foam cells and lipids accumulate forming an 
atheroma, SMC migrate from the medial layer to form a protective fibrous cap.  D) Over time the 
lipid core can become necrotic, the fibrous plaque may thin, if this happens it is prone to rupture 
at which point a thrombus may form.  (Figure adapted from Libby et al., 2011). 
 
1.4.1 The cellular pathology of atherosclerosis 
Dietary lipids are processed to form triacylglycerols, cholesteryl esters, phospholipids, 
free cholesterol all of which are packaged with apolipoproteins.  These can be used by cells of 
the small intestine to synthesise chylomicrons which are eventually released into the circulating 


























Chapter-1  General Introduction 
44 
 
be taken up by the liver in an apolipoprotein E (ApoE) dependent manner and used to synthesise 
very low density lipoproteins (VLDL) (Tiwari and Siddiqi, 2012).  VLDL is released back into the 
blood stream where it is degraded by lipoprotein lipase to produce LDL (Beisiegel et al., 1989).  
LDL is mainly composed of cholesteryl esters associated with ApoB-100 (Tiwari and Siddiqi, 
2012).  However, LDL is susceptible to oxidative damage, leading to the production of oxidised 
LDL (oxLDL) (Twigg et al., 2012).  Oxidised LDL has been shown to play a major role in 
atherosclerosis disease progression as it activates EC, macrophages and smooth muscle cells 
(SMC) (Pirillo et al., 2013).  The main receptors to be identified to have a role in oxLDL uptake by 
cells are scavenger receptor-A (SRA) and CD36 (Kunjathoor et al., 2002; Steinberg, 1997).  Both 
of these receptors have been identified to have a role in the innate immune response 
(Kunjathoor et al., 2002).  APOE-/- KO (knock-out) mice (a commonly used atherosclerosis disease 
model) coupled with either SRA-/- or CD36-/- KO were shown to have a decrease in atherosclerotic 
plaque sizes, compared to APOE-/- alone (Suzuki et al., 1997; Febbraio et al., 2000).  This suggests 
that both of these receptors have an important role in the uptake of oxLDL during 
atherosclerotic plaque development.  Cells also uptake oxLDL through receptor mediated 
endocytosis using lectin like oxidised low-density lipoprotein receptor-1 (LOX-1 or OLR1) 
(Murphy et al., 2008).  LOX-1 is expressed at very low levels by healthy EC however in response 
to inflammatory signals (such as TNFα) an increase in LOX-1 has been detected (Kume et al., 
1998).  LOX-1 has also been shown to be expressed by EC in early in atherosclerosis and by SMC 
and macrophages in more advanced plaques (Kataoka et al., 1999).   
Endothelial cells at branch points in arteries, where the blood flow is turbulent rather 
than laminar, are subjected to decreased shear stress, which is thought to make them 
susceptible to phenotypic changes (Passerini et al., 2004).  Changes such as a decrease in NO 
production, a vasodilator, which also inhibits platelet and leukocyte activation and an increase in  
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endothilin-1 (ET-1) and angiotensin II both known vasoconstrictors  (Thorin and Webb, 2010; 
Ziegler et al., 1998).  These findings have also been demonstrated to be common amongst 
atherosclerosis patients (Oemar et al., 1998; Lerman et al., 1995; Schieffer et al., 2000).  
Dysfunctional EC also begin to constitutively express inflammatory markers such as selectins, 
ICAM-1, VCAM-1 and PECAM-1 on their surface (Iiyama et al., 1999; Eriksson et al., 2001; Zibara 
et al., 2000).  The chemokine CCL2 has also been documented to be highly expressed in 
atherosclerotic plaques (Ikeda and Matsui, 2002). 
However, EC are not the only cells to have an altered phenotype in this disease.  Vascular 
SMC have been shown to undergo phenotypic changes and infiltrate the developing 
atherosclerotic plaque.  Under normal healthy conditions SMC can be found in the medial layer 
of the artery wall where their main function is to maintain vascular tone as well as produce 
collagen, elastin and proteoglycans, which constitute part of the surrounding extracellular matrix 
(Owens et al., 2004).  SMC retain their plasticity and respond to phenotypic changes in the 
surrounding environment, although ordinarily in health, they proliferate at an extremely low 
rate within the vessel wall (Rzucidlo et al., 2007).  In response to vascular injury, SMC proliferate 
and migrate at an increased rate, they also adopted a more secretory phenotype (Gorski and 
Walsh, 1995).  One of the first physical signs of phenotypic changes of SMC is a loss of vascular 
tone, resulting in stiffening of the arteries (arteriosclerosis) and the onset of hypertension, which 
is often associated with atherosclerosis (Rzucidlo et al., 2007). 
Cross talk between SMC and EC has been well documented during the development of 
atherosclerosis (Libby 2012).  SMC differentiate into a more secretory phenotype in response to 
the cytokines and chemokines produced by the activated EC and leukocytes (Wang et al., 1991).  
Conversely SMC secrete inflammatory cytokines and chemokines, which will activate the EC 
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aiding in platelet and leukocyte capture (Rainger et al., 2001; Barath et al., 1990).  TGF-β 
released by SMC has been demonstrated to activate EC and aid in platelet capture to intact 
endothelium (Figure 1-16) (Rainger and Nash, 2001; Tull et al., 2006).  Platelet capture by 
dysfunctional EC during early atherosclerotic plaque development has been well documented 
and is thought to be one of the key steps in plaque development (Burger and Wagner, 2003; Huo 
and Ley, 2004; Schober et al., 2002; Totani and Evangelista, 2010; von Hundelshausen et al., 
2001).  Once activated, platelets will release chemokines and aid in the inflammatory response 
(Figure 1-16), (von Hundelshausen et al., 2001).  Activated platelets are also known to express P-
selectin on their surface, it has been demonstrated that early platelet adhesion could play a role 
in leukocyte capture through P-selectin bridges (Figure 1-16), (Schober et al., 2002).  Kuckleburg 
et al, (2011) demonstrated preferential recruitment of monocytes by platelet P-selectin bridges, 








Figure 1-16: Platelets aid in monocyte capture to the endothelium through P-selectin bridges 
During the atherosclerosis disease process secretory phenotype smooth muscle cells secrete 
plasmin. Plasmin (a serine protease) cleaves TGF-β into its active form.  TGF-β stimulates EC 
which release vWf from Weibel Palade bodies so it can be trafficked to the surface.  vWf 
captures platelets through interaction with CD42b, these interactions are short lived and are 
able to break and reform resulting in the platelet rolling along the vWf matrix (indicated by the 
green arrow).  Platelets become activated and αIIbβ3 integrin undergoes a conformational change 
allowing it to bind to vWf, this results in the platelet becoming firmly adherent.  Activated 
platelets secrete CCL5 which activate monocytes through CCR1 or CCR5, resulting in monocyte 
activation and arrest.  CXCL4 activates EC through CXCR3b, and is thought to aid in monocyte 
transmigration (although this signal alone is insufficient to induce transmigration).  (Figure 
adapted from Kuckleburg et al., 2011). 
 
As well as recruiting platelets, dysfunctional EC are also able to recruit leukocytes due to 
the inflammatory molecules they express.  Eriksson et al, (2001) demonstrated leukocyte 
recruitment to atherosclerotic plaques in 5-18 month APOE-/- KO mice was dependent on 
selectin expression.  However monocytes have been shown to be the key leukocyte subset to be 
recruited at the onset of this disease.  The chemokine CCL2, highly chemotactic for monocytes 
has been shown to be present in the atherosclerotic plaque.  Absence of either the CCL2 or CCR2 
using CCL2-/- or CCR2-/- mice fed a high fat diet showed reduced monocyte infiltration into the 
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1998).  Once inside the intima, monocytes differentiate to form dendritic cells and macrophages 
which up regulate scavenger receptors such as LOX-1, CD36 and SRA (Woollard, 2013).  An 
increase in these receptors leads to increased uptake of oxLDL.  The lipid laden cell forms a foam 
cell, which is thought to be intrinsically inflammatory in nature (Libby, 2012).  This process is 
responsible for the characteristic fatty streaks seen at the beginning of this disease process 
(Libby, 2012), although foam cells are evident at all stages of plaque development.   
As the disease progresses antigen presenting cells (monocytes, macrophages and 
dendritic cells) will display peptides on MHC-II receptors allowing recruitment of helper T-
lymphocytes and a role for the adaptive immune response (Woollard, 2013).  However it is 
unclear whether the T-cell response is protective or detrimental to disease progression (Zhou et 
al., 2000; Ait-Oufella et al., 2006).   
1.4.2 Role of leukocyte-platelet aggregates in atherosclerosis 
Monocyte recruitment to the endothelium is an important step in atherosclerotic disease 
progression.  The role platelets play in aiding in this process may also be a key step.  It has been 
well documented that monocyte-platelet aggregates (MPA) and neutrophil-platelet aggregates 
(NPA) form in circulating blood, with increased incidence observed in patients suffering from 
diseases including DM, RA and atherosclerosis (Htun et al., 2006; Joseph et al., 2001; Furman et 
al., 1998; Harding et al., 2004).  This implies a potential role for these aggregates in disease 
progression. 
Atherosclerosis patients have been shown to have increased circulating activated 
platelets, which are identified through the expression of surface P-selectin.  It is thought that the 
main mechanism through which leukocyte-platelet aggregates form is through platelet P-selectin 
and monocyte PSGL-1 interaction (Gkaliagkousi et al., 2009).  Platelet P-selectin is therefore able 
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to interact with any leukocyte.  However evidence suggests that neutrophil-platelet and 
lymphocyte-platelet aggregates (LPA) form with a lower propensity than monocyte-platelet 
aggregates (Joseph et al., 2001; Gkaliagkousi et al., 2009; Michelson et al., 2001). 
Once MPA form, activated platelets release chemokines such as CCL5 which has been 
shown to activate monocytes, leading to increased CCL2 expression (Weyrich et al., 1996).  As 
well as increased activation of monocytes, there is also increased potential for heterotypic 
aggregates to be recruited to the endothelium, as platelets may be captured through additional 
pathways (other than the leukocyte adhesion cascade) such as through interactions with vWf 
expressed on the surface of activated EC. 
Upon platelet activation platelet microvesicles are generated.  These are known to 
express P-selectin, CD41 and CD42b (Shai et al., 2012).  Platelet microvesicles have also been 
documented to interact with monocytes and neutrophils (Forlow et al., 2000; Scholz et al., 
2002).  Expression of CD41 and CD42b may also allow for interactions and potential recruitment 
of leukocytes to surface expressed vWf on EC, although this remains speculative and is an 
experimental target of this thesis. 
We hypothesise that platelets or microvesicles generated upon their activation play a 
role in the recruitment of leukocytes in inflammation and inflammatory disease.  Our overall aim 
is to find out whether platelet or platelet derived microvesicles aggregate with leukocytes and 
whether platelet microvesicles have a potential role in aiding in monocyte recruitment in a 
chronic inflammatory disease environment. 
The specific aims of this thesis are: 
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1) To identify whether platelets can be captured by endothelial cells, using glomerular 
endothelial cells for the disease model.  
2) To identify if leukocyte-platelet or leukocyte-platelet microvesicle aggregates are 
generated upon platelet activation, using a variety of platelet agonists, also to find if 
differences occur in the rate or efficiency of aggregate formation depending on the 
agonist used.   
3) To identify a way of potentially blocking the interaction between leukocytes and 
platelets or leukocytes and platelet microvesicles. 

















2. Chapter 2- METHODS 
  
Chapter-2  Methods 
52 
 
2.1.0 Protocols for cell culture and platelet adhesion to GEnC 
2.1.1 Establishing cell line cultures  
Immortalized cell line glomerular endothelial cells (GEnC), a kind gift from Simon 
Satchell, University of Bristol, have been created by transducing primary GEnC with a 
temperature sensitive simian virus 40 large tumour antigen (SV40LT) and telomerase using 
retroviral vectors (Satchell et al., 2006).  When incubated at 33°C (5% CO2) cell line GEnC 
proliferate and can be sub-cultured (Satchell et al., 2006).  However incubating GEnC at 37°C (5% 
CO2) causes SV40LT to be ‘switched off’, as the temperature sensitive virus is removed and the 
cells growth is arrested.  Cell line GEnCs were cultured in complete endothelial cell growth 
medium (EGM2-MV) (Lonza). 
Immortalized cell line podocytes (a gift from Moin Saleem, University of Bristol), were 
also created using SV40LT and telomerase using retroviral vectors (Saleem et al., 2002).  When 
incubated at 33°C (5% CO2) podocytes proliferate and appear to form a monolayer.  However 
when incubated at 37°C (5% CO2) for 1-2 weeks they differentiate and form the classic foot like 
projections, associated with podocytes.  Podocytes were cultured in Roswell Park Memorial 
Institute (RPMI) medium (with L-glutamine and sodium bicarbonate) (Sigma) with supplements 
added as follows; 100U/ml penicillin, 0.1mg/ml streptomycin both components of penicillin 
streptomycin solution (Sigma), 2mM L-glutamine (Sigma), ITS (Sigma) containing recombinant 
human insulin 1µg/ml, human transferrin 1.1µg/ml and sodium selenite 1ng/ml and 10% (v/v) 
foetal Calf Serum (FCS) (Gibco). 
Both cell line GEnC and cell line podocytes were sub-cultured using the following 
method: Culture medium was removed from the flask by aspiration.  2mls 0.02% (w/v) 
ethylenediaminetetraacetic acid (EDTA) (Sigma) was added to the flask and left for 1 minute to 
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chelate cations, necessary for adhesion receptor function.  After 0.02% (w/v) EDTA was 
removed, 0.005g trypsin (Sigma) prepared in 0.02% (w/v) EDTA and was added to the flask.  Cells 
became rounded and detached from the culture substrate.  The trypsin was neutralized by 
adding twice the volume of complete medium.  The cell suspension was removed from the flask 
and centrifuged at 500g for five minutes.  Cells were suspended in their appropriate medium and 
seeded into either a 25cm2 or 75cm2 flask. 
For long term storage of cell line GEnC or podocytes they were sub-cultured as above, 
however, instead of seeding a fresh flask, cells were suspended in 90% FCS (gibco) 10% (v/v) 
dimethyl sulphoxide hybri-max (DMSO) (Sigma).  Cells were stored as 1ml aliquots frozen down 
in cool cell (Biocision), which is placed in a -80°C freezer, before being transferred to liquid 
nitrogen tanks for long term storage.  Cell line GEnC or podocytes were taken out of nitrogen 
storage and defrosted in luke warm water.  The 1ml contents was then added to 6ml of 
appropriate fresh medium and put straight into a 25cm2 culture flask, or a 75cm2 culture flask 
containing 10mls of fresh medium. The flask was incubated at 33°C until confluent. 
2.1.2 Sub-culturing primary GEnC (HRGEC) 
1mg/ml fibronectin (Sigma) (isolated from human plasma) was prepared in sterile water.  
25cm2 flasks were coated with 50µg of fibronectin for 1 hour.  Fibronectin was the 
recommended substrate for these cells.  A vial containing 5x105 primary GEnC (HRGEC ScienCell) 
was thawed at 37°C and cells were added to the previously coated 25cm2 flask along with 6ml of 
complete EGM2-MV.  The cells were sub-cultured using the following method.  Culture medium 
was removed from the flask by aspiration.  3mls 0.02% (w/v) EDTA was added to the flask for 1 
minute.  After 0.02% (w/v) EDTA was removed, 0.05% (w/v) trypsin (trypsin-EDTA Solution 10X -
SAFC biosciences) prepared in 0.02% (w/v) EDTA and was added to the flask.  Cells became 
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rounded and detached from the culture substrate. Trypsin was neutralized by adding 2mls FCS 
and 2mls complete EGM2-MV.  The cell suspension was removed from the flask and centrifuged 
at 300g for 5 minutes.  Cells were suspended in EGM2-MV medium and seeded into a 25cm2 
flask previously coated with 1mg/ml fibronectin (as described above).  Primary GEnC (HRGEC) 
were not sub-cultured for use in experiments beyond passage 3. 
2.1.3 Isolating and maintaining HUVEC primary cultures 
Full ethical approval and written consent was obtained before human umbilical cords 
were obtained from the Women’s Hospital, Birmingham.   Endothelial cells were isolated using 
collagenase digestion as described previously (Cooke et al., 1993).  Briefly, undamaged cord 
sections of about 3-4 inches, were sprayed with ethanol 70% (V/V).  The vein was cannulated 
and washed twice with PBS, incubated with collagenase (1X) (Worthington) at 37°C for 15 
minutes.  Cords were then massaged for one minute and flushed with PBS.  Cells were 
centrifuged at 500g for five minutes and suspended in 5 ml of complete M199 medium (Gibco) 
(penicillin-streptomycin 0.1mg/ml; amphotericin (Sigma), 2.5μg/ml; gentamycin (Sigma), 
35μg/ml; 1/500 human epidermal growth factor (Sigma), 10ng/ml; hydrocortisone (Sigma), 
1μg/ml and 20% heat inactivated FCS).  Human umbilical vein endothelial cells (HUVEC) were 
cultured in 4ml of M199 complete media in 25cm2 flasks pre-coated with 2% (w/v) gelatine. 
2.1.4 Assay for detection of vWf using fluorescence microscopy 
Cell line GEnC (batch 1) were seeded in a chamber slide with between 1x104 and 4.8x104 
cells/well they were left overnight at 37°C.  GEnC were either untreated for internal vWF 
detection or treated with 100U/ml TNFα (Sigma) and 10ng/ml TGFβ (R&D Systems) for 24 hrs for 
surface vWf detection.  GEnC were washed twice with Dulbecco's phosphate buffered saline 
(PBS) (Sigma), then, fixed with either (i) 2% (w/v) formaldehyde (FA) for 10 minutes (for surface 
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detection) or (ii) 2% (w/v) FA for 5 min followed by 1% (w/v) triton for 10 minutes.  Triton was 
used to puncture the membrane allowing the antibody to enter the cell. GEnCs were washed 
twice with PBS.  A 2% (w/v) BSA (Sigma) blocking solution (made using PBS with Ca2+ and Mg2+) 
was then left on the cells for 30 minutes. 10µg/100µl of either FITC labelled, sheep antihuman 
vWf antibody (AbD serotec cat. no. AHP 062F, polyclonal) or FITC labelled sheep IgG isotype 
control (polyclonal) antibody, (The Binding Site) was added in 1% (w/v) BSA, 2% (v/v) FCS in PBS.  
GEnC were then incubated with either vWf or isotype control antibody for 1 hour.  They were 
then incubated with 1µg/ml Hoechst 33342 component trihydrochloride (Invitrogen) to stain the 
nucleus.  GEnC were then washed five times with PBS. Images were taken using a fluorescent 
invert microscope (Olympus IX71) and Image Pro version 6.3 (Media Cybernetics) was used to 
add pseudo colour. 
For detection of internal vWf for cell line GEnC batch (2), these cells were incubated for 5 
days at 37°C (5% CO2) to ensure complete removal of the SV40LT virus.  Cell line podocytes were 
used as a negative control and were incubated at 37°C for one week, to differentiate and to 
allow for complete removal of SV40LT.  Primary HUVEC were used as a positive control and were 
cultured at 37°C (5% CO2).  These cells were seeded into separate wells of a chamber slide at 
1x104 cells/well.  These were left overnight at 37°C (5% CO2).  The protocol for detection of 
internal vWf was then followed as stated in paragraph above. 
2.1.5 Platelet isolation  
The protocol has been adapted from Tull et al (2006).  Blood from healthy volunteers 
was collected into a tube containing 10% (w/v) citrate phosphate dextrose solution (CPDA) 
(Sigma).  It was centrifuged at 200g for 10 minutes.  The platelet rich plasma (PRP) was collected 
and 0.013g theophylline (Sigma) was added to it, this was then centrifuged for 10 minutes at 
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1000g.  The pellet was then suspended in theophylline buffer; 0.15% (w/v) BSA, 1.3mg/ml 
theophylline, Dulbecco's phosphate buffered saline (PBS) - without calcium chloride and 
magnesium chloride and washed for 10 minutes at 1000g.  Platelets could then be suspended at 
desired concentration in appropriate buffer for use in experiments.   
2.1.6 Optimising calcein staining of platelets 
This technique was based on previous experiments, which were designed to detect 
platelet adhesion to HUVEC.  The protocol has been adapted from Tull et al (2006).  Platelets 
need to be stained with a fluorescent marker for use in assays designed to detect platelet 
surface adhesion to EC, in this case GEnC.  However it is important that the fluorescent stain is 
bright enough to be detected but does not increase platelet activation as this would cause the 
data to be misleading.  We tested the effect of staining platelets with 1µg/ml and 5µg/ml of 
calcein. 
Blood from a healthy volunteer was collected into a tube containing 5U/ml heparin 
(Sigma).  The heparinised blood was centrifuged at 1000g for 5 minutes and the platelet poor 
plasma (PPP) was collected.  Platelets (from the same donor) were isolated as described above 
(2.1.5 Platelet Isolation).  However, the platelet pellet was suspended in theophylline buffer at a 
concentration of 2x108 platelets/ml, and before continuing with the protocol, platelets were 
stained with either 1µg/ml or 5ug/ml of calcein (Sigma) for 20 minutes at room temperature (RT) 
in the dark.  The platelets were washed twice in 10mls theophylline buffer for 10 minutes at 
1000g.  2x108platelets/ml were then suspended in 80% PBS (with Ca2+ and Mg2+) (containing 
0.15% w/v BSA) and 20% PPP or instead suspended in theophylline buffer, 20µl of each was 
pipetted on to a glass slide.  Images were taken using a fluorescent invert microscope (Olympus 
IX71) and Image Pro version 6.3 (Media Cybernetics). 
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Platelets suspended in 80% (v/v) PBSA, 20% (v/v) autologous PPP (PBS buffer), in the 
presence of calcium, become activated and spread on a glass substrate (Figure 2-1A).  However, 
when incubated with 5µg/ml calcein in theophylline buffer fewer are activated, indicating that 
up to 5µg/ml calcein does not cause further platelet activation (Figure 2-1B).  Platelets 
suspended in PBS buffer on a glass substrate following incubation with both 1µg/ml and 5µg/ml 
calcein is demonstrated by figures 2-1C and D, respectively.  5µg/ml calcein shows a clearly 
visible stain (Figure 2-1D) and does not cause further platelet activation (Figure 2-1B).  We 
therefore chose to use this concentration when assessing platelet adhesion to GEnC. 
 
Figure 2-1: Calcein staining platelets 
Platelets were isolated from whole blood and pipetted onto a glass substrate, images taken 
using Olympus IX71 x64 magnification.  A) shows isolated, unstained platelets suspended in 80% 
(v/v) PBS 20% (v/v) platelet poor plasma on a glass substrate.  Platelets are activated and the 
characteristic spreading is clearly demonstrated.  B) shows platelets suspended in theophylline 
buffer stained with 5µg/ml calcein most of the platelets are not activated as they remain small 
and round, showing that calcein stain is not causing further platelet activation.  C) shows 
platelets isolated and suspended in PBS buffer (containing PPP), stained with 1µg/ml calcein, 
these platelets appear dim and are difficult for the software to detect.  D) shows platelets 
isolated and suspended in PBS buffer (containing PPP), stained with 5µg/ml calcein these appear 
bright and can easily be detected by the image pro software.  Scale bar represents 20µm. 
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2.1.7 Platelet adhesion to GEnC 
A 24 well plate was coated with 1% (w/v) gelatine diluted using PBS.  (GEnC batch 1) 
were sub- cultured (2.1.1 Establishing Cell Line Cultures).  They were seeded at a concentration 
of 1x105 cells per well.  They were left at 33°C (5% CO2) until confluent, then at 37°C overnight to 
ensure removal of SVLT40 virus, before  24 hour treatment with TNFα (100U/ml) or TGFβ 
(10ng/ml) or both cytokines in combination (at the same concentrations) in EGM2-MV media.  
Control wells had EGM2-MV medium change, each treatment was done in duplicate (Figure 2-
2A). 
Platelets were isolated  as previously descibed.  2x108 platelets/ml were stained with 
5µg/ml of calcein in theophylline buffer for 20 minutes at RT in the dark.  The platelets were 
washed twice in 10mls theophylline buffer for 10 minutes at 1000g, an extra wash step was 
added to the standard protocol to ensure the removal of excess calcein, as this is a fluorescent 
live cell stain any excess would stain the GEnC monolayers leading to false detection of  platelet 
adhesion.  2x108platelets/ml were then suspended in 80% (v/v) M199 -without phenol red 
(Gibco) containing 0.15% (w/v) BSA and 20% (v/v) PPP (from the heparinised blood).  When 
appropriate 5U/ml heparin was added at this point.  A small aliquot was treated with 10µM ADP 
(Sigma).  Either 300µl untreated or ADP stimulated platelet suspension containing 6x107 
platelets was added to the plate, which was incubated at 37°C for 1hr in the dark (Figure 2-2B). 
At the end of the incubation period the cells were fixed with 1% (w/v) FA for 10 minutes.  
Monolayers were then washed four times with PBS, before images were taken using fluorescent 
invert microscope (Olympus IX71) and Image Pro version 6.3 (Media Cybernetics) at x32 
magnification.  Using Image Pro version 5.0 (Media Cybernetics) the percentage coverage of the 
GEnC monolayer by platelets, was calculated, as well as the average size of the platelets/platelet 
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aggregates and the number of platelets/platelet aggregates adhering to the GEnC monolayer 
(Figure 2-3).  Unpaired one way or two way ANOVA analysis was carried out, using prism version 
5.01 (GraphPad Software).  The data was only included if the monolayer of the well was intact, 
as it is well known that platelets will adhere to the subendothelial matrix (Figure 2-4). 
 
 
Figure 2-2A: Cytokine treatment of GEnC in a 24 well plate  
Figure 2-2 shows the wells of a 24 well plate containing GEnC monolayers treated either with 
100U/ml TNF or 10ng/ml TGFβ, or a combination of both cytokines in EGM2-MV medium.  





Figure 2-2B: Incubation of GEnC monolayers with untreated or 10µM ADP stimulated platelets 
Suspensions of 6x107 platelets in 20% (v/v) PPP 80% (v/v) medium 199 (without phenol red) 
either unstimulated, or treated with 10µM ADP were added to cytokine stimulated or untreated 
GEnC monolayers and incubated for 1 hour at 37°C (5% CO2). 
 





Figure 2-3: Platelet adhesion analysis. 
Figure 2-3 demonstrates Image pro version 5.0 (Media Cybernetics) depicting fluorescent 
platelets compared to the black background.  The software is able to determine the number and 
size of the aggregates forming. 
 
 
Figure 2-4: Intact GEnC monolayer  
Figure 2-4 demonstrates an intact GEnC monolayer used in platelet adhesion assay.  Image taken 
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2.1.8 Assay for detecting cell surface markers using flow cytometry 




Primary antibodies     
CD54 (ICAM-1) –
allophycocyanin (APC) 
BD pharmingen 559771 HA58 1/50 
CD31 (PECAM-1 ) - PE 
(Phycoerythrin) 




ABD Serotec AHP062F Polyclonal 1/100 
Mouse Anti-CD62E Sigma S9555 1.2B6 1/200 
Secondary antibodies     
Goat-anti mouse-FITC DAKO F0479 Polyclonal 1/200 
Isotype antibodies     
Mouse IgG1 DAK-GO1  DAK-GO1 1/200 
Mouse IgG1-PE Immuno tool 21275514 PPV-06 1/50 
Sheep IgG1-FITC The Binding Site   1/100 
Mouse IgG- APC Biolegend 400122 MOPC-21 1/50 
 
Table 2-1: Antibodies for detection of cell markers, relevant isotypes and secondary antibodies 
 
As GEnC batch 2 appeared to have lost its characteristic cobblestone appearance this 
prompted us to test for EC markers, HUVEC were used as a positive control and the epithelial, 
podocyte cell line were used as a negative control.  A 25cm2 flask containing cell line GEnC (batch 
2) were left at 37⁰C (5% CO2) for at least 5 days, for growth arrest to take place and to ensure 
complete removal of the SV40LT.  A 25cm2 flask containing cell line podocytes was left at 37⁰C 
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(5% CO2) for at least 7 days to differentiate and for removal of SV40LT virus.  The cells were then 
sub-cultured as previously described and seeded into a 24 well plate (1x105 cells/well) along with 
primary HUVEC (which had been cultured at 37⁰C (5% CO2) throughout.  The cells were left at 
37⁰C (5% CO2) overnight to allow them to adhere.  Each cell type was cultured in its own 
appropriate medium throughout. For ICAM-1 and PECAM-1 detection wells containing each cell 
type were treated with 100U/TNFα for 4 hours prior to removal from the plate.  For E-selectin 
detection, cells were treated with 1000U/TNFα for 4 hours prior to removal from the plate.  This 
is because these markers are part of the leukocyte adhesion cascade and are only expressed as 
part of the inflammatory response. 
For detection of either ICAM-1 or PECAM-1 cells were removed from each well of the 
plate as previously described, cells were transferred into flow cytometry tubes.  2mls ice-cold 2% 
(w/v) BSA in PBS was added to increase wash volume and for non-specific blocking.  As cells 
were live they were washed at 4⁰C, 500g for 5 mins.  The supernatant was removed and the cell 
pellet was suspended in either 50µl 2% (w/v) BSA in PBS containing allophycocyanin (APC) 
labelled mouse anti-human ICAM-1 (CD54) antibody or relevant concentration of APC labelled 
mouse IgG isotype control antibody, or PE labelled mouse anti human PECAM-1 antibody or 
relevant concentration of PE labelled mouse IgG antibody (Table 2.1).  The cells were incubated 
with antibody on ice for 40 minutes, in the dark.  2ml ice-cold 2% (w/v) BSA in PBS was added to 
increase wash volume and the cells were centrifuged at 4°C, 500g for 5mins.  The cells were then 
suspend and stored in 300μl of 2% (w/v) FA.  Before running flow cytometry the cells were 
centrifuged at 500g and suspended in 300µl PBS for data acquisition. 
For detection of E-selectin cells were washed with 2% (w/v) BSA in PBS.  Then incubated 
for 30 minutes on ice, with 200µl/well of 2% (w/v) BSA in PBS containing either mouse 
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monoclonal anti- human E-selectin (CD62E) antibody or mouse IgG1 isotype antibody (Table 2-
1).  Each well was then washed with 0.5mls 2% (w/v) BSA in PBS, 3 times.  Before incubating on 
ice, in the dark with 200µl/well of 2% (w/v) BSA in PBS, containing FITC labelled polyclonal goat 
anti-mouse antibody (Table 2-1).  The cells were then washed, once, with 0.5mls 2% (w/v) BSA in 
PBS and then with 0.5mls of 0.02% (w/v) EDTA per well.  0.5mls of cell dissociation buffer (Gibco) 
(an isotonic and enzyme free solution of salts and chelating agents and cell conditioning agents 
in PBS) was then added to each well and the plate was incubated at 37 ⁰C, for 15 minutes, until 
cells rounded up and detached.  The cells were then transferred to flow cytometry tubes.  
Washes were preformed in 2% (w/v) BSA as before.  The pelleted cells were then suspended in 
300µl of 2% (w/v) FA to fix them ready for analysis.  Before running flow cytometry the cells 
were centrifuged at 500g and suspended in 300µl PBS for data acquisition. 
For detection of internal vWf cells were removed from the plate as previously described 
once cells had rounded and detached from the flask, they were transferred to flow cytometry 
tubes, containing 2mls ice-cold 5% (v/v) FCS in PBS to neutralize trypsin.  Cells were then washed 
at 4°C 500g for 5 minutes.  The supernatant was removed and the cells were suspended in 50µl 
medium A (Invitrogen fix and perm kit) and incubated in the dark for 15 minutes at RT.  2ml of 
5% (v/v) FCS in PBS was added to each tube to increase wash volume and then centrifuged at 
500g for 5 minutes and the supernatant removed.  The cell pellet was suspended in 50µl of 
medium B (Invitrogen fix and perm kit) containing either FITC labelled sheep anti-human vWf 
antibody (AbD serotec) or FITC labelled sheep IgG isotype control antibody, (The Binding Site) at 
a 1/100 dilution.  This was then incubated at 37⁰C in the dark for 40 minutes.  Cells were then 
washed in 2mls of 5% (v/v) FCS in PBS, 500g for 5 minutes.  The cells were suspended in 300µl of 
PBS ready for flow cytometry. 
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Data was acquired using a DAKO Cyan flow cytometer 1.5x103 events for each cell type 
were collected based on the size and granularity of the cells this is demonstrated by figure 2-5, 
gates G1 (HUVEC), G3 (Podocytes) and G5 (GEnC batch 2).  Analysis was carried out using Dako 
Summit 4.3 software.  A gate was set to include 5% of the isotype control for each cell type, 
(Figure 2-5), gates G2 (HUVEC), G4 (Podocytes) and G6 (GEnC batch 2), the median fluorescent 
intensity (MFI) of ICAM-1 in each gate was recorded.  The MFI of the isotype for each cell type 
was also recorded and could be subtracted to calculate the change in MFI.  This analysis was 
repeated for PECAM-1, E-selectin and vWf. 
 
Figure 2-5: Gating strategy to assess cell markers on HUVEC, podocytes and batch 2 GEnC  
Figure 2-5 demonstrates the gating strategy for collecting 1.5x104 events based on size and 
granularity for A) HUVEC (G1), B) podocytes (G3) and C) GEnC batch 2 (G5).  A gate was then set, 
which included 5% of the isotype control and the MFI for surface ICAM-1 expression found in 
this gate was recorded.  This was repeated for each cell type A) HUVEC gate (G2), B) podocyte 
gate (G4) and C) GEnC batch 2 gate (G6).  This method was adopted for analysis of surface 
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2.2.0 Method development for detection of leukocyte-platelet aggregates in whole blood 
For experiments to determine leukocyte-platelet aggregate formation, blood was 
collected from a healthy volunteer and immediately transferred to a tube containing 10% citrate 
phosphate dextrose solution (CPDA).  Cells were fixed with 1% (w/v) FA for 10 minutes followed 
by two wash steps at 500g for 5 minutes in 3mls PBS, unless stated otherwise.  In order for flow 
cytometry data to be acquired, red cells were lysed using ACK lysis buffer (Gibco) according to 
manufacturer’s instructions.  ACK was added at x10 starting volume of whole blood, this was 
mixed gently 3 times and incubated for 10 minutes at RT.  ACK was diluted using PBS ~ x10 
volume added, to prevent further lysis and damage to leukocytes, and samples were centrifuged 
at 500g for 5 minutes.  To remove any residual ACK this wash step was repeated using 5-10mls 
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CD3-PerCP BD bioscience 345766 SK7 10/100 T-Lymphocytes 
CD14-PE Immuno Tools 21270144 MEM-18 1/100 Monocytes 
CD14- APC e-Bioscience 17-0149-42 61D3 0.1µg/100µl Monocytes 





e-Bioscience 25-0168-42 eBioCB16 0.012µg/100µl Monocytes 
/Neutrophils 
CD20-PEcy7 AbCam Ab82002 B-Ly1 5/100 B-Lymphocytes 
CD42b- APC BD-Pharmingen 551061 HIP1 7/100 Platelets 
P-selectin 
CD62P-FITC 
BD-Pharmingen 555523 AK-4 1/50 Platelets 
CD162 PE e-Bioscience 12-1629-42 FLEG 0.024µg/100µl Leukocytes 
Isotype      
Mouse IgG1-PE Immuno Tools 21275514 PPV-06 1/100 or 
0.012µg/100µl 
 
Mouse IgG1-FITC DAKO(Alere) YYX092701 
 
 2/100 or 
0.025µg/100 
 









Table 2-2: Flow cytometry antibodies  
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2.2.1 Lysing red blood cells with ACK lysis buffer 
Blood from a healthy volunteer was collected into 10% (w/v) CPDA and aliquoted into 
0.3ml volumes.  Blood aliquots were either fixed or left untreated.  ACK lysis buffer was used to 
lyse red blood cells following manufactures instructions.  The remaining live cells were fixed.  
Cells were suspended in 100µL PBS with CD14 (Immuno Tools) and CD3 antibodies (BD 
bioscience) for 30 minutes (Table 2-2), cells were washed twice in 5mls PBS at 500g for five 
minutes.  Cells were then suspended in 300μl PBS for analysis by flow cytometry. 
Data was acquired using a Dako Cyan flow cytometer, a total of 2.5x105 events were 
collected (including all leukocyte cell types) based on the size and granularity of the cells, 
analysis was carried out using Dako Summit 4.3 software.  Figure 2-6A and B demonstrate that 
lysis of live RBC with ACK lysis buffer is not successful as the leukocyte populations can’t be 
distinguished from each other.  However Figure 2-6C and D demonstrate that fixing with 1% FA 
prior to treatment with ACK, allows effective lysis to occur, without damaging leukocytes.  As 
leukocyte subpopulations can clearly be identified based on differences in their size and 
granularity.  This is further confirmed by the use of antibodies against the monocyte marker 
CD14 and the T-cell marker CD3 (Figure 2-6D). 




Figure 2-6: Red blood cell lysis with ACK lysis buffer 
A and B) both show live blood cells treated with ACK lysis buffer based on size and granularity, 
however the lysis method has not been effective as there appears to be red cell contamination.  
B) Shows that damage to leukocytes has occurred, based on the change in size and granularity of 
CD3 positive lymphocytes (purple) and CD14 positive monocytes (red).  C) and D) both show 
previously fixed blood where red blood cells have been lysed with ACK lysis buffer.  D) The CD3 
positive lymphocyte (purple), CD14 positive monocyte (red) and neutrophil subpopulations can 
clearly be identified. 
 
2.2.2 Using fixed or live cells for antibody staining  
When used for detection of leukocyte-platelet aggregates in whole blood, samples would 
need to be fixed at the end of a time course, to prevent any further leukocyte-platelet aggregate 
formation from occurring.  However, we wanted to make sure that antibodies could recognise 
their receptor once cells were fixed.  Blood from a healthy volunteer was collected into 10% (v/v) 
CPDA and aliquoted into 0.3ml aliquots.  Aliquots were either fixed immediately or cells were left 
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live.  One fixed and one live aliquot was incubated for 30 minutes at RT or on ice with the 
following antibodies; PE labelled CD14 antibody, FITC labelled CD16 and APC labelled CD42b, 
(Table 2-2).  The remaining live cell aliquots were fixed.  RBC were lysed.  Samples were 
suspended in 300μl PBS for analysis by flow cytometry, data was acquired using a Dako Cyan 
flow cytometer, a total of 2x104 events were collected in the monocyte gate based on the size 
and granularity (Figure 2-7).  Analysis was carried out using Dako Summit 4.3 software. 
The data revealed that incubating live whole blood samples at either RT or on ice with 
CD14 and CD16 antibody resulted in the activation of monocytes and both receptors being shed 
(Figure 2-7 D and E).  However, when cells are fixed prior to incubation with CD14 and CD16 
antibody the monocyte populations (CD14+CD16- and CD14+CD16+) can clearly be identified 
(Figure 2-7 A-C).  
2.2.3 Measuring MPA formation at a defined shear rate 
Ideally, it would have been better to carry out experiments to look at MPA formation at a 
defined shear rate.  1ml of blood collected into 10% (v/v) CPDA, from a healthy volunteer was 
added to a cone and plate viscometer and blood was sheared at a known rate of either 46S-1, 
115S-1 or 230-1 for 30 minutes.  At 5, 15 and 30 minutes a 200μL aliquot of blood was taken and 
fixed.  An aliquot of blood was also fixed shortly after phlebotomy as a control.  The samples 
were then suspended in 300uL PBS and incubated with PE labelled CD14, FITC labelled CD16 and 
APC labelled CD42b antibodies for 30 minutes (Table 2-2).  Red cells were lysed and cells were 
suspended in 300uL PBS ready for flow cytometry.  Analysis was carried out using Dako Summit 
4.3 software.  However, following incubation in the cone and plate viscometer the auto 
fluorescence of the cells was altered and they produced a strong FITC signal.  An example of 
unstained samples which were sheared at 115S-1 and 230-1 are shown below (Figure 2-8). 




Figure 2-7: Fixed or live antibody stain 
A) shows whole blood which has been fixed with 1% (w/v) FA, then incubated at room temperature (RT) for 30 minutes or B) on ice for 30 minutes, 
with CD14 and CD16 antibodies before lysis with ACK.  C) demonstrates whole blood which has been in incubated at RT for 30 minutes or D) on ice for 
30 minutes with antibodies, before fixing with 1% (w/v) FA and red blood cell lysis with ACK lysis buffer.  Gate R26, which includes the monocyte 
population based on their size and granularity has been applied (demonstrated by blue arrow) to a CD14 vs CD16 plot.  A and B demonstrate that 
when cells are fixed prior to incubation with antibodies the monocyte population based on CD14 and CD16 expression can clearly be distinguished.  
However C and D demonstrate that incubation with antibodies at either 4°C or RT before cells are fixed results in the loss of CD16 expression by 
monocytes in whole blood. 
















































Figure 2-8: Auto fluorescence of leukocytes is altered after incubation in the cone and plate 
viscometer 
Whole blood was A) fixed prior to any treatment, or incubated in the cone and plate viscometer 
for 30 minutes at B) 115S-1 or C) 230S-1 before fixing.  Data were acquired using flow cytometry.  
A) demonstrates that fixed blood has low auto fluorescence.  B) and C) indicate that following 
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2.3.0 Final protocol for detection of leukocyte-platelet aggregates in whole blood 
2.3.1 Detection of leukocyte-platelet aggregates in whole blood using flow cytometry  
Blood was collected from a healthy volunteer and immediately transferred to a tube 
containing 10% (v/v) CPDA.  300μL of blood was aliquoted into 5ml tubes.  Some aliquots were 
fixed immediately for a control (0 minute) and also to calibrate the flow cytometer.  Remaining 
aliquots were incubated with a platelet agonist, at either a high or low concentration (Table 2-3) 
at 37°C on a roller mixer for 5 minute intervals, ranging between 5-30 minutes and 60 minutes.  
A high concentration of platelet agonist can be defined as; causing full aggregation of washed 
platelets.  A low concentration is the lowest concentration of agonist shown to cause full 
aggregation of washed platelets of highly responsive donors.  Untreated samples were incubated 
on a roller mixer at 37°C for 30 minutes and 60 minutes.  At the end of the incubation period 
samples were fixed.  Samples were suspended in 300µL PBS.  The following antibodies, from a 
previously prepared master mix, were added; PE labelled CD14 antibody, FITC labelled CD16 and 
APC labelled CD42b (GPIb) (Table 2-2).  Of the immediately fixed aliquots one was left unstained, 
another was used to prepare an isotype (Table 2-2) another had FITC CD16, PE CD14 and APC 
isotype control (Table 2-2 and Figure 2-12).  Single colours were added to individual aliquots for 
compensation of the flow cytometer.  After 30 minutes incubation with antibody, RBC were 
lysed.  Each sample was suspended in 300μl of PBS.  Data were acquired using a Dako Cyan flow 
cytometer, a total of 2x104 events were collected in the monocyte gate based on the size and 
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Platelet receptor(s) Platelet Agonist Company Concentration 
P2Y1 P2Y12 ADP Sigma 30µM 
P2Y1 P2Y12 ADP  3µM 
PAR1 TRAP* Alta Biosciences 100µM 
PAR1 TRAP*  10µM 
TP U46619 Cayman Chemical 
Company 
10µM 
TP U46619  3µM 
CLEC2 Rhodocytin Gift from Johannes Eble 
(University of Münster) 
100nM 
CLEC2 Rhodocytin  30nM 






CD36 Oxidised LDL Intracell (USA) 
Cat no. RP-047 
50µg/ml 
 
Table 2-3: Table of agonists used and the receptor, through which they are known to activate 
platelets 









Figure 2-9: Allophycocyanin isotype control 
 
Whole blood was fixed with 1% (w/v) FA and incubated with CD14 (PE), CD16 (FITC) and APC IgG 
for 30 minutes before red blood cells were lysed.  Leukocytes were suspended in PBS and data 
were acquired using flow cytometry.  Gating is set using 0 minute time point.  There is little to 
no, non specific binding of APC Isotype to A) CD14+CD16- monocyte subset, B) CD14+CD16+ 
monocyte subset, C) neutrophils or D) lymphocytes. 
 
2.3.2 Leukocyte-platelet aggregate detection; analysis using Summit software 
Summit version 4.3 was used to analyse the flow cytometry data acquired.  The same 
gating strategy was used for analysing data from each experiment.  The monocyte population 
was defined by size and granularity (Figure 2-10), as well as by CD14 and CD16 expression.  The 
gating strategy ensured minimal contamination by other blood cells.  Monocytes could then be 
split into two populations CD14+CD16- (~90% population) and CD14+CD16+ (~10% population), 
(Figure 2-10).  CD42b and CD14 dual positive staining indicated CD14+CD16- monocyte-platelet 
aggregate formation (MPA).  CD42b and CD16 dual positive staining indicated MPA formation for 
the CD14+CD16+ subset of monocytes.  0 minute (control) was used for applying gates to define 
dual positive events for both monocyte populations (Figure 2-10).  The gates were not changed 
between samples and the percentage MPA for each time point was recorded. 
The neutrophil population was defined by size and granularity (Figure 2-11).  The gating 
strategy was set to minimise contamination by other leukocytes (Figure 2-11).  CD42b and CD16 
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dual positive staining indicated neutrophil-platelet aggregate (NPA) formation.  The 0 minute 
(control) was used for gating on dual positive events (Figure 2-11).  The gates were not changed 
between samples and the percentage NPA were recorded for each time point. 
The lymphocyte population was defined by size and granularity (Figure 2-12).  CD42b 
positive events with the same granularity as lymphocytes indicated lymphocyte-platelet 
aggregate (LPA) formation.  The 0 minute time point was used for gating on CD42b positive 
events (Figure 2-12).  The gates were not changed between samples and the LPA were recorded 









Figure 2-10: Gating strategy for detecting MPA in lysed whole blood 
Gate R1 defines monocytes by size and granularity (some CD14+CD16+ monocytes can be found 
in the lymphocyte region).  Gate R2, monocytes defined by CD14 expression and granularity.  
Gate R2 is then applied to a CD14 vs CD16 plot (indicated by blue arrow) and gate R3 is set to 
include events expressing low levels of CD14 and CD16. A combination of gate R1 and R2 and not 
R3 is used to define the monocyte population (a ‘not’ gate is indicated by brown arrow).  This 
can subsequently be split into two populations ~90% CD14+CD16- (gate R4) and ~10% 
CD14+CD16+ (gate R5).  Gate R4 is then applied to CD42b vs CD14 plot, dual positive expression 
of both platelet CD42b and monocyte CD14 markers (gate R6) defines a CD14+CD16- monocyte 
platelet aggregate.  Gate R5 is then applied to CD42b vs CD16 plot, expression of both platelet 
CD42b and monocyte CD16 markers (gate R7) defines a CD14+CD16+ monocyte platelet 












































Figure 2-11: Gating strategy for detecting NPA in lysed whole blood 
Gate R15 defines neutrophils by size and granularity.  Gate R15 is then applied to a CD42b vs 
CD16 plot (indicated by blue arrow) and gate R16 is set to include events expressing low levels of 
CD16.  A combination of gate R15 and not R16 is used to define the neutrophil population (a 
‘not’ gate is indicated by brown arrow).  Gate R17 incudes dual positive expression of both 
platelet CD42b and neutrophil CD16 markers and defines neutrophil-platelet aggregates. 
 
 
Figure 2-12: Gating strategy for detecting LPA in lysed whole blood 
Gate R20 defines lymphocytes by size and granularity.  Gate R20 is then applied to a CD42b vs ss 
plot (indicated by blue arrow).  Gate R21 includes events which have the same granularity as the 
lymphocyte population but are positive for the expression of platelet specific CD42b this defines 
a lymphocyte-platelet aggregate. 
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2.3.3 Determining the level of platelet specific CD42b present on monocytes and neutrophils 
following treatment of whole blood with a platelet agonist 
It was important to establish the MFI of the CD42b being expressed in each leukocyte 
subpopulation region.  This will suggest whether the increase in leukocyte-platelet aggregate 
formation is likely to be due to leukocytes binding to platelets, or leukocytes adhering to platelet 
derived microvesicles (PMV).  Summit version 4.3 was used to analyse the flow cytometry data 
acquired.  The same gating strategy was used for analysing data from each experiment.  
Untreated platelets (0 minute) were defined by size and granularity.  A gate was set to include 
95% of the total platelets expressing CD42b, this was defined as the ‘platelet’ gate (gate R9 
Figure 2-13D).  A gate was set to include the remaining events this was defined as the 
‘microvesicle’ gate (gate R10 Figure 2-13D). 
Monocytes were defined using the same gating strategy as before (Figure 2-10 and 
Figure 2-14).  To find the CD42b MFI on the CD14+CD16- monocyte population gate R4 (Figure 2-
14) can now be applied to CD42b histogram with the ‘platelet’ and ‘microvesicle’ gates (Figure 2-
14).  (These gates were previously defined in figure 2-13.)  An increase in events in gate R11 
suggests microvesicle accumulation by the CD14+CD16- monocyte subpopulation, whereas 
events, which occur in gate R12 suggest platelet adhesion to this monocyte subpopulation 
(Figure 2-14).  For the CD14+CD16+ monocyte subset (gate R5 Figure 2-14) can now be applied to 
the CD42b histogram.  An increase in events in gate R13 suggest microvesicle accumulation by 
the CD14+CD16+ monocyte subpopulation, whereas events in gate R14 suggest platelet adhesion 
to this monocyte subpopulation (Figure 2-14).  The MFI and percentage events in these gates 
can be recorded for each subpopulation at each time point.  The neutrophil population (defined 
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Figure 2-13: Gating Strategy for Defining ‘Platelet’ and ‘PMV’ Gates 
A) Gate R8 defines platelets by size and granularity.  B) Gate R8 is applied to a CD42b histogram 
(indicated by the blue arrow) gate R9 is set to include 100% of the platelet peak.  C) Shows the 
gate moved (indicated by the green arrow) and set to include 95% of the events shown in the 
original platelet peak.  D) shows gate R9 which can now be defined as the platelet gate (95% 




































Figure 2-14: Gating strategy for comparing CD42b MFI in the platelet and PMV gates, for 
monocyte subsets, following treatment with a platelet agonist  
 
Gate R1 defines monocytes by size and granularity (some CD14+CD16+ monocytes can be found 
in the lymphocyte region).  Gate R2 defines monocytes by their expression of CD14 and 
granularity, this gate is then applied to a CD14 vs CD16 plot (indicated by the blue arrow).  Gate 
R3 removes events expressing low levels of CD14 and CD16.  A combination of gate R1 and R2 
and not R3 is used to define the monocyte population (a brown arrow is used to indicate a ‘not’ 
gate).  Monocytes can be further divided into two subpopulations ~90% CD14+CD16- (gate R4) 
and ~10% CD14+CD16+ (gate R5).  Gate R4 can then be applied to a CD42b histogram to show 
CD42b expression in CD14+CD16- monocyte gate.  An increase in CD42b MFI in gate R11 suggests 
platelet microvesicle accumulation by CD14+CD16- monocytes.  An increase in CD42b MFI in gate 
R12 suggests platelet adhesion to CD14+C16-monocytes.  Gate R5 can be applied to a CD42b 
histogram, increases in CD42b MFI in R13 will suggest CD14+CD16+ monocytes accumulating 
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Figure 2-15: Gating strategy for comparing CD42b MFI in the platelet and PMV gates, for 
neutrophils, following Treatment with a Platelet Agonist 
Gate R15 defines neutrophils by size and granularity.  Gate R15 is then applied to a CD42b vs 
CD16 plot (indicated by blue arrow) and gate R16 is set to include events expressing low levels of 
CD16.  A combination of gate R15 and not R16 is used to define the neutrophil population (a 
‘not’ gate is indicated by brown arrow).  Gate R16 can then be applied to a CD42b histogram to 
show CD42b expression in the neutrophil gate.  An increase in CD42b MFI in gate R18 suggests 
platelet microvesicle accumulation by neutrophils.  An increase in CD42b MFI in gate R19 




2.3.4 Five minute time course with calf thymus histones to assess the effects on leukocyte-
platelet aggregate formation 
Samples were processed as previously described except, samples were incubated for 
between 5s, and 5 minutes at 37°C on a roller mixer following treatment with 1mg/ml calf 
thymus histones (CTH).  For controls a sample was fixed shortly after phlebotomy and an 
untreated sample was incubated for 5 minutes.  Samples were analysed as previously described. 
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2.3.5 Titration of calf thymus histones and histone H4 to assess the effects on leukocyte-
platelet aggregate formation 
Whole blood samples from healthy volunteers, collected into 10% (v/v) CPDA were 
incubated for 30 mins at 37°C on a roller mixer with 0.25, 1, 5, 10, 25 100, and 1000µg/ml CTH.  
Or 1, 5, 10, 25, 100µg/ml recombinant histone H4 (New England Bio Labs).  Untreated blood 
(control) was also incubated for 30 minutes or fixed immediately after phlebotomy.  Samples 
were then processed and analysed as described previously. 
2.3.6 Identifying leukocyte-platelet aggregates based on P-Selectin expression 
Whole blood samples from healthy volunteers, collected into 10% (v/v) CPDA were 
incubated for 30 mins at 37°C on a roller mixer, either untreated or with 30µM ADP, 100µM 
TRAP or 1µg/ml CRP-XL.  As a control a sample was fixed shortly after phlebotomy (0 minute).  
However, the master mix of antibodies added on this occasion included PE labelled CD14 
antibody, PE-Cy7 labelled CD16, APC labelled CD42b (GPIb) and FITC labelled mouse anti-human 
P-selectin antibody (Table 2-2).  An isotype control was prepared at the relevant concentrations 
(Table 2-2).  Samples were processed as described previously.  On this occasion analysis also 
included leukocyte-platelet aggregate expression based on P-selectin expression, which used a 
similar gating strategy to those described in figure 2-12, 2-13 and 2-15, except flow cytometry 
plots showed (P-selectin instead of CD42b) P-selectin vs CD14, P-selectin vs CD16 and P-selectin 
vs side scatter for determining CD14+CD16- MPA, CD14+CD16+ MPA/NPA and LPA respectively.  
FITC IgG for each leukocyte is shown in Figure 2-16 (APC IgG is used at the same concentration as 
previously-figure 2-9). 
 




Figure 2-16: FITC-IgG isotype control 
Whole blood was fixed with 1% (w/v) FA and incubated with CD14 (PE), CD16 (PEcy7) and FITC 
IgG for 30 minutes before red blood cells were lysed.  Leukocytes were suspended in PBS and 
data were acquired using flow cytometry.  Gating is set using 0 minute time point.  There is little 
to no, non specific binding of FITC Isotype to A) CD14+CD16- monocyte subset, B) CD14+CD16+ 
monocyte subset, C) neutrophils or D) lymphocytes. 
 
2.3.7 Surface PSGL-1 expression by leukocyte subsets   
Whole blood samples from healthy volunteers, collected in 10% (v/v) CPDA were 
aliquoted into 300µl volumes and incubated for 30 mins at 37°C on a roller mixer either 
untreated or with, 100µM TRAP or 1µg/ml CRP-XL.  As a control a sample was fixed shortly after 
phlebotomy (0 minute).  Samples were processed as described previously.  However on this 
occasion each sample was split in two and a different master mix of antibodies was added to 
each; 1) APC labelled CD14, FITC labelled CD16 and PE labelled PSGL-1 (Table 2-2). 2) PerCP 
labelled CD3, PEcy7 labelled CD20 and PE labelled PSGL-1 (Table 2-2).  Data was acquired using a 
Dako Cyan flow cytometer, a total of 2x104 events were collected in the monocyte gate, 
lymphocyte gate or neutrophil gate based on the size and granularity of the cells.  Summit 
version 4.3 was used to analyse the flow cytometry data acquired.  The same gating strategy was 
used for analysing data from each experiment (Figure 2-18-2-20).  Isotype control for each 
leukocyte subset is shown in figure 2-17. 




Figure 2-17: PE IgG isotype for each leukocyte subset 
Whole blood was fixed with 1% (w/v) FA and incubated with; A),B) and C) CD14 (APC), CD16 
(PECy7) and PE IgG or D) and E) CD3 (PerCP) CD20 (PECy7) and PE IgG for 30 minutes before red 
blood cells were lysed.  Leukocytes were suspended in PBS and data were acquired using flow 
cytometry.  Gating is set using 0 minute time point.  There is little (<2%) to no, non specific 
binding of PE IgG Isotype to A) CD14+CD16- monocyte subset, B) CD14+CD16+ monocyte subset, 
C) neutrophils, D) T- lymphocytes or E) B-lymphocytes. 
 




Figure 2-18: PSGL-1 expression on monocyte subsets 
Gate R1 defines monocytes by size and granularity (some CD14+CD16+ monocytes can be found 
in the lymphocyte region).  Gate R2, monocytes defined by CD14 expression and granularity.  
Gate R2 is then applied to a CD14 vs CD16 plot (indicated by blue arrow) and gate R3 is set to 
include events expressing low levels of CD14 and CD16.  A combination of gate R1 and R2 and 
not R3 is used to define the monocyte population (a ‘not’ gate is indicated by brown arrow).  
This can subsequently be split into two populations ~90% CD14+CD16- (gate R4) and ~10% 
CD14+CD16+ (gate R5).  Gate R4 is then applied to PSGL-1 vs CD14 plot the MFI of PSGL-1 and 
percent positive (gate R7) can be recorded.  Gate R5 is then applied to PSGL-1 vs CD16 plot, the 













Figure 2-19: PSGL-1 expression on neutrophils 
Gate R1 defines neutrophils by size and granularity.  Gate R2 is then applied to a CD16 vs 
granularity plot (indicated by blue arrow) and gate R2 is set to include events expressing high 
levels of CD16.  Gate R1 and R2 define the neutrophil population which can be applied to a PSGL-
1 vs CD16 plot.  The MFI of PSGL-1 and percentage of PSGL-1 positive neutrophils can be 





Figure 2-20: PSGL-1 expression on lymphocyte subsets 
Gate R1 defines lymphocytes by size and granularity.  Gate R2 is then applied to a CD3 positive T-
cells.  Gate R3 is set to include the CD20 positive B-cells.  Gate R2 can be set on PSGL-1 vs CD3 
and the MFI of PSGL-1 and percentage of PSGL-1 positive T-cells can be recorded (Gate R7). Gate 
R3 can be set on PSGL-1 vs CD20 and the MFI of PSGL-1 and percentage of PSGL-1 positive B-cells 
can be recorded (Gate R11). 
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2.3.8 Titration of P-selectin blocking antibody (G1) in whole blood 
2.5µg/ml, 5µg/ml, 10µg/ml and 20µg/ml of P-selectin blocking (Cat. No. 252-020 clone 
G1) antibody (Ancell, USA) was added to 0.3mls blood (collected into 10% v/v CPDA from healthy 
volunteers).  100µM TRAP was added and samples were incubated at 37°C for 30 minutes.  
Samples were washed in ice cold 1.7mg/ml EDTA in PBS (to prevent platelet -aggregates 
forming).  Samples were incubated at RT for 20 minutes in the dark, with 1/200 dilution of FITC 
labelled goat anti-mouse secondary antibody (DAKO cat. no. F0479).  Samples were fixed and 
incubated with APC labelled CD42b antibody for 30 minutes.  Red cells were lysed.  Data were 
acquired using Dako Cyan flow cytometer, Summit version 4.3 was used to analyse the data 
acquired.  A gate was set on the platelet population based on size and granularity.  A gate was 
then set to include all CD42b positive events (platelets) the percentage of the CD42b positive 
platelets expressing P-selectin was recorded and plotted (Figure 2-21).  ~95% of CD42b positive 
platelets were P-selectin positive.  We decided to use this concentration for blocking 
experiments. 























Figure 2-21: P-selectin blocking antibody (G1) titration 
P-selectin blocking antibody (G1) was titrated on platelets in whole blood.  Up to ~95% platelets 
based on size and granularity and CD42b expression have P-selectin antibody bound. 
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2.3.9 Leukocyte-platelet aggregate formation in the presence of P-Selectin blocking antibody 
20µg/ml of mouse anti-human P-selectin blocking antibody (G1) or the same 
concentration of unlabelled mouse IgG1 (eBiosience Cat. no. 14-4714-82, clone P3.6.2.8.1) was 
added to 300µL of whole blood (collected into 10% v/v CPDA from healthy volunteers).  Other 
aliquots were left untreated at this point. Following the addition of 30µM ADP, 100µM TRAP, 
1µg/ml CRP-XL, or 100µg/ml human recombinant H4 histone, samples were incubated for 30 
minutes at 37°C on a roller mixer.  An untreated control was fixed shortly after phlebotomy.  
Samples were then processed and leukocyte-platelet aggregates were analysed as described 
previously (Figure 2-10 - 2-12). 
2.4.0 Generating monocyte-microvesicle aggregates 
2.4.1 Isolation of platelet microvesicles. 
Platelets were isolated as described previously.  Platelets were suspended at a required 
concentration in 0.15% (w/v) PBSA.  2.5ml of each platelet suspension was incubated with 
platelet agonists at 37°C for 30 minutes.  Samples were split into 2 x 1.25ml aliquots and 
centrifuged at 2000g for 20 minutes and 13000g for 2 minutes. Supernatants were collected 
each time.  1ml was stored at -80°C (for further experiments).  The remaining 1ml was analysed 
using Nanosight LM10 version C (Nanosight Ltd) and Nanosight NTA version 2.2 software 
(Nanosight Ltd).  Nanosight software is able to track PMV and calculate the size distribution and 
concentration of the vesicles present (Figure 2-22).  To give an accurate measurement the 
Nanosight must track a minimum of 200 PMV.  So this could be achieved the minimum track 
length was set to 10.  This allowed 200 particles to be tracked and caused the least change in 
mean diameter and concentration/ml compered to auto settings (Figure 2-23)




Figure 2-22: Nanosight tracking 
Demonstrates Nanosight background settings to identify as many microvesicles as possible, with as little background detected as possible, the 
Nanosight tracks the particles, which allows the number and size of the microvesicles to be determined





























































Figure 2-23: Comparing selected track length for Nanosight analysis 
Microvesicles generated by incubating untreated platelets (8x108/ml) at 37°C for 30 minutes.  A) 
Demonstrates concentration of PMV detected by Nanosight.  B) shows the mean diameter 
detected by the Nanosight and C) shows the number of tracks detected by the Nanosight.  Over 
200 tracks need to be detected for Nanosight analysis to be considered accurate.  C) shows that 
less than 200 tracks are detected when the track length is left at auto, when the track length is 
set to 10 enough tracks are detected and A) and B) show the smallest change in the data 
compared to auto. 
 
2.4.2 Titration of number of platelets for generating microvesicles 
Platelets were isolated as previously described.  Platelets were suspended in 0.15% (w/v) 
PBSA (with Ca2+ and Mg2+) at concentrations of 2x108, 4x108, and 8x108 platelets/ml.  PMV were 
generated as described previously, using 100µM TRAP as the platelet agonist.  TRAP was chosen 
as it appeared to be the strongest agonist in the context of microvesicle generation in whole 
blood.  Data from the Nanosight analysis using 2x108 platelets/ml did not have a high enough 
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track number for an accurate PMV concentration to be determined.  However a higher 


















Figure 2-24: Increasing platelet number and the effect on PMV generation 
Microvesicles generated by incubating isolated washed platelets with 100µM TRAP for 30 




2.4.3 Comparing platelet agonists in their ability to cause microvesicle generation in washed 
isolated platelets 
Previous data suggested that a higher concentration of platelets lead to more PMV being 
generated.  We decided to use a concentration of 8x108 platelets/ml as this would enable us to 
generate the most microvesicles. Platelets were isolated as described previously.  Platelets were 
suspended in 0.15% (w/v) PBSA (with Ca2+ and Mg2+) at a concentration of 8x108 platelets/ml.  
PMV were generated as previously described using either 100µM TRAP, 1µg/ml CRP-XL, or 10µM 
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U46619 as platelet agonists.  10µM U46619 and 1µg/ml CRP-XL were used in combination to see 
if stimulating platelets through two different pathways lead to an increase in the number of 
platelet microvesicles. 
2.4.4 Monocyte isolation 
Blood from healthy volunteers was collected into EDTA.  MACS buffer 2mM EDTA, 0.5% 
BSA in PBS was prepared.  2.5mls of Histopaque 1077 (Sigma) was layered on top of 2.5mls 
Histopaque 1119 (Sigma) in a 10ml tube the reconstituted blood was layered on top, this was 
centrifuged at 1000g for 40 minutes.  The histopaque creates a density gradient so that when 
the blood is centrifuged the RBC (which are heaviest) will collect at the bottom of the tube, the 
leukocytes will also be separated into two bands.  Polymorphic nuclear cells (PMN), the heavier 
cells, form a band above the red blood cells and the lighter cells which form a band higher up the 
density gradient which contains peripheral blood mononuclear cells (PBMC).  The cells in the top 
band were collected and suspended in 10 ml MACS buffer.  Cells were centrifuged at 200g for 6 
minutes at RT (this would allow PBMC cells to pellet but not platelets.)  This wash step was 
repeated.  PBMC were then suspended in 1ml of ice cold MACS buffer and washed at 200g at 4°C 
for 6 minutes. 
PMBC were suspended in MACS buffer at a concentration of 108/ml in a total volume of 
100µL, containing 20µL of CD14+ beads (MACS Miltenyi).  This was incubated on ice for 20 
minutes.  The wash volume was increased to 1ml with ice cold MACS buffer and PBMC were 
centrifuged at 500g for 6 minutes at 4°C.  PBMC were suspended in 500µL of MACS buffer and 
put through a prewashed (MACS buffer) MS column (MACS Miltenyi), which is contained within 
a magnet.  The column was washed three times with 500µL of MACS buffer each time.  The 
monocytes will be attached to the CD14+ magnetic beads and remain in the column, the 
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lymphocytes (and any remaining contaminating platelets) will be washed out of the column.  
Column was removed from the magnet and flushed with 1ml MACS buffer to isolate monocytes 
with >95% purity.  Monocytes were suspended in 1ml ice cold MACS buffer and centrifuged at 
500g for 6 minutes.  Monocytes were suspended at desired concentration in 0.15% (w/v) PBSA. 
2.4.5 Generating monocyte-PMV aggregates 
Platelet microvesicles (from healthy volunteers) were generated as previously described.  
Monocytes (from healthy volunteers) were isolated as previously described.  1ml of PMV (in 
0.15% w/v PBSA) were defrosted at RT after storage in -80°C.  1x106 monocytes were suspended 
in 0.15% w/v PBSA (control) or 1ml of platelet microvesicles, samples were incubated at 37°C for 
30 minutes on a roller mixer.  Remaining monocytes were fixed for unstained control and single 
staining to calibrate the flow cytometer.  At the end of the incubation period samples were fixed.  
The following antibodies were added; PE labelled CD14 antibody, FITC labelled CD16, APC 
labelled CD42b from a previously prepared master mix (Table 2-2).  Of the immediately fixed 
aliquots one was left unstained, another was used to prepare an isotype (Table 2-2).  Samples 
were incubated for 30 minutes on ice.  At the end of the incubation period samples were washed 
twice in 0.15% (w/v) PBSA at 500g for 5 minutes.  Each sample was suspended in 300μl of PBS 
ready for analysis.  Data were acquired using a Dako Cyan flow cytometer, a total of 2x104 events 
were collected in the monocyte gate based on the size and granularity of the cells.  Analysis was 
carried out as previously described.  Figure 2-25 demonstrates there is little to no, nonspecific 
binding of the Isotype controls to monocytes.  




Figure 2-25: Allophycocyanin IgG isotype with isolated monocytes 
Washed isolated monocytes were incubated with previously isolated platelet microvesicles for 
30 minutes at 37°C.  Samples were fixed and incubated with IgG isotype antibodies labelled with 
PE, FITC or APC.  A) monocytes defined by size and granularity, B) APC IgG, C)PE IgG and D) FITC 
IgG. 
 
2.4.6 New Nanosight prism 
The Nanosight prism was replaced due to the occurrence of unforeseen damage.  
However, the new prism appeared to have better resolution, which lead to an increase in the 
number of particles being tracked, and a higher concentration/ml being detected.  A sample 
from the same donor which had been stored at -80°C was analysed using the new Nanosight 
prism.  This was compared to data previously obtained from the old prism.  ~4x more particles 
could now be detected compared to previous data (Figure 2-26). 
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Figure 2-26: Differences between the new Nanosight prism and the old Nanosight prism 
Microvesicles generated by incubating 2.5ml isolated, washed platelets (8x108/ml) with 1µg/ml 
CRP-XL for 30 minutes at 37°C.  Each 1ml aliquot was measured using the Nanosight, with the old 
prism and the new.  An increase (~x4) in PMV can be detected with the new prism. 
 
2.4.7 APES coating microslides 
 A small piece of 1mm (diameter) tubing was attached to the end of a glass 
microslide (1mm x 50mm x 0.1mm W x L x D) this allowed it to be attached to the end of a 
pipette.  The microslide was filled with acetone (Fisher Scientific) which was then expelled.  This 
was done twice.  The microslide was filled with 1% (w/v) (3-aminopropyl)triethoxysilane (APES) 
(Sigma) in acetone and left for 10 minutes, before washing with 1% (w/v) APES and then 
acetone.  Microslides were filled with deonised water and then autoclaved. 
2.4.8 Flow assay protocol 
Previously prepared APES coated microslides were incubated with 100µg/ml human vWf 
(HTI) at 37°C for 2 hours.  At the end of the incubation period slides were incubated for a 
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minimum of 1 hour with 1% (w/v) BSA (for blocking) or for controls slides were incubated with 
1% (w/v) BSA at 37°C for a minimum of 1 hour.  In some experiments, slides were incubated with 
P-selectin blocking antibody (G1) or IgG control for 30 minutes immediately before use. 
The glass slide was connected to a Harvard syringe pump, which perfused wash or 
sample at a wall shear stress of 0.1Pa (Figure 2-27).  At the other end, the channel was 
connected to an electronic switching valve (Lee Products, Gerards Cross, UK), which allowed 
selection from two reservoirs containing sample; monocytes (in some instances 
monocyte/microvesicle) or wash 0.15% (w/v) PBSA (Figure 2-27).  Monocytes were perfused for 
a total of 3.5 minutes.  After 1 minute of initiating perfusion, digital images of the experiment 
were collected every 340ms over a 17s period, for 6 different fields of view on the slide (Figure 
2-27). 
The recordings were analysed with Image-Pro 5.0 software (Media Cybernetics).  Phase 
bright monocytes, which made interactions with vWf of at least 340ms in duration were classed 
as ‘rolling’.  Any phase bright monocytes, which were stationary throughout the duration of the 
17s recording, were classed as ‘adherent’ (Figure 2-28).  Both populations were counted and 
averaged for 6 fields of view and the percentage of rolling monocytes was calculated.  The 
number of adherent cells/mm2 was calculated using the calibrated microscope field dimensions, 
to find the surface area of the image of the vWf coated microslides and multiplying by the 
number of cells counted. 




Figure 2-27: Flow assay setup 
Flow assay was set up as above.  The vwf or BSA coated microslide (1mm x50mm x0.1mm, W x L 
x H) was within a temperature controlled heat box (37°C).  Wash buffer (0.15% w/v BSA) was 
placed in a syringe cut off (1) and sample in syringe cut off (2) both were connected to a two way 
valve.  The appropriate buffer or sample could be perfused by selecting using the two way valve.  
The outlet of the two way valve was connected to the microslide and the Harvard syringe pump 





Figure 2-28: Monocyte interacting with vWf coated slide 
Any phase bright monocytes (indicated by the red arrow), which made interactions with vWf for 













Digital capture and 
analysis
Microslide
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2.4.9 Monocyte adhesion to vWf coated slides   
Early experiments indicated that monocytes may be interacting with vWf coated slides.  
We therefore thought it important to test which flow rate gave minimal, but measurable, 
interactions.  Previously prepared APES coated microslides were incubated with 100µg/ml 
human vWf (HTI) at 37°C for 2 hours.  At the end of the incubation period slides were incubated 
for a minimum of 1 hour with 1% (w/v) BSA (for blocking). 
Monocytes were isolated (from healthy volunteers) as previously described and 
suspended at 1x106 cells/ml.  Using the Harvard syringe pump to control the flow rate 
monocytes were perfused at a wall shear stress of either 0.05Pa, 0.1Pa, 0.2Pa for a total of 3.5 
minutes.  0.1Pa was chosen for as a low level of measurable interactions between monocytes 
and vWf coated microslides were observed at this shear stress (Figure 2-29).  Data was acquired 
and analysed as stated previously.   
 
Figure 2-29:  Monocytes perfused over vWf coated microslides at different shear stresses 
Isolated monocytes (mixed subsets) incubated for 30 minutes at 37°C (in the absence of PMV) 
were perfused across 100μg/ml vWf substrate at wall shear stresses of 0.05Pa, 0.1Pa and 0.2Pa.  
A) There was a decrease in monocyte capture as shear stress increased.  B) ‘Rolling’ was defined 
as interaction with the substrate for at least 1 frame (340ms).  The majority (>95%) of monocytes 
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2.4.10 Monocyte-microvesicle aggregates adhesion to vwf coated microslides 
Monocyte-PMV aggregates were generated as previously described.  Immediately after 
the 30 minute incubation period samples were added to the appropriate reservoir.  During the 
30 minute incubation period vWf coated slides were simultaneously incubated with P-selectin 
blocking antibody (G1) 20µg/ml or IgG control antibody (eBioscience Cat. no. 14-4714-82, clone 
P3.6.2.8.1) at the same concentration.  Data were acquired and analysed as previously 
described. 
2.5.0 Western blot for detection of P-Selectin contamination of vWf 
An 8% separating gel was prepared (10ml); deionised Water 4.6ml; 1.5M TRIS (Sigma) pH 
8.8 2.5ml; 10% (w/v) SDS (Sigma) 100µl; acrylamide/bis (30%/0.8% w/v) (Geneflow) 2.7ml; 10% 
(w/v) APS (Sigma) 90µl and TEMED (Sigma) 10µl.  Once set, a stacking gel was prepared; 
deionised water 2.94ml; 0.5M TRIS HCL (Sigma) pH6.8 (1.25ml); 10% (w/v) SDS 50µl; 
acrylamide/bis (30%/0.8%); 10% (w/v) APS 50µl; and TEMED 10µl.  This was layered on top of 
the separating gel and allowed to set.  Two gels were prepared in parallel. 
Once set the gels were placed into an electrophoresis rig (Biorad) which was filled with 
25mM Tris base and 190mM glyceine (Geneflow), 0.1% SDS dissolved in deonised water.  2x 
Laemmli buffer was prepared; 20% (v/v) glycerol (Sigma), 10% (v/v) 2-mecaptoethanol (Sigma), 
4%(w/v) SDS, 0.004%(w/v) bromophenol blue (Sigma) and 125mM Tris base pH 6.8 (adjusted 
with HCL).  Samples containing 100µg recombinant human P-selectin (R&D systems) or 250µg 
human vWf were added to an equal volume of Laemmli buffer (40µL: 40µL) and heated to 70°C 
for 10 minutes.  Heating the sample in the presence of 2-mecaptoethanol will break disulphide 
bonds and denature the protein. 
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20µL of each sample was loaded on to the gel.  Ladder was added to one lane.  The gel 
was left to electrophorese at 200V for 45 minutes.  Gels were removed from the tank.  One gel 
was stained with coomassie blue (G250) for 1 hour at RT.  This was later left in destain  40% (v/v) 
methanol (Sigma), 10% (v/v) acetic acid (Sigma) in deoinised water, for 2 hours before being 
incubated with 25ml instant blue (expedion) for ~1 hour. 
The other gel was used for western blotting.  Polyvinylidene fluoride (PVDF) membrane 
(Immobilon) was soaked in methanol for 5s before rinsing in deoinised water for 2 minutes.  
Stacking gel was removed with a scalpel, before, gel, membrane, filter paper and sponges were 
equilibrated in pre chilled (4°C) transfer buffer for 15 minutes.  (Transfer buffer; 20% v/v 
methanol, 190mM glycine (Sigma) and 25mM TRIS base.)  The gel and membrane were 
assembled between filter paper and sponges.  The protein is negatively charged (due to the SDS) 
and will move towards the positive electrode, the membrane must be positioned towards the 
positive electrode to ensure proper transfer of bands.  Electrophorese was carried out at 4°C for 
1 hour at 100V. 
PBS-t was prepared; 0.1% (w/v) tween-20 (Sigma) in PBS.  The membrane was removed 
from the tank and incubated for 1 hour with 20% (w/v) powdered milk (marvel) dissolved in PBS-
t.  The membrane was washed three times with PBS-t.  The membrane was cut in half (each had 
identical amounts of protein and ladder) one was incubated with 0.1µg/ml sheep anti human P-
selectin antibody (R&D systems) in 5ml PBS-t, the other in 5ml PBS-t, at 4°C on a roller mixer.  
The following day membranes were washed in PBS-t for 10 minutes at RT and rinsed twice in 
PBS-t.  Membranes were then incubated with 20mls PBS-t containing 0.1µg/ml donkey anti-
sheep horseradish peroxidase (HRP) conjugated secondary antibody (Abcam) for 1 hour at RT. 
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Membranes were rinsed three times in PBS-t and then washed for 10 minutes in PBS-t.  
Following on from this, membranes were incubated with ECL detection mix (GE healthcare) for 5 
minutes at RT.  ECL is the susbstrate for HRP and allows for its detection on photographic film 
(Amersham).  Membranes were detected on photographic film following a 10s exposure. 
 
2.6.0 Statistics 
Data are expressed as mean ± standard deviation (SD) or standard error of the mean 
(SEM).  Data have been analysed using Prism software, using one or two-way ANOVA followed 




















3. Chapter 3- PLATELET ADHESION TO 
GLOMELULAR ENDOTHELIAL CELLS UNDER 
PROINFLAMMATORY CONDITIONS 
  




The kidneys have several functions, which include blood pressure regulation and 
retaining electrolyte balance.  However, the role they are best known for is within the urinary 
system, where they filter the blood to remove waste products and produce urine.  The main 
apparatus involved in filtration of the blood, the glomerulus, requires a specialised structure to 
be able to carry out this role (White, 2012). 
A specialised ball of capillaries forms the glomerular filter (White, 2012).  It consists of 
glomerular endothelial cells (GEnC) surrounded by epithelial cells, known as podocytes (White, 
2012).  Between these cells is a glomerular basement membrane (GBM), synthesised by both cell 
types.  Together these make up the glomerular filtration barrier (GFB) (St John and Abrahamson, 
2001).  The glomerulus is surrounded by the Bowman’s capsule (space), which collects the waste 
products, which pass through the GFB (Miner, 2011).  The waste, which eventually forms urine, 
then passes into the proximal convoluted tubule and towards the ureters and into the bladder, 
from where it is later excreted from the body (White, 2012). 
GEnCs are a specialised type of endothelial cell, which contain fenestrations, 60-80nm 
wide (Satchell, 2004).  These fenestrations are wide enough to allow water and waste products 
such as urea to pass through.  However, they are covered in a negatively charged glycocalyx, 
200-400nm thick, which helps to prevent large proteins passing through the vessel wall (Satchell, 
2004).  Specialised epithelial podocytes, wrap around the glomerular vessel, protruding foot like 
projections, which make contact with the GBM (Miner, 2011).  The spaces between these 
projections form slit diaphragms, which allow the passage of waste products into the Bowman’s 
capsule (Welsh and Saleem, 2010).  Podocytes are known to produce angiopoietin (ang1) and 
vascular endothelial growth factor (VEGF), (Satchell, 2004).  Glomerular endothelial cells express 
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the corresponding receptors for these agents, Tie2 and VEGFR2, suggesting that podocytes are 
able to regulate the functional phenotype of GEnCs.  When GEnC monolayers were treated with 
ang1 an increase in transepithelial electrical resistance (TEER) of up to 11.4Ωcm2 was observed 
(Satchell, 2004).  In vivo a reduction in permeability would prevent proteins passing across the 
GBM (Satchell, 2004).  This demonstrates evidence of cross talk between the two cell types. 
If damage occurs to the GFB then it may become ‘leaky’ allowing larger proteins to pass 
into the urine (Menon and Valentini, 2010).  Over time, the worsening damage will result in 
complete loss of function of the GFB so it is no longer able to filter the blood (White, 2012).  This 
will have severe effects on health and will lead to a patient needing kidney dialysis for the 
remainder of their life, unless a suitable kidney donor becomes available.  The glomerulus is a 
specialised microvascular capillary bed, which has a large volume of blood pass through it and 
the structure of the glomerulus makes it particularly vulnerable to inflammatory disease (White, 
2012; Passerini et al., 2004).  Inflammation of the glomerulus is known as glomerulonephritis, of 
which there are many causes.  It is thought that platelet adhesion to GEnC could have an 
important role early in disease development.  Mouse models have shown that platelets are 
recruited to GEnC after mice have been administered with anti-GBM antibody (Devi et al., 2010).  
P-selectin expressed by activated platelets has been shown to aid leukocyte recruitment in this 
model (Devi et al., 2010). 
Earlier work carried out by Tull et al., (2006) using a co-culture system, involving 
secretory phenotype SMC and HUVEC demonstrated that these SMC, associated with the 
inflammatory disease atherosclerosis, could prime EC to capture platelets.  SMC signalling 
through TGF-β leads to the release of vWf from EC, so it can be expressed on the surface of the 
EC and form a matrix.   Platelets are known to be able to bind to vWf through interactions firstly 
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with CD42b, allowing platelet capture from flow and platelet rolling.  Then upon platelet 
activation, through αIIbβ3 integrin firm adhesion can occur.  Platelets have also been shown to 
play an important role in leukocyte capture in this model (Kuckleburg et al., 2011).  This implies 
they may have an important role in early development of an inflammatory disease more 
generally.  The co-culture methods previously used to study the interaction between SMC and 
HUVEC, can be used to replicate the renal glomerular environment, as GEnC and podocytes can 
be co-cultured in the same way.  This would allow investigation into how the cells of the 
glomerulus interact during inflammatory episodes. 
The hypothesis for this project is that GEnC will capture platelets using a mechanism 
involving a vWf matrix forming on the cell surface.  Platelets adherent to GEnC will aid in 
leukocyte capture, through surface P-selectin expression.  Cross talk with podocytes will down 
regulate platelet adhesion and therefore leukocyte capture.  The aims for this study were to 
investigate: 
1) If cell line GEnC retained endothelial cell properties and markers  
2) If platelets can adhere to GEnC under proinflammatory conditions   
3) If antibodies against platelet receptors CD42b and αIIbβ3 inhibit platelet adhesion to 
GEnC  
4) If inhibiting platelet activation through ADP receptors depletes platelet adhesion to 
GEnC 
5) If GEnC are able to capture platelets under flow conditions 
6) If podocytes regulate platelet adhesion to GEnC. 




3.2.1 Immunocytochemistry to detect the presence of vWf 
Cell line GEnC, cell line podocytes or HUVEC were seeded in a chamber slide with 
between 1x104 and 4.8x104 cells/well, they were left overnight at 37°C.  GEnC were either 
untreated or treated with 100U TNFα and 10ng/ml TGFβ for 24 hours.  Cells were fixed with 
either (i) 2% (w/v) FA for 10min (for surface detection of vWF) or (ii) 2% (w/v) FA for 5 min 
followed by 1% (w/v) triton for 10mins.  This was followed by incubation with 2% (w/v) PBSA 
blocking solution for 30 minutes.  Then incubation with either FITC labelled, sheep antihuman 
vWf antibody or FITC labelled sheep IgG isotype control antibody in 2% (v/v) FCS, 1% (w/v) PBSA 
for 1 hour.  After, cells were treated with 1µg/ml Hoechst component trihydrochloride to stain 
the nucleus.  Images were taken using a fluorescent invert microscope (Olympus IX71) and 
Image Pro software.  For further details see methods section 2.1.1 and 2.1.4. 
3.2.2 Platelet adhesion to GEnC monolayers under static conditions 
A 24 well plate was coated with 1% (w/v) gelatine diluted using PBS.  GEnC were seeded 
at a concentration of 1x105 cells per well and left at 33°C until confluent.  They were then left at 
37°C overnight before 24 hour treatment with TNF (100U) or TGF (10ng/ml) in EGM2-MV media 
or both cytokines in combination (at the same concentrations).  Control wells had EGM2-MV 
media changed. 
Platelets were isolated and suspended at a concentration of 2x108/ml in theophylline 
buffer and stained with 5μg/ml calcein.  Platelets were washed twice before being suspended at 
a concentration of 2x108/ml in 20% (v/v) autologous platelet poor plasma 80%(v/v) M199 
(without phenol red) containing 0.15% (w/v) BSA.  Platelets were either left untreated or treated 
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with 10µM ADP.  300µL of platelet suspension containing 6x107 platelets were added to each 
well, GEnC were incubated for 1 hour at 37°C.  Cells were fixed by the addition of 1% (w/v) FA.  
Cells were washed and images were taken using fluorescent invert microscope (Olympus IX71).  
Analysis was carried out using Image Pro (Image Pro Express software) and graphpad prism 
version 5.0. For further details see methods 2.1.5-2.1.7. 
3.2.3 Flow cytometry for detection of GEnC cell markers  
Cell line podocytes were differentiated for one week at 37°C, and cell line GEnC batch 2 
were left at 37°C for five days to ensure complete removal of the temperature sensitive SV40LT 
virus.  These cells, along with primary HUVEC, were seeded into 24 well plates and grown to 
confluence.  For detection of ICAM-1 or PECAM-1 cells were treated with 100U TNFα for 4 hours.  
For detection of E-selectin cells were treated with 1000U TNFα for 4 hours.  For detection of 
internal vWf cells were left untreated. 
For ICAM-1 and PECAM-1 detection, cells were removed from the plate using 0.005g 
trypsin in 0.02% (w/v) EDTA and washed in ice cold 2% (w/v) PBSA.  Cells were incubated on ice 
with APC labelled ICAM-1 or PE-labelled PECAM-1 or relevant isotype controls for 40 minutes 
before fixing with 2% (w/v) FA.  For E-selectin detection, cells in a 24 well plate were incubated 
on ice with unlabelled anti human E-selectin for 30 minutes, wells were washed and cells were 
incubated with FITC labelled polyclonal goat anti-mouse antibody.  Following this incubation, 
cells were removed from the plate using cell dissociation buffer and transferred to flow 
cytometry tubes.  Cells were fixed using 2% (w/v) FA and washed in PBSA before data were 
acquired using flow cytometry. 
For detection of internal vWf, cells were removed from the plate using 0.005g trypsin in 
0.02% (w/v) EDTA and washed in PBS containing 5% (v/v) FCS.  Cells were suspended in 
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Invitrogen fix and perm medium A for 15 minutes in the dark.  Cells were then washed again, 
before being suspended in medium B, containing either FITC labelled vWf antibody or relevant 
isotype control.  After a 40 minute incubation, cells were washed in PBS containing 5% (v/v) FCS, 
suspended in PBS and data were acquired using flow cytometry.  For further details see methods 
section 2.1.8. 
3.3.0 Results 
3.3.1 Batch 1 cell line GEnC retain endothelial morphology 
Before assays studying platelet adhesion to GEnC could be carried out, it was important 
to confirm that GEnC (batch 1) expressed vWf, as previous data from our lab indicates that this is 
an important part of the mechanism involved in EC capture of platelets (Tull et al., 2006).  Figure 
3-1A, shows the characteristic string like appearance of vWf on the cell surface after 24 hour 
treatment, with 100U TNFα and 10ng/ml TGFβ.  Figure 3-1B, demonstrates total vWf expression 
of GEnC, including both the vWf present in Weibel Palade bodies; the GEnC internal stores, as 
well as the string like surface vWf.  Figure 3-1C and 3-1D confirm there is minimal nonspecific 
binding to either the surface or internal stores of vWf by an appropriate isotype control.  This 
demonstrates that cell line GEnC (batch 1) express vWf, confirming they are endothelial cells and 









Figure 3-1: Expression of endothelial cell marker vWF by batch 1 GEnC 
GEnC were cultured at 33°C until confluent monolayers formed, the cells were then incubated at 
37°C overnight to remove the temperature sensitive simian virus 40 large tumour antigen and 
prevent further growth.  For surface detection of vWf A) and C) GEnC were treated for 24 hours 
with 100U/ml TNFα and 10ng/ml TGFβ before fixing with 2% (w/v) formaldehyde.  For detection 
of total von Willebrand factor (vWf), B) and D) cells were left untreated before fixing with 2% 
(w/v) formaldehyde, followed by 1% (w/v) triton.  A) and B) have been incubated for 30 minutes 
with FITC labelled sheep anti-human vWf antibody, C) and D) with sheep anti-human Isotype 
control (green).  All have been treated with 0.1% (v/v) Hoescht nuclear stain (blue).  A) 
demonstrates the characteristic sting like surface expression of vWf associated with 
inflammation.  B) shows GEnC total vWf including both surface expressed and within internal 
stores (Weibel Palade bodies).  C) and D) confirm there is minimal nonspecific binding of isotype 
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3.3.2 Platelet adhesion to batch 1 GEnC in the presence of coagulation 
Calcein stained platelets can be detect using fluorescent microscopy.  This staining 
technique can be applied to detect platelet adhesion to confluent (unstained) GEnC monolayers.  
The size of the aggregates and the number of (individual) platelets or platelet aggregates 
adhering can also be determined.  No additional heparin was added to the final platelet 
suspension for experiments represented by figures 3-2 - 3-8, meaning that these experiments 
have been done in the presence of coagulation.  A significant increase in percentage platelet 
coverage (~12%) is observed after GEnC treatment with TNFα & TGFβ, but not with TGFβ alone 
(Figure 3-2, 3-3 and 3-4).  Treatment of platelets with ADP had no significant effect on 
percentage platelet coverage, for both untreated GEnC and TNFα and TGFβ treated GEnC (Figure 
3-4).  This data demonstrates that treatment of the endothelium is responsible for an increase in 
platelet adhesion, rather than platelet activation. 
As platelets may adhere to GEnC as individual platelets or platelet aggregates, in order to 
count the number of either of these adhering to the GEnC monolayer we have used the term 
‘particles’ throughout this chapter to describe this.  Neither GEnC treatment with TGFα, TNFα & 
TGFβ, or platelet treatment with ADP had a significant effect on the number of particles 
adhering to GEnC (Figure 3-5 and 3-6).  However, there is a significant increase in the size of the 
platelet aggregates forming after treatment with TNFα and TGFβ (~40µm) but not TGFβ alone 
(Figure 3-7).  There is also a significant increase in the size of the platelet aggregates forming 
after platelet treatment with ADP (Figure 3-8).  GEnC treatment and platelet treatment 
combined leads to aggregates ~100µm, together figure 3-5, 3-6, 3-7 and 3-8 indicate that the 
increase in percentage platelet coverage of GEnC is due to larger aggregates forming rather than 
an increase in the number of individual platelets.




Figure 3-2: Platelet adhesion to GEnC in the presence of fibrin deposition 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature sensitive simian virus 40 large tumour antigen and 
prevent further growth.  GEnC were then treated with 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  
GEnC were then incubated with washed, isolated platelets stained with 5µg/ml calcein (suspended in 20% v/v PPP, 80% v/v M199 medium), which 
were either untreated or treated with 10µM ADP, for 1 hr.  Cells were fixed with 1% (w/v) formaldehyde and washed three times with PBS before 
images were acquired with Olympus IX71 fluorescent invert microscope and image pro 6.3.  Figure 3-2 demonstrates an example of platelet adhesion 
to GEnC monolayers, A) untreated (control), B) TGFβ C) TNFα & TGFβ, D) untreated EC and ADP treated platelets and E) TNFα and TGFβ treated GEC 
and ADP treated platelets.  Scale bar represents 30µm. 
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Figure 3-3: The effects of TNFα and TGFβ on platelet adhesion to GEnC 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 
37°C.  GEnC were then incubated with washed, isolated, platelets (suspended in 20% v/v PPP, 
80% v/v M199 medium), which had been stained with 5μg/ml calcein, for 1 hr.  Cells were fixed 
with 1% (w/v) formaldehyde and washed three times with PBS before images were taken using 
Olympus IX71 fluorescent invert microscope.  Data were analysed using image pro-software.  
One way ANOVA (P<0.05) indicates that EC treatment has an effect on platelet adhesion.  There 
is a significant increase in platelet adhesion to GEnC following GEnC treatment with TNFα & 
TGFβ compared to untreated control.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 
respectively, post hoc test Dunnett’s.  Data are mean +/- SEM of 2-3 experiments. 
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Figure 3-4: The effects of ADP treatment of platelets on their adhesion to GEnC 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  GEnC 
were then incubated with washed, isolated platelets (suspended in 20% v/v PPP, 80% v/v M199 
medium), stained with 5µg/ml calcein, which, were either not activated or incubated with 10µM 
ADP for 1 hr.  Cells were then fixed with 1% (w/v) formaldehyde and washed three times with 
PBS, before images were taken using Olympus IX71 fluorescent invert microscope.  Data were 
analysed using image pro-software.  Two-way ANOVA indicates that GEnC treatment with TNFα 
& TGFβ has a significant effect on increasing percentage platelet coverage (P<0.05) post hoc test 
Bonferroni not significant.  However platelet treatment with ADP has no effect (ANOVA ns).  
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Figure 3-5: The effects of TNFα and TGFβ on the number of fluorescent particles detected on 
GEnC 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 
37°C.  GEnC were then incubated with washed, isolated, platelets (suspended in 20% v/v PPP, 
80% v/v M199 medium), stained with 5µg/ml calcein, for 1 hr.  Cells were fixed with 1% (w/v) 
formaldehyde and washed three times with PBS, before images were taken using Olympus IX71 
fluorescent invert microscope.  Data were analysed using image pro-software.  ANOVA (ns) 
indicates that GEnC treatment does not affect the number of platelets or platelet aggregates 
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Figure 3-6: The effects of ADP on the number of fluorescent particles detected on GEnC 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  GEnC 
were then incubated with washed, isolated platelets, (suspended in 20% v/v PPP, 80% v/v M199 
medium), stained with 5µg/ml calcein, which, were either not activated or incubated with 10µM 
ADP for 1 hr.  Cells were then fixed with 1% (w/v) formaldehyde and washed three times with 
PBS, before images were taken using Olympus IX71 fluorescent invert microscope.  Data were 
analysed using image pro-software.  Two-way ANOVA indicates that neither GEnC treatment 
with TNFα & TGFβ or platelet treatment with ADP has any effect on the number of adherent 
platelets or platelet aggregates (particles) to the GEnC monolayer (ANOVA ns).  Data are mean 
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Figure 3-7: The effects of TNFα and TGFβ on the size of fluorescent particles detected on GEnC 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 
37°C.  GEnC were then incubated with washed, isolated, platelets (suspended in 20% v/v PPP, 
80% v/v M199 medium), stained with 5µg/ml calcein, for 1 hr.  Cells were fixed with 1% (w/v) 
formaldehyde and washed three times with PBS, before images were taken using Olympus IX71 
fluorescent invert microscope.  Data were analysed using image pro-software.  ANOVA (P<0.01) 
confirms that GEnC treatment has a significant effect on the size of the platelet aggregates 
adhering.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, post hoc test 
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Figure 3-8: The effect of ADP treatment on the size of fluorescent particles detected on GEnC 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  GEnC 
were then incubated with washed, isolated platelets, (suspended in 20% v/v PPP, 80% v/v M199 
medium), stained with 5µg/ml calcein, which, were either not activated or incubated with 10µM 
ADP for 1 hr.  Cells were then fixed with 1% (w/v) formaldehyde and washed three times with 
PBS, before images were taken using Olympus IX71 fluorescent invert microscope.  Data were 
analysed using image pro-software.  Two-way ANOVA indicates that both GEnC treatment with 
TNFα & TGFβ (P<0.05) and platelet treatment with ADP (P<0.05) has an effect on the size of the 
platelet aggregates adhering to the GEnC monolayer.  However, both treatments act 
independently to each other (ANOVA ns).  *,** and *** indicate P<0.05, P<0.01 and P<0.001 
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3.3.3 Platelet adhesion to batch 1 GEnC in the absence of fibrin  
To inhibit the fibrin deposition 5U/ml of heparin was added to the final platelet 
suspension.  This allowed the assay to be repeated when coagulation was inhibited (Figure 3-9).  
Percentage platelet coverage of GEnC monolayers was significantly increased (~2%) after GEnC 
treatment with TNFα and TGFβ (Figure 3-10).  There was no significant increase detected 
following treatment of GEnC with either of these cytokines alone (Figure 3-10 and 3-11).  A 
combination of GEnC cytokine treatment and platelet treatment with ADP led to a further 
increase in the percentage platelet coverage (~10%), (Figure 3-10).  In this instance, platelet 
treatment with ADP was able to significantly increase percentage platelet coverage of untreated 
GEnC monolayers, demonstrating that platelet activation alone could have an effect (Figure 3-
11). 
The number of adherent particles on GEnC monolayers was significantly increased after 
GEnC treatment with TNFα and TGFβ (Figure 3-12 and 3-13).  However, platelet treatment with 
ADP had no effect on the overall numbers of adherent particles (Figure 3-13).  The size of the 
platelet aggregates which formed was significantly increased, after cytokine treatment of GEnC 
or after platelet treatment with ADP (Figure 3-14 and 3-15).  Together, this data indicates that 
GEnC treatment with TNFα and TGFβ increases both the number of platelets adhering and the 
overall size of the aggregates which form, but platelet treatment with ADP only affects the size 
of the aggregates which form (Figure 3-12, 3-13, 3-14 and 3-15).




Figure 3-9: Platelet adhesion to GEnC when coagulation is inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature sensitive simian virus 40 large tumour antigen and 
prevent further growth.  GEnC were then treated with 100U/ml TNFα, 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left untreated 
overnight at 37°C.  GEnC were then incubated with washed, isolated platelets stained with 5µg/ml calcein (suspended in 20% v/v PPP, 80% v/v M199 
medium), which were either untreated or treated with 10µM ADP, for 1 hr.  Cells were fixed with 1% (w/v) formaldehyde and washed three times 
with PBS before images were taken using Olympus IX71 fluorescent invert microscope.  Figure demonstrates an example of platelet adhesion to GEnC 
monolayers, A) untreated (control), B) TNFα, C) TGFβ D) TNFα & TGFβ, E) untreated EC and ADP treated platelets and F) TNFα and TGFβ treated GEC 
and ADP treated platelets.  Scale bar represents 30µm.
A B C
D E F
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Figure 3-10: The effect of TNFα and TGFβ on platelet adhesion to GEnC when coagulation is 
inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with 100U/ml TNFα, 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left 
untreated overnight at 37°C.  GEnC were then incubated with washed, isolated platelets 
(suspended in 20% v/v PPP, 80% v/v M199 medium), stained with 5µg/ml calcein, for 1 hr.  Cells 
were fixed with 1% (w/v) formaldehyde and washed three times with PBS before images were 
taken using Olympus IX71 fluorescent invert microscope.  Data were analysed using image pro-
software.  One way ANOVA (P<0.01) indicates that EC treatment has an effect on platelet 
adhesion.  There is a significant increase in platelet adhesion to GEnC following GEnC treatment 
with TNFα & TGFβ compared to untreated control.  *,** and *** indicate P<0.05, P<0.01 and 
P<0.001 respectively, post hoc test Dunnett’s.  Data are mean +/- SEM of 5 experiments. 
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Figure 3-11: The effect of ADP treatment of platelets on their adhesion to GEnC when 
coagulation is inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  GEnC 
were then incubated with washed, isolated platelets, (suspended in 20% v/v PPP, 80% v/v M199 
medium), stained with 5µg/ml calcein, which, were either not activated or incubated with 10µM 
ADP for 1 hr.  Cells were then fixed with 1% (w/v) formaldehyde and washed three times with 
PBS before images were taken using Olympus IX71 fluorescent invert microscope.  Data were 
analysed using image pro-software.  Two-way ANOVA (P<0.05) indicates that both GEnC 
treatment with TNFα & TGFβ and platelet treatment with ADP has a significant effect on 
increasing percentage platelet coverage.  However ANOVA (ns) indicates that these two 
treatments show no interaction with each other.  Bonferroni indicates there is a significant 
increase in percentage platelet coverage after GEnC treatment with TNFα and TGFβ or after 
platelet treatment with ADP.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, 
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Figure 3-12: The effect of TNFα and TGFβ on the number of fluorescent particles detected on 
GEnC when coagulation is inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with 100U/ml TNFα, 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left 
untreated overnight at 37°C.  GEnC were then incubated with washed, isolated, platelets, 
(suspended in 20% v/v PPP, 80% v/v M199 medium), stained with 5µg/ml calcein, for 1 hr.  Cells 
were fixed with 1% (w/v) formaldehyde and washed three times with PBS before images were 
taken using Olympus IX71 fluorescent invert microscope.  Data were analysed using image pro-
software.  ANOVA (P<0.01) indicates that GEnC treatment significantly increases the number of 
particles adhering.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, post hoc test 
Dunnett’s.  Data are mean +/- SEM of 5 experiments. 
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Figure 3-13: The effect of platelet treatment with ADP on the number of fluorescent particles 
detected on GEnC when coagulation is inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  GEnC 
were then incubated with washed, isolated platelets, (suspended in 20% v/v PPP, 80% v/v M199 
medium), stained with 5µg/ml calcein, which, were either not activated or incubated with 10µM 
ADP for 1 hr.  Cells were then fixed with 1% (w/v) formaldehyde and washed three times with 
PBS before images were taken using Olympus IX71 fluorescent invert microscope.  Data was 
analysed using image pro-software.  Two-way ANOVA (P<0.05) indicates that GEnC treatment 
with TNFα & TGFβ causes a significant increase in the number of adherent platelets or platelet 
aggregates (particles) adhering to the GEnC monolayer (post hoc test Bonferroni not significant).  
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Figure 3-14: The effect of TNFα and TGFβ on the size of fluorescent particles detected on GEnC 
when coagulation is inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with 100U/ml TNFα, 10ng/ml TGFβ, both 100U/ml TNFα and 10ng/ml TGβ or left 
untreated overnight at 37°C.  GEnC were then incubated with washed, isolated, platelets 
(suspended in 20% v/v PPP, 80% v/v M199 medium), stained with 5µg/ml calcein, for 1 hr.  Cells 
were fixed with 1% (w/v) formaldehyde and washed three times with PBS before images were 
taken using Olympus IX71 fluorescent invert microscope.  Data were analysed using image pro-
software.  ANOVA (P<0.01) confirms that GEnC treatment has a significant effect on the size of 
the platelet aggregates adhering.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 
respectively, post hoc test Dunnett’s.  Data are mean +/- SEM of 5 experiments. 
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Figure 3-15: The Effect of ADP treatment on size of fluorescent particles detected on GEnC 
when coagulation is inhibited 
Confluent monolayers of GEnC were incubated at 37°C overnight to remove the temperature 
sensitive simian virus 40 large tumour antigen and prevent further growth.  GEnC were then 
treated with both 100U/ml TNFα and 10ng/ml TGβ or left untreated overnight at 37°C.  GEnC 
were then incubated with washed, isolated platelets (suspended in 20% v/v PPP, 80% v/v M199 
medium), stained with 5µg/ml calcein, which, were either not activated or incubated with 10µM 
ADP for 1 hr.  Cells were then fixed with 1% (w/v) formaldehyde and washed three times with 
PBS before images were taken using Olympus IX71 fluorescent invert microscope.  Data were 
analysed using image pro-software.  Two-way ANOVA indicates that both GEnC treatment with 
TNFα & TGFβ (P<0.05) and platelet treatment with ADP (P<0.05) has any effect on the size of the 
platelet aggregates adhering to the GEnC monolayer.  However both treatments act 
independently to each other (ANOVA ns).  Bonferroni indicates a significant increase in size of 
platelet aggregates adhering to GEnC monolayers after GEnC treatment with TNFβ and TGFβ or 
platelet treatment with ADP.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, 
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3.3.4 Characterising the phenotype of batch 2 cell line GEnC  
Our collaborators in Bristol who produced the cell line GEnC, do not recommend its use 
after passage 41 (P41) as it has not been proven to retain endothelial cell properties past this 
point.  Therefore, to continue the study earlier passage GEnC were required.  When culturing cell 
line GEnC (batch 2) there appeared to be a change in the phenotype of these cells, they lost their 
classic cobblestone appearance and began to appear longer and thinner (Figure 3-16).  This 
prompted tests for EC markers.  Primary HUVEC, cell line GEnC batch 2 and cell line podocytes all 
expressed surface ICAM-1 in response to 4 hour treatment with TNFα (Table 3-1). 
The epithelial podocytes cell line did not express PECAM-1 (change in MFI compared to 
isotype 0.62 which is negligible), (Table 3-2).  GEnC (batch 2) however, did express this marker 
(change in MFI compared to isotype ~80.69) but at lower levels than HUVEC (change in MFI 
compared to isotype ~245) (Table 3-2).  Table 3-3 demonstrates that the epithelial cell line 
podocytes did not express E-selectin in response to treatment with 1000U TNFα.  However, and 
surprisingly, cell line GEnC (batch 2) did not express E-selectin either (Table 3-3).  HUVEC 
expressed high levels of E-selectin in response to 1000U TNFα (Table 3-3).  Moreover, Table 3-4 
clearly demonstrates that cell line GEnC (batch 2) and podocytes did not express vWf (either on 
the surface or internal stores), (Table 3-4).  However, HUVEC express high total levels of vWf 
(change in MFI ~256 compared to the isotype control), (Table 3-4). 
 
3.3.5 Immunocytochemistry to detect vWf in batch 2 cell line GEnC  
To further confirm the flow cytometry data which demonstrated there was no vWf 
expression by the GEnC cell line (batch 2) and to check that podocytes were indeed negative for 
this marker, we used immunocytochemistry.  Figure 3-17 clearly demonstrates that both cell line 
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GEnC (batch 2) and cell line podocytes do not express any internal or surface vWf.  However, in 
accordance with the flow cytometry data HUVEC again demonstrated express high levels of 
internal and surface vWf expression (Figure 3-17).  There is no nonspecific binding of the isotype 
control to any of the cell types (Figure 3-17).  
3.3.6 Primary GEnC do not express vWf 
A possible short term solution to the problem of obtaining GEnC, which was suitable for 
use in platelet adhesion assay experiments, was using primary GEnC.  As human tissue is not 
readily available, this had to be bought from an external source, making it too expensive to make 
it a viable source to continue the project long term.  However figure 3-18 demonstrates that 
primary GEnC (HRGEC) were unable to form a proper monolayer.  Figure 3-19C demonstrates 
that cell line GEnC expressed high levels of both internal and surface vWf.  Primary GEnC 
(HRGEC) may have expressed very low levels of vWf, although as classic punctate staining of the 
Weible Palade bodies can’t be detected, the small amount of staining observed may be due to 
nonspecific binding of the vWf antibody to these particular cells (Figure 3-19A).  Figure 3-19C 
and D show primary GEnC (HRGEC) and cell line GEnC (batch 1) do not bind sheep anti-human 
isotype control.  The little to no vWf expressed by primary GEnC (HRGEC) meant that we were 
unable to use them for platelet adhesion assays as vWf is an important part of the mechanism 
for platelet capture by EC.




Figure 3-16: Batch 2 cell line GEnC morphology 
A) GEnC cell line (batch 2) below P41, grown at 33°C and 5% CO2.  The cells have not yet reached confluence but they are irregular shapes and sizes.  
They don’t display classic cobble stone appearance.  B) shows GEnC cell line (batch 2) after 24hrs at 37°C and 5% CO2.  Some of the cells appear to 
have lost contact inhibition and have grown over each other.  Other cells have started to die.  This destroys the monolayer, so it is no longer suitable 
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 Isotype MFI ICAM-1 MFI      Change in MFI 
HUVEC 14.48 857.70 843.22 
Podocytes 10.85 360.46 349.61 
GEnC 7.29 498.93 491.64 
 
Table 3-1: Surface ICAM-1 expression by HUVEC, podocytes and GEnC 
Confluent monolayers of each cell type primary HUVEC, podocyte cell line and GEnC cell line 
(batch 2) were cultured in 24 well plates.  One well of each was treated with 100U TNFα for 4 
hours before being removed from plates and incubated with APC labelled ICAM-1 or relevant 
isotype control on ice.  Data were acquired using flow cytometry.  A gate was set to contain 5% 
of the isotype control and the MFI for ICAM-1 was recorded in this gate.  Table 3-1 demonstrates 
that all three cell types express ICAM-1.  HUVEC express the highest levels and podocytes the 




 Isotype MFI PECAM-1 MFI Change in MFI 
HUVEC 16.14 260.43 244.29 
Podocytes 16.73 17.35 0.62 
GEnC 28.76 109.45 80.69 
 
Table 3-2: Surface PECAM-1 Expression by HUVEC and GEnC but not podocytes 
Confluent monolayers of each cell type primary HUVEC, podocyte cell line and GEnC cell line 
(batch 2) were cultured in 24 well plates.  One well of each was treated with 100U TNFα for 4 
hours before being removed from plates and incubated with PE labelled PECAM-1 or relevant 
isotype control on ice.  Data were acquired using flow cytometry.  A gate was set to contain 5% 
of the isotype control and the MFI for PECAM-1 was recorded in this gate.  Table 3-1 
demonstrates that HUVEC and GEnC express PECAM-1, with HUVEC expressing the highest 
levels.  Podocytes do not express this marker.  Data are MFI from one experiment. 
 
 
Chapter 3-                                            Platelet adhesion to GEnC under proinflammatory conditions  
130 
 
 Isotype MFI E-selectin MFI Change in MFI 
HUVEC 12.99 209.69 196.7 
Podocytes 19.33 15.57 -3.76 
GEnC 20.78 20.78 0 
 
Table 3-3: Surface E-selectin expression by HUVEC but not podocytes or GEnC 
Confluent monolayers of each cell type primary HUVEC, podocyte cell line and GEnC cell line 
(batch 2) were cultured in 24 well plates.  One well of each was treated with 1000U TNFα for 4 
hours before incubation with unlabelled mouse anti-human E-selectin antibody or relevant 
isotype control for 30 minutes in the dark, followed by incubation with FITC-labelled polyclonal 
goat anti-mouse secondary antibody.  Cells were removed from the plate.  Data were acquired 
using flow cytometry.  Data suggests that only HUVEC express surface E-selectin after treatment 
with TNFα.  Data are MFI from one experiment. 
 
 Isotype MFI vWf MFI Change in MFI 
HUVEC 13.97 270.01 256.04 
Podocytes 13.97 17.35 3.38 
GEnC 24.98 24.98 0 
 
Table 3-4: Total vWf expression by HUVEC, podocytes and GEnC 
Confluent monolayers of each cell type HUVEC, podocyte cell line and GEnC cell line (batch 2) 
were cultured in 24 well plates.  Cells were removed from plates and incubated with Invitrogen 
fix and perm kit (according to the manufacturers instructions).  Cells were then incubated with 
FITC labelled vWf antibody or relevant isotype control.  Data were acquired using flow 
cytometry.  HUVEC express vWf, podocytes may express very low levels but GEnC do not express 
any.  Data are MFI from one experiment. 
   




Figure 3-17: Immunocytochemistry for detection of vWf on Batch 2 GEnC 
Cell line GEnC (batch 2) and cell line podocytes were cultured at 33°C until confluent monolayers formed, the cells were then incubated at 37°C 
overnight to remove the temperature sensitive simian virus 40 large tumour antigen and prevent further growth.  (Primary) HUVEC have been grown 
to confluence at 37°C.  Cells were fixed with 2% (w/v) formaldehyde, followed by 1% (w/v) triton.  A) B) and C) have been incubated for 30 minutes 
with FITC labelled sheep anti-human vWf antibody, D) E) and F) with sheep anti-human Isotype control (green).  All have been treated with 0.1% (v/v) 
Hoescht nuclear stain (blue).  A) Podocyte cell line do not express vWf D) there is no nonspecific binding of relevant isotype control to cell line 
podocytes.  B) shows cell line GEnC (batch 2) do not express vWf and E) demonstrates there is no nonspecific binding of relevant isotype control to 
GEnC cell line (batch 2) C) shows total von Willebrand factor expression by HUVEC, (F) HUVEC does not bind isotype control.  Scale bar represents 
50µm.




Figure 3-18: Primary GEnC (HRGEC) morphology  
Passage 1 primary GEnC (HRGEC) a monolayer has not formed.  There are places where the cells 
have lost contact inhibition and are growing over each other and spaces where the cells have 








Figure 3-19: Immunocytochemistry for detection of vWf in primary GEnC 
Cell line GEnC (batch 1) and were cultured at 33°C, the cells were then incubated at 37°C 
overnight to remove the temperature sensitive simian virus 40 large tumour antigen and prevent 
further growth.  Primary GEnC (HRGEC) were cultured at 37°C.  Cells were fixed with 2% (w/v) 
formaldehyde, followed by 1% (w/v) triton.  A) and B) have been incubated for 30 minutes with 
FITC labelled sheep anti-human vWf antibody, C) and D) with sheep anti-human Isotype control 
(green).  All have been treated with 0.1% (v/v) Hoescht nuclear stain (blue).  A) total von 
Willebrand factor expression primary GEnC, (C) primary GEnC isotype control C) total von 
Willebrand factor expression by cell line GEnC (batch 1).  D) Cell line GEnC isotype control 











Here, immortalized Cell line GEnC were chosen instead of primary GEnC as human kidney 
tissue is not readily available and could not be used as a reliable source.  Cell line GEnC and cell 
line podocytes were created by transducing primary cells with a temperature sensitive simian 
virus 40 large tumour antigen (SV40LT) and telomerase using retroviral vectors (Saleem et al., 
2002; Satchell et al., 2006).  When they are incubated at 33°C (5% CO2) they proliferate and 
should have a cobble stone appearance forming a confluent monolayer, they can also be sub-
cultured (Saleem et al., 2002; Satchell et al., 2006).  However, at 37°C SV40LT can be ‘switched 
off’ as the temperature sensitive virus is removed and the cells growth is arrested (Saleem et al., 
2002; Satchell et al., 2006). 
Under normal conditions EC produce NO, which, prevents platelet activation. This is 
through a mechanism which inhibits the release of platelet intracellular calcium, thus preventing 
the release of α and δ granule contents as well as conformational change occurring to αIIbβIII 
integrin (Gkaliagkousi et al., 2007).  However, upon activation EC reduce NO production.  For 
studying the effects of platelet adhesion to GEnC, monolayers of GEnC have been treated with 
the cytokines TNFα and TGFβ.   
In vivo TNFα is released from activated cells (such as macrophages) and it stimulates 
surrounding EC leading to the upregulation of inflammatory markers such as E-selectin, ICAM-1 
and PECAM-1, all key players in the leukocyte adhesion cascade (Ley et al., 2007).  TGFβ is 
thought to be released from secretory phenotype SMC, a phenotypic change associated with 
atherosclerosis (Tull et al., 2006).  TGFβ activates EC to release vWf to the surface, this enables 
EC to capture platelets, which in turn aid in leukocyte capture through the formation of P-
selectin bridges (Tull et al., 2006; Kuckleburg et al., 2011).  As previous evidence suggests that 
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vWf is crucial for platelet capture by EC, before any platelet adhesion assays were carried out we 
confirmed that the GEnC (batch 1) used in our experiments expressed vWf. 
The platelet adhesion assays were carried out in the presence of coagulation (more 
widely associated with venous thrombosis) and repeated when coagulation was inhibited by the 
addition of extra heparin.  There are two main coagulation pathways the extrinsic pathway and 
the contact activation pathway, these merge to form the common pathway and both result in 
fibrin deposition.  During inflammation, TNFα stimulates tissue factor (TF) expression on 
endothelial cells (Petäjä, 2011).  This starts the extrinsic pathway of the coagulation cascade in 
which serine proteases are converted from their zymogen form into their active form (Levi et al., 
2004).  The contact activation pathway is the lesser important of the two coagulation pathways, 
which is initiated following endothelial damage and exposure of collagen (Davie et al., 1991).  
This pathway should not play any role in these experiments where EC monolayers are intact.  
Thrombin, a well known and potent platelet activator, is produced as a by product of the 
coagulation cascade, which ultimately results in fibrin deposition (Coughlin, 2000).  Fibrin allows 
platelet crosslinking to occur through binding to αIIbβ3 integrin, resulting in stable clot formation 
(Levi et al., 2004). 
 Under static conditions where coagulation was able to occur, we have demonstrated 
that there is an increase in percentage platelet coverage of GEnC monolayers after GEnC 
treatment with TNFα and TGFβ, this is higher in the presence of coagulation (~12%), than in the 
presence of heparin (~2%).  Coagulation results in increased levels of fibrin being available, 
allowing platelets to aggregate more readily, increasing the size of the platelet aggregates 
forming and therefore increasing the platelet percentage coverage of GEnC.  In the presence of 
coagulation, activation of platelets with ADP did not significantly increase platelet adhesion to 
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GEnC.  This could be due to the effects of ADP being masked by the coagulation cascade and the 
presence of thrombin a more powerful platelet activator. 
Combined cytokine treatment results in the expression of vWf on the surface of the 
GEnC, allowing platelet adhesion to occur to these cells.  This adhesion is first supported by 
CD42b but this interaction will lead to transient increases in cytosolic Ca2+ levels, platelet 
activation and release of ADP from δ granules.  ADP is known to play a role in a positive feedback 
loop during platelet activation, encouraging platelet aggregates to form.  The data suggests 
there is no interaction between cytokine treatment of GEnC and ADP treatment of platelets 
when platelets adhere to GEnC under static conditions.  This is not surprising as these two 
treatments act through two different mechanisms in order to increase platelet adhesion. 
Data from this study clearly demonstrates that treatment of GEnC with either TNFα or 
TGFβ alone is not enough to significantly increase platelet adhesion to GEnC.  In line with this 
Tull et al, (2006) also found that cytokine treatment of EC (in this case HUVEC) with TNFα did not 
lead to an increase in platelet adhesion.  This is expected as TNFα increases E-selectin, PECAM-1 
and ICAM-2, which play important roles in leukocyte adhesion rather than platelet adhesion.  
However Tull et al, (2006) clearly demonstrated that TGFβ signalling alone was able to 
significantly increase platelet adhesion to EC through interactions with surface vWf. 
Primary GEnC  are known to express the serine/threonine kinase receptors TGFβR1 and 
TGFβR2, which form heterodimers in response to TGFβ binding, allowing TGFβ signalling to occur 
(Choi and Ballermann, 1995).  Podocytes are known to produce TGFβ in response to oxLDL or 
high glucose (Ding et al., 1997; Pavenstädt et al., 2003).  TGFβ signalling can lead to apoptosis in 
both cell types (Choi and Ballermann, 1995; Pavenstädt et al., 2003).  It has also been implicated 
in glomerosclerosis, leading to damage to the GFB (Soon Lee, 2013; Mozes et al., 1999).  This 
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implies a role for TGFβ signalling in disease and implies that cross-talk between EC and 
podocytes can occur through this signalling pathway.  However, it has not yet been 
demonstrated if TGFβ signalling in GEnC leads to the release of vWf from internal stores and its 
expression on the cell surface. 
The data from this study shows no significant increase in platelet adhesion after 
treatment with TGFβ alone, suggesting that in this case TGFβ signalling is not enough to cause 
the release of vWf from internal stores and expression on the surface.  However, had more GEnC 
(batch 1) been available it would have been interesting to confirm whether this was the case 
using immunocytochemistry to detect surface vWf.  It would also have been interesting to find 
out if treatment of primary GEnC with TGFβ was enough to significantly increase platelet 
adhesion (had a reliable source of primary GEnC been available).  It could be that cell line GEnC 
loose receptors over time or due to immortalisation and are less responsive than primary cells. 
Our collaborators at Bristol have  demonstrated that cell line GEnC retain primary GEnC 
properties until passage 41 (Satchell et al., 2006).  They should express endothelial cell markers 
such as E-selectin, PECAM-1 (CD31), ICAM-2 (CD102), VEGFR-2 and von Willebrand factor (vWf) 
(Satchell et al., 2006).  They do not recommend the use of GEnC past P41.  Unfortunately on 
completion of the first objectives, earlier passage GEnC were required.  On receiving new GEnC 
(batch 2) there was an obvious change in phenotype, these cells did not form the characteristic 
‘cobblestone’ EC monolayer.  Data in this study demonstrates that after 4 hour treatment of 
GEnC (batch 2) with TNFα these cells do not express high levels of PECAM-1, or any E-selectin.   
E-selectin expression on primary HUVEC has previously been shown to peak after 4 hour 
treatment with TNFα, which is why this time point was chosen (Rainger and Nash, 2001).  We 
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also demonstrate GEnC (batch 2) do not express any vWf.  This implies the loss of EC markers 
from these cells. 
The lack of vWf, a crucial part of the mechanism for platelet adhesion to EC in our model, 
makes them unsuitable for use in further experiments.  The use of this cell line therefore had to 
be discontinued.  Primary GEnC (HRGEC) were purchased to try to continue the study, however, 
due to expense this would not have been a viable long term plan.  Unfortunately these cells also 
failed to express vWf and were also not useful for these experiments. 
Conclusions 
We have demonstrated that GEnC monolayers treated with TNFα and TGFβ express a 
matrix of vWf on the surface.  We have also demonstrated that under static conditions, after 
treatment of GEnC with these cytokines platelet adhesion is significantly increased compared to 
the untreated control.  Platelet treatment with ADP further increased platelet adhesion to GEnC 
in the presence of heparin.  However, if coagulation was able to occur ADP had no effect, 


















4. Chapter 4- MONOCYTE-PLATELET AGGREGATE 
FORMATION IN RESPONSE TO TREATMENT WITH 
TRAP OR HISTONES 
  





Elevated levels of monocyte-platelet aggregates (MPA) have been detected in 
conjunction with several inflammatory diseases including, SLA, RA, DM, cerebrovascular 
ischemia, ischaemic stroke as well as atherosclerosis (Furman et al., 2001; Harding et al., 2004; 
Htun et al., 2006; Ishikawa et al., 2012; Joseph et al., 2001; Shantsila and Lip, 2009).  This 
indicates a potential role for MPA in inflammatory diseases.  Of particular interest to us is the 
possibility that MPA contribute to disease progression in atherosclerosis. 
There are several mechanisms through which leukocyte-platelet aggregate formation 
could play a role in disease progression.  The formation of these heterotypic aggregates allows 
for cross-talk to occur between the two cell types, forming a potentially important link between 
inflammation and thrombosis.  Platelet recruitment to dysfunctional endothelial cells is also 
thought to occur early in inflammatory diseases such as atherosclerosis (Ross, 1999).  Platelets 
adherent to dysfunctional EC both in vitro and in vivo have been demonstrated to aid in 
leukocyte recruitment.  Indeed, preferential recruitment of monocytes by adherent platelets was 
observed in some models (e.g. Kuckleburg et al., 2011).  This mechanism could have an 
important role in disease progression.  It is also possible that MPA, which form in the circulation 
could have an increased chance of recruitment to damaged or dysfunctional endothelial cells.  
Platelet activation has been shown to be important in MPA formation (Michelson et al., 
2001).  There are several routes through which platelets can become activated (Rivera et al., 
2009).  One important pathway which results in irreversible platelet activation is through PAR-1 
and PAR-4 signalling induced by thrombin.  PAR-1 is thought to be the most responsive of these 
receptors and therefore most important receptor at lower concentrations of thrombin (Kahn et 
al., 1999).  Thrombin is generated as part of the coagulation cascade, of which the end product, 




fibrin, has an important role in platelet crosslinking and clot formation (Coughlin, 2000).  Thus, 
thrombin generation is an example of crosstalk between coagulation and thrombosis (Coughlin, 
2000).  End stage atherosclerosis can result in plaque rupture, which triggers thrombus 
formation, leading to localised increase in thrombin (Coughlin, 2000; Libby, 2012; Ross, 1999).  
The clinical outcome may potentially be fatal for the patient as it can result in myocardial 
infarction (MI) or stoke (Ross, 1999).  However, patients who have survived have been shown to 
have increased levels of circulating MPA, following MI (Mickelson et al., 1996).  As platelet 
activation plays an important role in MPA formation, and as thrombin is known to be active in 
this phase of disease, it is not unreasonable to assume that the PAR-1 pathway plays some role 
in MPA formation. 
Histones are proteins which are used to package DNA into chromatin. There are four 
histones H2A, H2B, H3 and H4 which associate to form an octomer which DNA is able to wrap 
around (Peterson and Laniel, 2004).  Upon cellular death or severe damage histones will be 
released from the cell into the circulation or tissue fluids, where they are thought to have 
antimicrobial properties (Fuchs et al., 2011, 2010).  However, they are also known to be 
extremely damaging to surrounding host cells, with histone H3 and H4 being most damaging (Xu 
et al., 2009).  Both of these histones have been shown to activate platelets, with H4 being the 
most potent platelet activator (Semeraro et al., 2011).  It was first thought histones activated 
platelets through a charge based interaction.  However, it has now been demonstrated that 
histone H4 stimulates platelets, at least in part, through the TLR-2 and TLR-4 receptors (Fuchs et 
al., 2011; Semeraro et al., 2011).  Following MI which results in tissue necrosis, it is likely that 
histones will be released into the circulation where they may potentially activate platelets.  This 
suggests that histones may also have an important role in MPA formation. 




Activated platelets are known to shed platelet microvesicles (PMV) from their plasma 
membrane, which can be identified by positivity for platelet specific markers such as CD42b, 
CD41 and P-selectin (CD62P) (Hargett & Bauer 2013; Flaumenhaft et al. 2009).  Elevated levels of 
microvesicles have been identified in patients suffering from chronic inflammatory diseases such 
as atherosclerosis and following trauma (Beyer and Pisetsky, 2010).  PMV adhesion to isolated 
neutrophils, another leukocyte subset, has indeed been demonstrated to occur in vitro (Forlow 
et al., 2000).  It is therefore possible that PMV could also interact with monocytes in a similar 
manner.  We hypothesized that after treatment of whole blood with a platelet agonist, 
generation of PMV would occur and that these PMV, along with platelets, would have the ability 
to bind to monocytes and form MPA. 
It is also well known that monocytes are a heterogeneous cell type, of which there are 
two main subsets including the CD14+CD16- (90% population) and the CD14+CD16+ (10% 
population) (Shantsila et al., 2011).  Following MI in a mouse model, the healing myocardium has 
been shown to be dominated by different monocyte subsets during the repair process 
(Nahrendorf et al., 2007).  The more pro-inflammatory (equivalent CD14+CD16- monocyte 
subset) Ly6-Chi were shown to be recruited at high levels during the early response.  As 
recruitment of this subset decreased, Ly6-Clo (equivalent CD14+CD16+ monocyte subset) 
recruitment increased, this subset is able to produce inflammation resolving and growth repair 
signals (Nahrendorf et al., 2007).  It is possible that differences occur in the ability of these 
monocyte subsets to form heterotypic aggregates with platelets. 
Our aims for this chapter therefore were to determine; 




1) If activation of platelets in whole blood with TRAP or histones would lead to the 
formation of MPA and to specifically assess the level of CD42b accumulation by 
monocytes following this treatment. 
2) If platelet activation through these two different routes had any effect on the rate, or 
efficiency of MPA formation. 
3) If there was preferential binding of platelets to a subset of monocytes following 
treatment with either agonist. 
 
4.2.0 Methods 
4.2.1 MPA Formation in Whole Blood Following Treatment with TRAP, CTH or Human 
Recombinant Histone H4 
Briefly CPDA anti-coagulated whole blood (from a healthy volunteer) was gently stirred 
and incubated at 37°C for up to 1 hour, either untreated or with 100μM or 10μM thrombin 
receptor activating peptide (TRAP) a protease receptor 1 (PAR1) signalling peptide (SLFFRN), 
between 0.25-1mg/ml calf thymus histones (CTH) or between 1-100µg/ml human recombinant 
histone H4.  Analysis of MPA formation was determined using flow cytometry for the monocyte 
markers CD14, CD16 and the platelet marker CD42b (Figure 4.1).  Statistical analysis was carried 









4.3.1 The Effect of Platelet Activation through PAR-1 Signalling on MPA Formation in Whole 
Blood 
Our first aim was to determine if activation of platelets in whole blood could lead to MPA 
formation and specifically assess the CD42b accumulation by the monocyte population. We 
therefore used a high concentration of a well known and potent platelet agonist; TRAP.  This 
(SLFFRN) peptide version of TRAP causes platelet activation by signalling through PAR-1.  
Following treatment of stirred whole blood at 37°C with 100μM TRAP and measurement of 
aggregation by dual coloured flow cytometry, there was a significant increase in MPA formation 
for both CD14+CD16- and CD14+CD16+ monocyte subsets after 15 minute incubation compared 
to the 0 minute control (Figures 4-2A and B).  A maximum of ~70% CD14+CD16- monocytes were 
positive for the platelet marker CD42b after 60 minutes (Figures 4-2A).  Whereas ~55% of 
CD14+CD16+ subset were positive for CD42b at this time point (Figure 4-2B).  Figures 4-1A, B, 4-
2A and B, show no significant increase in monocyte associated platelet markers are detected in 
samples incubated and stirred at 37°C for up to 60 minutes, without the addition of TRAP.





Figure 4-1: MPA Formation in the Presence of 100µM TRAP 
Whole blood was fixed prior to treatment (0 minute) or incubated for up to 60 minutes at 37°C with or without 100µM TRAP.  Monocyte-platelet 
aggregates (MPA) were detected using flow cytometry with antibodies against the platelet marker CD42b and monocyte markers CD14 and CD16.  
The flow cytometry plots in A) show the increase in percentage MPA over time for the CD14+CD16- monocyte subset and B) CD14+16+ monocyte 
subset.  (Representative experiment from data set of 3).




























































































Figure 4-2: MPA formation in whole blood after addition of 100µM TRAP 
Whole blood incubated with or without the addition of 100μM TRAP, at 37°C and mixed.  The control (0) was fixed prior to any treatment.  Data were 
acquired using flow cytometry.  A significant increase in MPA formation after 15 minute incubation with TRAP was observed for A) the CD14+CD16- 
monocyte population and B) the CD14+CD16+ monocyte population.  Both monocyte subsets showed a significant increase in MPA formation over 
time (ANOVA P<0.001).  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, post hoc test Dunnett’s.  Data are mean +/- SEM of 3 
experiments.





4.3.2 Determining the level of CD42b accumulation by monocytes in response to platelet 
activation through PAR1  
Having measured the efficiency of MPA formation (as a percentage of positive 
monocytes) in response to addition of TRAP to whole blood, we wanted to determine the 
accumulation of CD42b by monocytes.  Figure 4-3 shows an example of the accumulation of 
platelet marker CD42b by the CD14+CD16- monocyte population, over time, following treatment 
with TRAP.  The increase in CD42b median fluorescent intensity (MFI) was surprisingly low, even 
at the 30 minute time point.  Indeed, compared to the mean MFI of whole platelets from the 
same experiment, which have been included in this plot, the MFI for CD42b on TRAP induced 
MPA did not approach that of a single activated platelet (Figure 4-3).  The effects of TRAP when 
visualised as a time course was even more surprising.  This analysis showed that over time 
monocytes were accumulating CD42b in quanta, which were lower than individual platelets, but 
cumulative over the duration of the experiment (Figure 4-4 and 4-5).  One possible explanation 
for this is that monocytes may be accumulating platelet derived microvesicles produced upon 
platelet activation, rather than binding whole platelets.  Notably, on the CD14+CD16+ (but not 
the CD14+CD16-) monocytes there was an indication that low levels of monocytes were 
associated with a single or multiple platelets (small peaks with an MFI ≈ that of single platelets 
were observed on this subset at early time points).  This response was transient and was lost 
after 15 minutes and was representative of rare interactions (Figure 4-5). 
To further investigate the level of CD42b accumulation by monocytes over time we 
developed a gating strategy that would show CD42b accumulation (MFI) by monocytes following 
treatment with platelet agonists (see Methods chapter 2.3.3 for details).  We termed the gate 
containing the low MFI the microvesicle gate and the gate containing high MFI the platelet gate.  





After treatment with 100µM TRAP the MFI of CD42b on the CD14+CD16- monocyte 
subset in the microvesicle gate increased over time reaching a maximum at 60 minutes (Figure 
4-4 and 4-6B).  The percentage of events in this gate also increased over time (Figure 4-6D).   
There was no change in MFI or percentage positive cells in the untreated controls (Figure 4-6 B 
and D).  The MFI shown in the platelet-monocyte gate never reached that of a resting platelet 
(Figure 4-6C).  Indeed, the increase in percentage events, which is detected over time is due to 
the tail of the low MFI peak drifting into this gate (Figure 4-6E).  There was no change in the MFI 
or percentage of events in any untreated samples (Figure 4-6C and E).  The data suggests that 
CD14+CD16- monocytes may possibly accumulate PMV in this instance.   
The formation of MPA on CD14+CD16+ monocytes was qualitatively different for the 
CD14+CD16- subset.  Here, after treatment with 100µM TRAP the MFI of CD42b in the 
microvesicle gate reached a maximum at 60 minutes (Figure 4-7B).  The percentage of events in 
the microvesicle gate also showed an increase over time (Figure 4-7D).  The MFI in the platelet 
gate was higher than that of a resting platelet between 5-15 minutes although the percentage of 
events in this gate remained low (Figure 4-7C and 4-7E).  This indicates that a small number of 
the CD14+CD16+ monocytes may be binding one or more whole platelets during this part of the 
time course.  There was no change in MFI or percentage events for any of the untreated controls 
(Figure 4-7B, C,D and E).






Figure 4-3: Flow cytometry overlay showing CD42b MFI of resting platelet and MPA formed after treatment with 100µM TRAP 
Whole blood was fixed prior to any treatment and the CD42b MFI of resting platelets was determined.  Whole blood was incubated at 37°C for 30 
minutes with 100µM TRAP.  Monocytes were identified by CD14, CD16 expression and CD42b MFI of monocyte-platelet aggregates was detected.  
















Figure 4-4: Flow cytometry overlay indicating CD42b expression on the CD14+CD16- monocyte population after treatment with 100µM TRAP 
Whole blood was incubated at 37°C for up to 60 minutes with 100µM TRAP.  Monocytes were identified by CD14, CD16 expression and CD42b on 
monocyte-platelet aggregates was detected.  The overlay demonstrates the CD42b on the CD14+CD16- monocyte subset increases over time but 
remains low.  (Data shows 1 representative experiment from 3).  
 






Figure 4-5: Flow cytometry overlay indicating CD42b expression on the CD14+CD16+ monocyte population after treatment with 100µM TRAP 
Whole blood was incubated at 37°C for up to 60 minutes with 100µM TRAP.  Monocytes were identified by CD14 and CD16 expression and CD42b on 
monocyte-platelet aggregates was detected.  The overlay demonstrates the CD42b on CD14+CD16+ monocytes increases over time but remains low.  
However, smaller peaks with a high MFI at 5mins, 10mins and 15mins were observed.  (Data shows 1 representative experiment from 3).






Figure 4-6: CD42b expression on the CD14+CD16- monocyte population after treatment with 
100µM TRAP 
Whole blood was incubated with or without the addition of 100μM TRAP at 37°C and mixed. 
Control (0) was fixed prior to any treatment.  Data were acquired using flow cytometry.  A) 
Demonstrates the gating strategy at the 5 minute time point.  B) and D) show an increase in the 
CD42b MFI and percent positive cells respectively, in the microvesicle gate, over time, for the 
CD14+CD16- monocyte population.  C) Shows the CD42b MFI in the platelet gate, E) 
demonstrates the increase in percent positive cells in the platelet gate over time.  Data are mean 
+/- SEM of 3 experiments. 


















































































































Figure 4-7: CD42b expression on the CD14+CD16+ monocyte population after treatment with 
100µM TRAP 
Whole blood was incubated with or without the addition of 100μM TRAP at 37°C and mixed.  
Control (0) was fixed prior to any treatment. Data were acquired using flow cytometry.  A) Shows 
the gating strategy at the 5 minute time point.  B) and D) show the increase in the CD42b MFI 
and percentage of positive events, respectively, in the microvesicle gate, over time, for the 
CD14+CD16+ monocyte subset.  C) Shows that a small number of CD14+CD16+ MPA have a CD42b 
MFI higher than that of a resting platelet following 5-15 minutes treatment.  E) Shows an 

























































































































4.3.3 The effect of a lower concentration of TRAP on MPA formation in whole blood 
Having demonstrated that activation of platelets in whole blood through the PAR-1 
pathway leads to an increase in MPA formation over time and that monocyte accumulation of 
CD42b is lower than that of a resting platelet in most instances.  We now wanted to find out if a 
lower concentration of PAR-1 agonist, TRAP (10μM) would have a similar effect.  A significant 
increase in MPA formation compared to 0 minute control was detected for both monocyte 
subsets after 10 minute incubation with TRAP (Figure 4-8 A and B). 
We now wanted to assess the accumulation of the platelet specific marker, CD42b, by 
both monocyte populations.  Firstly, the CD14+CD16- subset showed an increase in CD42b MFI in 
the microvesicle gate (Figure 4-9A).  This suggests potential accumulation of PMV over time.  At 
30-60 minutes the MFI reaches that of a resting platelet (Figure 4-9B).  However, this should be 
interpreted with caution as the MFI of a resting platelet is surprisingly low in this instance 
(Figure 4-9B). 
The CD14+CD16+ monocyte subset again shows an increase in CD42b MFI over time 
(Figure 4-10B).  Again, suggesting potential accumulation of PMV over time.  After 5-10 minute 
treatment with 10μM TRAP the CD42b MFI is far greater than that of a resting platelet indicating 
that at these early time points, platelets may in fact be adhering to monocytes (Figure 4-10B).  
The CD42b MFI remains close to that of a resting platelet throughout the time course.  However, 
the data should be interpreted with caution as the resting platelet MFI is low in this instance 
(Figure 4-10B).




























































































Figure 4-8: MPA formation in whole blood after addition of 10µM TRAP 
Whole blood was incubated with or without the addition of 10μM TRAP at 37°C and mixed.  Control (0) blood was fixed prior to any treatment.  Data 
were acquired using flow cytometry.  A significant increase in MPA formation after 10 minute incubation with TRAP compared to (0) control was 
demonstrated for A) the CD14+CD16- monocyte population and B) the CD14+CD16+ monocyte population.  Both monocyte subsets showed a 
significant increase in MPA formation over time (ANOVA P<0.001).  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, post hoc test 
Dunnett’s.  Data are mean +/- SEM of 4 experiments.
































































































Figure 4-9: CD42b expression on the CD14+CD16- monocyte population after treatment with 
10µM TRAP 
Whole blood was incubated with or without the addition of 10μM TRAP at 37°C and mixed.  
Control (0) was fixed prior to any treatment.  Data were acquired using flow cytometry.  A) 
Shows the increase in the CD42b MFI in the microvesicle gate for the CD14+CD16- monocyte 
population, over time.  B) Shows the CD42b MFI of the CD14+CD16- MPA is equal to that of a 
resting platelet following 30-60 minutes treatment with TRAP.  C) Shows a decrease in CD42b 
positive events in the microvesicle gate over time and D) shows an increase in the percent 
positive events in the platelet gate over time.  Data are mean +/- SEM of 4 experiments. 
 































































































Figure 4-10: CD42b expression on the CD14+CD16+ monocyte population after treatment with 
10µM TRAP 
Whole blood was incubated with or without the addition of 10μM TRAP at 37°C and mixed. 
Control (0) fixed prior to any treatment.  Data were acquired using flow cytometry.  A) Shows the 
increase in the CD42b MFI in the microvesicle gate for the CD14+CD16+ monocyte population 
over time.  B) Shows the CD42b MFI on the CD14+CD16+ monocyte population is higher than a 
resting platelet following 5-10 minute treatment and remains roughly equal to that of a resting 
platelet throughout the remainder of the time course.  C) Shows a decrease in percentage of 
CD42b positive events in the microvesicle gate over time and D) shows an increase in the 
















4.3.4 Determining the level of MPA formation in whole blood in response to treatment with 
calf thymus histones 
Having determined that MPA form in whole blood in response to platelet activation 
through a well known signalling pathway (PAR-1), we now wanted to find out if activating 
platelets using a very different signalling pathway would lead to an increase in MPA formation.  
It is thought that histones activate platelets through charge based interactions and through TLR-
2 and TLR-4 receptors (Semeraro et al., 2011), thus we used histones derived from calf thymus 
(CTH) to stimulate whole blood. 
After 60 minutes of incubation of whole blood with CTH no significant increase in MPA 
can be detected compared to the 0 minute control for the CD14+CD16- monocyte subset (Figure 
4-11A).  However, in contrast to this, a significant increase in MPA formation can be detected for 
the CD14+CD16+ subset as early in the time course as 5 minutes (Figure 4-11B).  This increase 
remains fairly constant, between 25-35% MPA formation throughout (Figure 4-11B).  Again, 
there is no significant increase in MPA in blood which has been incubated for up to 60 minutes, 
without the addition of any CTH (Figure 4-11A and B). 
We now wanted to assess the level of CD42b accumulation by monocytes following 
treatment with CTH.  Figure 4-12 demonstrates that there is no change in the platelet marker, 
CD42b MFI of the CD14+CD16- subset over time after treatment with CTH.  However, figure 4-13 
indicates that after treatment with CTH a separate CD42b positive peak can be detected 
between 5-60 minutes for the CD14+CD16+ subset.  Further analysis revealed that the CD42b MFI 
of this subset equalled the CD42b MFI of a resting platelet, after 10 minute treatment with CTH 
(Figure 4-14B).  The percentage of events appearing in this gate remains above 8% throughout 
the time course (Figure 4-14 D).  This suggests that the CD14+CD16+ monocyte subset are most 





likely binding platelets.  This time there is very little change in the CD42b MFI in the microvesicle 
gate and very little change in the percentage of the events occurring in this gate (Figure 4-14A 
and C).  This suggests that in this instance PMV adhesion to monocytes has very little, to no role 
in MPA formation upon platelet activation with CTH. 
4.3.5 MPA formation after five minute treatment with calf thymus histones 
After demonstrating that five minute (300s) treatment of whole blood incubated and 
stirred at 37°C with CTH leads to an almost maximum response in CD14+CD16+ monocyte-
platelet aggregate formation, we decided to further study the effect CTH had on MPA formation 
within five minutes.  Blood incubated for 300s without the addition of CTH showed no significant 
increase in MPA formation compared to 0 minute control, for both monocyte subsets (Figure 4-
15A and B).   
After 5s incubation with CTH (agonist added at room temperature and fixed after 5s) a 
significant increase can be seen compared to 0 minute control  for the CD14+CD16- monocyte 
subset (Figure 4-15A).  A significant increase can also be detected after 30s treatment with CTH 
for both monocyte subsets (Figure 4-15A and B).  This is the maximum response observed for 
both subsets. CD14+CD16- showed ~15% MPA formation and CD14+CD16+ ~50% MPA formation 
(Figure 4-15A and B).  A similar result to that observed in a previous time course was again seen 
after 300s (5 minutes) treatment with CTH, ~25% MPA formation for the CD14+CD16+ monocyte 
subset but no effect on the CD14+CD16- monocyte subset (Figure 4-11 A, B and 4-15A and B).   
Having demonstrated that MPA form (for both monocyte subsets) after 5-30s treatment 
with CTH, we wanted to determine the accumulation of CD42b by monocytes.  Figure 4-16A and 
C demonstrate an increase in the CD42b MFI and the percentage of events occurring in this gate 
after 5 and 30s treatment with CTH.  It could be that the CD14+CD16- monocyte subset may be 





accumulating platelet derived microvesicles at these early time points.  Figure 4-16 B and D 
suggests that it is unlikely that whole platelets are binding to this monocyte subset, as the MFI 
never reaches that of a resting platelet, despite the small increase in the percentage of events 
occurring in that gate after 5 and 30s.  In this instance a similar pattern is seen with the 
CD14+CD16+ monocyte subset (Figure 4-17A-D). 
4.3.6 Titration of CTH and the effect on MPA formation in whole blood 
After finding 30 minutes incubation with 1mg/ml CTH caused a significant increase in 
MPA formation for the CD14+CD16+ monocyte subset, which appeared to be mainly due to 
platelet adhesion, in this instance.  We now wanted to find out if a lower concentration of CTH 
could have a significant effect on heterotypic aggregate formation at this time point.  We could 
not detect significant increases in the formation of MPA at concentrations below 1mg/ml, for 
either subset of monocytes (Figure 4-18A and B).



























































































Figure 4-11: MPA formation in whole blood after addition of 1mg/ml CTH 
Whole blood was incubated with or without the addition of 1mg/ml CTH, at 37°C and mixed.  The control (0) was fixed prior to any treatment.  Data 
were acquired using flow cytometry.  A) No significant increase in MPA formation can be seen compared to 0 minute (untreated) control for the 
CD14+CD16- monocyte population.  B) A significant increase in MPA formation can be detected after 5 minute treatment with CTH for the 
CD14+CD16+ monocyte population.  Treatment of the CD14+CD16+ monocyte subset with CTH showed a significant effect on MPA formation over time 











Figure 4-12: Flow cytometry overlay indicating CD42b expression on the CD14+CD16- monocyte population after treatment with 1mg/ml CTH 
Whole blood was incubated at 37°C for up to 60 minutes with 1mg/ml CTH.  Monocytes were identified by CD14, CD16 expression and CD42b MFI on 
monocyte-platelet aggregates was detected using flow cytometry.  The overlay demonstrates the CD42b MFI on CD14+CD16- monocyte subset does 
not change over time.  (Data shows 1 representative experiment from 4). 
 






Figure 4-13: Flow cytometry overlay indicating CD42b expression on the CD14+CD16+ monocyte population after treatment with 1mg/ml CTH 
Whole blood was incubated at 37°C for up to 60 minutes with 1mg/ml CTH.  Monocytes were identified by CD14, CD16 expression and CD42b MFI on 
monocyte-platelet aggregates was detected using flow cytometry.  The overlay demonstrates the CD42b MFI on CD14+CD16+ monocyte subset is 
increased after treatment with CTH and remains the same throughout the time course.  (Data shows 1 representative experiment from 4). 
































































































Figure 4-14: CD42b expression on the CD14+CD16+ monocyte population after treatment with 
1mg/ml CTH  
Whole blood was incubated at 37°C with or without 1mg/ml CTH, control (0) fixed prior to 
treatment, data were acquired using flow cytometry.  A) and C) shows no change in the CD42b 
MFI or events occurring in the microvesicle gate, respectively, for the CD14+CD16+ monocyte 
population.  B) Shows the CD42b MFI is higher than a resting platelet following 10-60 minute 
treatment with CTH D) shows an increase in the percentage of events occurring in the platelet 
gate compared to untreated blood.





















































































Figure 4-15: MPA formation in whole blood after addition of 1mg/ml CTH 
Whole blood was incubated at 37°C with or without 1mg/ml CTH, control (0) fixed prior to treatment, MPA were detected using flow cytometry.  A) 
CD14+CD16- monocyte population and B) CD14+CD16+ monocyte population both show a significant change in MPA formation over time, ANOVA 
P<0.001 and ANOVA P<0.01, respectively.  (*,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, compared to 0 minute, blood fixed prior 
to any treatment, post hoc test Dunnett’s.)  Data are mean +/- SEM of 3 experiments.


































































































Figure 4-16: CD42b expression on CD14+CD16- monocyte population after treatment with CTH 
Whole blood was incubated at 37°C with or without 1mg/ml CTH.  Control (0) was fixed prior to 
treatment.  Data were acquired using flow cytometry.  A) and C) demonstrate a small increase in 
CD42b MFI and percent positive cells, respectively, in the microvesicle gate, after 5-30s 
treatment with CTH, for the CD14+CD16- monocytes.  B) Demonstrates that the MFI of 
CD14+CD16- MPA never reaches that of a resting platelet, D) demonstrates an increase in 
percent CD42b positive CD14+CD16- MPA in the platelet gate at 5s and 30s.  Data are mean +/- 
SEM of 3 experiments. 
 
 






























































































Figure 4-17: CD42b expression on CD14+CD16+ monocyte population after treatment with CTH 
Whole blood was incubated at 37°C with or without 1mg/ml CTH. Control (0) was fixed prior to 
treatment.  Data were acquired using flow cytometry.  A) indicates that the CD14+CD16+ MPA 
have a small increase in CD42b MFI in the microvesicle gate following 5-30s treatment with CTH, 
C) shows an increase in percent positive cells in this gate, at 5 and 30s time points.  B) Shows 
that the CD42b MFI of CD14+CD16+ MPA never reaches that of a resting platelet, although D) 
demonstrates a large increase in CD42b percent positive cells in this gate at 5s and 30s.  Data are 
mean +/- SEM of 3 experiments.  
















































































Figure 4-18: Titration of calf thymus histones and their effect on MPA formation 
Whole blood was incubated and stirred at 37°C for 30 minutes with varying concentrations of calf thymus histones.  The control (0) indicates 
untreated whole blood also incubated for 30 minutes.  Data were acquired using flow cytometry for monocyte markers CD14, CD16 and the platelet 
marker CD42b.  A) CD14+CD16- monocyte population, (ANOVA P<0.01) demonstrates a significant effect of increasing concentration of CTH on MPA 
formation.  B) CD14+CD16+ monocyte population, ANOVA (P<0.001) indicates a significant effect of increasing CTH concentration on MPA formation.  
(*,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, compared to 0μg/ml, post hoc test Dunnett’s.) Data are mean +/- SEM of 5-6 
experiments.





4.3.7 MPA formation after treatment with recombinant human histone H4 
Having demonstrated (using CTH) that histones are able to induce MPA formation in 
whole blood we decided to use a more biologically relevant version of histones for a human 
system, recombinant human histone H4.  H4 was chosen as it has been previously demonstrated 
to activate platelets (Semeraro et al., 2011).  Treatment with 100μg/ml H4 was shown to 
significantly increase percentage MPA formation for both monocyte subsets after 30 minutes 
compared to untreated controls (Figure 4-19 A and B).  There was no significant increase in MPA 
formation for either subset after treatment with a lower concentration of H4 (Figure 4-19A and 
B). 
After finding a significant increase in percentage MPA formation after treatment of 
whole blood with 100μg/ml H4 histones, we wanted to assess the CD42b accumulation by the 
monocyte subsets.  After treatment with 100μg/ml H4, figure 4-20 and 4-21 show that in this 
instance, MPA appear to have a CD42b MFI similar to that of a resting platelet.  Interestingly, we 
observed a similar pattern of response for the CD14+CD16+ monocyte subset and the 
CD14+CD16- monocytes.  This is of interest, as it indicates that there is a qualitative difference in 
the response of human cells to histones derived from different species. 



















































































Figure 4-19: Titration of recombinant histone H4 and its effect on MPA formation in whole blood 
Whole blood was incubated and stirred at 37°C for 30 minutes with between 1-100μg/ml human recombinant H4 histone.  The control (0μg/ml) also 
incubated for 30 minutes without the addition of any agonist. Data were acquired using flow cytometry.  A) Shows percentage MPA formation 
CD14+CD16- monocyte subset, ANOVA (P<0.01), indicates an increase in MPA formation in response to increasing H4 concentration.  B) Shows 
percentage MPA formation for the CD14+CD16+ monocyte subset, ANOVA (P<0.001), indicates an increase in MPA formation in response to increasing 
H4 concentration.  (*,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, compared to 0μg/ml, post hoc test Dunnett’s).  Data are mean +/- 
SEM of 4 experiments.




























































































Figure 4-20: CD42b expression on the CD14+CD16- monocyte population after treatment with 
human recombinant histone H4 
Whole blood was incubated and stirred at 37°C for 30 minutes with between 1-100μg/ml human 
recombinant H4 histone.  Control (0μg/ml) has been incubated for 30 minutes without the 
addition of any agonist.  Data were acquired using flow cytometry.  A) Shows a small increase in 
CD42b MFI in the microvesicle gate, after treatment with 100μg/ml H4.  While C) shows an 
increase in the percent of CD42b positive cells in this gate.  B) Demonstrates that the CD42b MFI 
of MPA formed after treatment with 100μg/ml H4 histones reaches that of a resting platelet.  D) 
Demonstrates a large increase in the percent CD42b positive cells in this gate after treatment 
with 100μg/ml H4.  Data are mean +/- SEM of 4 experiments. 
 
 





























































































Figure 4-21: CD42b expression on the CD14+CD16+ monocyte population after treatment with 
human recombinant histone H4 
Whole blood was incubated and stirred at 37°C for 30 minutes with between 1-100μg/ml human 
recombinant H4 histone. Control (0μg/ml) has been incubated for 30 minutes without the 
addition of any agonist.  Data were acquired using flow cytometry.  A) Shows a small increase in 
CD42b MFI in the microvesicle gate after treatment with 100μg/ml H4, C) also shows an increase 
in the CD42b positive cells in this gate.  B) Demonstrates that the CD42b MFI of MPA formed 
after treatment with 100μg/ml H4 histones reaches that of a resting platelet.  D) Demonstrates a 
large increase in percent CD42b positive in this gate after treatment with 100μg/ml H4.  Data are 















An interesting point of contention arises from our observations using unstimulated blood 
in regard to the true level of circulating monocytes that are positive for platelet markers.  Our 
own data from fixed whole blood (0 minute control- fixed within 10 minutes of venepuncture) 
showed on average that 4% of circulating monocytes were positive for the platelet marker 
CD42b.  This is in contrast to data from other laboratories, e.g. Passacquale et al, (2011).  These 
authors showed a baseline of ~25% monocytes forming aggregates with platelets in fixed 
untreated blood.  However, in the latter study the blood was not fixed immediately after 
phlebotomy, being incubated  with antibodies against CD14, CD16 and CD42b, followed by a 
period during which RBC were lysed before fixing (Passacquale et al., 2011).  Moreover, 
Passacquale used a less stringent gating strategy, than that currently adopted to identify 
monocyte populations during flow cytometry analysis.  These differences in sample processing 
and measurement could explain discrepancies between the data.  
However, it is important to highlight that these may not be the only confounding 
parameters when measuring the baseline levels MPA in healthy, circulating, whole blood.  Thus, 
we found that stirred, unstimulated whole blood samples (on a roller mixer) for up to 60 
minutes, at 37°C showed no significant increase in MPA formation compared to blood which had 
been rapidly fixed.  This data is important for 2 reasons.  Firstly, it shows that platelet activation 
is necessary, for a significant number of MPA to form under the conditions used in our 
experiments, under stringent conditions of stirring.  Secondly, it strongly indicates that 
monocyte-platelet interactions are readily formed in whole blood under static conditions (i.e. 
without shear).  However, these do not represent true levels of monocyte-platelet interaction, 
being an artefact of post phlebotomy treatment.  Interestingly, Harding et al, (2007), tested the 





effect of a time delay on monocyte-platelet aggregate formation in whole blood at room 
temperature.  They observed an average of ≈2% increase in MPA formation every 10 minutes in 
citrated whole blood samples.  Together, these data imply that caution is required in interpreting 
data on the levels of MPA formation in the circulation using anticoagulated whole blood to make 
measurements, as there is a propensity for platelets and monocytes to aggregate under static 
conditions, within minutes of blood withdrawal.  Importantly, these interactions may be labile, 
as imposition of shear forces disrupts this process. 
The anticoagulant itself can also have an effect on MPA formation, EDTA chelates 
calcium and inhibits platelet activation, this is not a sensible anticoagulant to use when studying 
MPA formation as its use will lead to a reduction in the numbers of MPA detected (Basavaraj et 
al., 2012).  However, there is an increase in MPA formation at baseline in whole blood collected 
in heparin compared to blood collected in citrate (Basavaraj et al., 2012).  This means that 
heparinised blood would have increased MPA formation as an artefact of the anticoagulant.  
Throughout this study, blood has been collected into CPDA to avoid increased or decreased MPA 
formation being detected as a result of the anticoagulant used. 
Our data clearly demonstrates that treatment of whole blood with a known platelet 
agonist, in this case TRAP or CTH, results in an increase in MPA formation over time.  This is in 
agreement with previous studies, which have also indicated that activation of platelets through 
the PAR1 pathway increases MPA formation in whole blood (Jensen et al., 2001; Xiao and 
Théroux, 2004).  In the current study a lower concentration of TRAP (10μM) was found to be just 
as effective as a higher one (100μM).  Previous aggregometry data using washed isolated 
platelets stimulated with 10μM TRAP has shown that maximal platelet activation can be 
achieved using this concentration of agonist (Stephens et al., 2005).  If maximal response to the 





platelet agonist is also achieved in whole blood, then it is likely that there will be no difference in 
MPA formation between these concentrations.   However, the data showed an increase in donor 
variability at lower concentrations of TRAP, with some donors clearly more responsive than 
others at these marginal concentrations.  Future work should determine the sensitivity of MPA 
formation to platelet agonists, as the concentrations used currently represent robust 
stimulation, and our data indicates that this may not be required to induce interactions between 
platelets and monocytes. 
It has been well documented that upon platelet activation CD42b positive platelet 
microvesicles are generated (Flaumenhaft et al., 2009; Hargett and Bauer, 2013).  Indeed, 
previous studies using activation of platelets through the PAR-1 pathway, resulted in robust 
microvesicle generation (Heijnen et al., 1999; Nygaard et al., 2014).  TRAP peptide has also 
previously been reported to increase microvesicle shedding in sheared (10,000S-1) samples of 
whole blood (Chow et al., 2000).  Our time course data demonstrate that monocytes accumulate 
CD42b in quanta that are significantly less than whole platelets, implying that monocytes could 
be accumulating PMV over time rather than binding to whole platelets.  Interestingly, most 
studies report MPA formation as the percentage increase in monocytes which become positive 
for platelet markers in response to platelet activation. Very few have determined the number of 
platelets adhering per monocyte, or have reported the MFI of flow cytometry experiments.  One 
exception is work by  Xiao and Théroux, (2004), who showed that blood from acute coronary 
syndrome (ACS) patients had a baseline of 45% MPA formation with 4 platelets adhering per 
monocyte, this was increased upon TRAP treatment to 95% MPA formation with 10 platelets 
adhering per monocyte.  (Unstimulated whole blood from healthy controls was shown to have 
15% MPA formation with 3 platelets adhering to each monocyte.)  This is in contrast to data 
from the current study, which suggests that PMV generated upon platelet activation, may 





adhere to monocytes, with whole platelets occasionally binding to CD14+CD16+ monocytes 
within the first 15 minutes of the time course.  However, the study by Xiao et al (2004) involves 
blood incubated under static conditions for 15 minutes before detection of MPA formed by a 
heterogeneous monocyte population using flow cytometry, with CD42a as a platelet marker.  
Static conditions could encourage whole platelet binding and we would interpret this study as 
measuring artifactual interactions between monocytes and platelets. Indeed, the concept that 
15% of monocytes in healthy individuals are circulating with on average 3 adherent platelets 
would seem to make little physiological sense.  
In this study we measured formation of MPA using CD42b as a platelet marker on 
monocytes.  Upon platelet activation with thrombin surface expression of CD42b has been 
shown to decrease (Hourdillé et al., 1992; Schmitz et al., 1998; Hourdillé et al., 1990).  CD42b is 
believed to be expressed on the platelet surface in lipid rafts, which upon activation become 
incorporated into the actin cytoskeleton (Hourdillé et al., 1990; Munday et al., 2010).  Other 
studies have indicated that this translocation may be reversible, although surface expression 
decreased after 10 minute treatment with thrombin, it was found to recover over time, peaking 
at 60 minutes (Michelson et al., 1994).  If a low concentration of thrombin was used to activate 
platelets (less than 0.1U/ml), CD42b surface expression was found to be fully recoverable 
however, at higher concentrations (2U/ml), only partially recoverable (Michelson et al., 1994).  
This may be indicative of shedding of the receptor on MV after activation, with lost molecules 
being replenished to some extent from internal stores.  Future studies of MPA formation in 
whole blood should optimise the use of other markers such as CD41 and/or P-selectin in 
conjunction with CD42b to determine, which is the most robust marker of MPA formation.  





In contrast to the data which suggests PMV adhere to monocytes, observed during a 60 
minute time course, following treatment with TRAP, further analysis of MPA formed after 
treatment with 1mg/ml CTH revealed that whole platelets were most likely binding to 
monocytes in response to this agonist.  Lower concentrations of this agonist were shown to have 
no significant effect on MPA formation.  Platelet adhesion occurred after 10 minute treatment 
with 1mg/ml CTH and continued throughout the 60 minute time course.  Specifically, platelets 
adhered only to the CD14+CD16+ monocyte subset and no effect was seen on the larger 
CD14+CD16- subset.  Although the behaviour after treatment with CTH is very different to that 
observed after treatment with TRAP, in both instances the adhesion of whole platelets only 
occurred on the CD14+CD16+ monocyte subset.  It is unclear as to why this should be, but this 
observation certainly merits further scrutiny. 
As an almost maximum amount of MPA could be detected after 5 minute treatment with 
CTH we felt it was important to look at earlier time points with this agonist.  There was some 
indication that at early time points (˂ 1 minute) very few cells accumulated low numbers of 
microvesicles in this assay, although whether these were generated by CTH stimulated platelets 
or represent the constitutive population of platelet marker positive microvesicles, ordinarily 
resident in the plasma is not known.  With respect to the binding of whole platelets, analysis 
suggested a biphasic response, with a very small number of monocytes rapidly (i.e. within 5-30s) 
binding platelets which were then shed.  This was then followed by a slower but more sustained 
accumulation of platelets by a more substantial proportion of monocytes (≈20%).  We did not 
ascertain whether very early and transient responses were evident after TRAP stimulation, but 
further work could include repeating this short time course with this agonist to find out if the 
levels of CD42b expression follow similar patterns. 





The data generated with CTH was interesting, especially as it highlighted a monocyte 
subset specific accumulation of platelets.  However, we felt it was important to use a more 
biologically relevant version of histones in human blood and opted to treat samples with 
recombinant human histone H4.  This has previously been shown to be the most potent histone 
in the context of platelet activation (Semeraro et al., 2011).  A titration revealed that this histone 
was effective at concentrations an order of magnitude lower than CTH, significantly increasing 
MPA formation.  Interestingly, a significant increase in MPA formation was detected for both 
monocyte subsets, implying that there is a differential response of platelets to bovine and 
human histones.  Further analysis revealed that this was likely to be due to whole platelet 
binding to monocytes.  The fact that H4 was effective at a lower concentration than CTH is not 
surprising, as H4 would only account for a small proportion of the CTH mixture, and as other 
histones have been shown to have minimal effects on platelet activation it is probably safe to 
assume that the H4 in CTH was largely responsible for the response to this agonist (Semeraro et 
al., 2011). 
Conclusions 
We have demonstrated that platelet activation is required for MPA formation.  Upon 
platelet activation through the PAR-1 signalling pathway there is a significant increase in MPA 
formation over time.  The data suggests that this could be due to PMV being generated upon 
platelet activation and subsequently adhering to monocytes.  In contrast to this, treatment with 
CTH leads to a significant increase in CD14+CD16+ monocytes forming MPA and this appears to 
be mainly due to platelet adhesion to this monocyte subset.  However, use of recombinant 
human histone H4 resulted in MPA formation for both monocyte subsets, which appeared to be 
mainly due to whole platelet adhesion to both monocyte subsets.









5. Chapter-5 MONOCYTE-PLATELET 
AGGREGATE FORMATION IN RESPONSE TO 
TREATMENT WITH OTHER PLATELET AGONISTS 
  




Formation of MPA has been reported to increase in patients with chronic inflammatory 
diseases, including those with atherosclerosis (Furman et al., 1998; Harding et al., 2007; Htun et 
al., 2006; Joseph et al., 2001; Shantsila et al., 2011).  An increase in platelet activation is often 
reported alongside these observations and it is thought to have an important role in MPA 
formation (Xiao and Théroux, 2004).  However, there are several signalling pathways through 
which platelet activation can occur (Rivera et al., 2009). 
These include platelet activation through glycoprotein VI (GPVI) (Nieswandt and Watson, 
2003).  If damage occurs to the endothelium, the subendothelial matrix will be exposed.  Unlike 
the endothelium, which works to prevent platelet activation (through NO production amongst 
other mechanisms), the subendothelial matrix contains collagen, a potent platelet activator 
(Rivera et al., 2009).  Localised platelet activation under these circumstances is necessary to 
prevent haemorrhage.  Under conditions of high shear stress platelets will be captured through 
weak interactions between platelet CD42b and vWf (Rivera et al., 2009).  These weak 
interactions will allow platelets to roll until platelet GPVI binds to collagen, which results in 
platelet activation and firm adhesion (Nieswandt and Watson, 2003).  Unstable atherosclerotic 
plaque rupture can lead to exposure of collagen and platelet activation through this mechanism 
(Libby, 2012).  However, upon activation platelets themselves will generate ADP and 
thromboxane, which further enhances platelet activation, in an autocrine or paracrine fashion 
through positive feedback loops (Rivera et al., 2009).  As MPA have been found at increased 
levels following atherosclerotic plaque rupture, (Sarma, 2002) this suggests a potential role for 
platelet activation by collagen, ADP and thromboxane. 
Chapter-5                               MPA formation in response to treatment with other platelet agonists 
181 
 
Oxidised LDL plays a significant role in the development of atherosclerosis.  It is thought 
to be a potential platelet activator acting through LOX-1 or CD36, scavenger receptors expressed 
on the platelet cell surface (Chen et al., 2001; Korporaal et al., 2007).  Upon plaque rupture there 
is also a chance platelets could come into contact with oxLDL, and low levels of oxLDL have been 
measured in the circulation of patients with atherosclerosis 
Podoplanin is the only known endogenous ligand for platelet CLEC-2 (Hughes et al., 
2010).  Podoplanin is expressed by kidney podocytes, lung type I alveolar cells and lymphatic 
endothelial cells (Hughes et al., 2010).  Activation through this receptor can also occur upon 
binding of rhodocytin, produced by the Malayan pit viper, Calloselasma rhodostoma.  Now a 
commonly used agent for activating platelets through this signalling pathway (Suzuki-Inoue et 
al., 2006).  To our knowledge the effect of platelet activation through the CLEC-2 pathway on 
MPA formation has not yet been investigated. 
Platelet activation often leads to PMV generation and it has been suggested that the 
resulting PMV are able to interact with monocytes (Beyer and Pisetsky, 2010; Mause et al., 
2005).  Formation of MPA (or indeed monocyte-microvesicle aggregates) could have important 
implications for disease progression as this would provide a mechanism for cross talk between 
inflammation and thrombosis.  Previous data has also suggested increased recruitment of MPA 
to EC (Kuckleburg et al., 2011).  This could potentially occur through either leukocyte 
recruitment to selectins or through platelet recruitment to vWf.  Data from the previous chapter 
has demonstrated that differences occur in the ability of MPA to form upon the route of platelet 
activation, we therefore believed it was necessary to screen more agonists. 
Our aims for this chapter therefore were to determine; 
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1) If the route of platelet activation had any effect on the rate, or total percentage 
increase in MPA formation. 
2) To assess the accumulation of the platelet specific marker CD42b, by monocytes over 
time. 
3) If there was any difference in the ability of monocyte subsets to form MPA or if there 
were any differences in the levels of CD42b accumulated by each subset over time. 
5.2.0 Methods 
5.2.1 MPA formation in whole blood following treatment with platelet agonist reagents 
Briefly CPDA anti-coagulated whole blood was gently stirred and incubated at 37°C with 
platelet agonists including 10µM and 3µM thromboxane mimetic U46619, 100nM and 30nM 
rhodocytin, 30µM and 3µMADP, 1µg/ml collagen related peptide (cross linked form) CRP-XL, 
1mg/ml calf thymus histones or 50µg/ml oxLDL.  Analysis of MPA formation was determined 
using flow cytometry for the monocyte markers CD14, CD16 and the platelet marker CD42b.  
Statistical analysis was carried out using Graph Pad Prism version 5.0.  (For further detail see 











5.3.1 The effect of platelet activation through different signalling pathways on MPA formation 
in whole blood 
We wished to determine if the route of platelet activation causes any difference in the 
rate, or extent of heterotypic aggregate formation.  To do this whole blood was incubated and 
stirred with a range of platelet agonists including thromboxane mimetic U46619, snake venom 
toxin rhodocytin, ADP, CRP-XL as well as oxLDL. 
Differences between agonists were indeed observed.  Thus, dealing with the CD14+CD16- 
monocyte subset first; we observed a difference in the dynamics of MPA formation, with ADP 
inducing significant MPA formation within 15 minutes (Table 5-1).  However, by 30 minutes all of 
the agents that delivered an increase in MPA formation had done so, with the exception of 
oxLDL (Table 5-1).  Using the 60 minute time point as an exemplar, most agonists delivered MPA 
with ≈ 40% efficiency (Table 5-1).  Rhodocytin however, appeared the more potent of the 
agonists delivering MPAs with an efficiency of ≈ 70% (Table 5-1).  MPA formation with the 
CD14+CD16+ subset of monocytes showed broadly similar patterns (Table 5-2). 





Table 5-1: MPA formation for the CD14+CD16- monocyte subset after treatment with various platelet agonists 
Table 5-1 shows the mean percentage monocyte-platelet aggregate formation (CD14+CD16- monocyte subset), in stirred whole blood, incubated at 
37°C in response to different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  *,** and 
*** indicate P<0.05, P<0.01 and P<0.001 respectively post hoc test (Dunnett’s) following a One-way ANOVA.  (Data are mean +/- SEM; ADP 4-7 






Table 5-2: MPA formation for the CD14+CD16+ monocyte subset after treatment with various platelet agonists 
Table 5-2 shows the mean percentage monocyte-platelet aggregate formation (CD14+CD16+ monocyte subset), in stirred whole blood, incubated at 
37°C in response to different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  *,** and 
*** indicate P<0.05, P<0.01 and P<0.001 respectively post hoc test (Dunnett’s) following a One-way ANOVA.  (Data are mean +/-SEM ADP 4-7 
experiments, CRP-XL 4 experiments, U46619 3 experiments, rhodocytin 3 experiments and oxLDL 5-6 experiments.) 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
30μM ADP 2.1± 0.4 8.3±2.3 8.1±0.8 24.6±4.3 * 33.5± 7.8 *** 37.2±6.4 *** 42.9±4.2 *** 41.7±7.6 *** 12.0±4.8 15.6±7.0 P<0.0001
1μg/ml CRP-XL 2.5± 0.4 4.8±0.5 5.3±0.5 6.7±2.2 14.1±6.5 18.5±5.1 29.1±9.0 ** 33.6±8.2 *** 9.8±1.8 12.2±4.4 P< 0.001
10μM U46619 3.3±1.0 4.6±1.2 6.1±1.4 12.6±3.0 18.5±2.8 * 32.1±4.2 *** 38.1±7.1 *** 39.4±2.6 *** 7.7±1.1 9.5±1.5 P<0.0001
100nM Rhodocytin 2.1±0.3 4.4±0.7 4±0.2 10.8±1.5 21.0±5.4 *** 47.6±4.2 *** 58.8±2.5 *** 67.9±2.4 *** 3.3±0.8 5.0±1.8 P<0.0001
50μg/ml oxLDL 2.8±0.6 5.8±1.1 6±1.0 6.9±1.2 6.8±1.9 6.8±1.8 6.5±1.9 12.8±5.5 6.9±2.4 7.8±2.3 ns
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
30μM ADP 3.0±0.5 8.4±3.1 8.0±1.1 21.3±3.8* 27.2±7.2 *** 32.7±5.3 *** 38.3±2.7 *** 31.5±6.5 *** 7.9±1.9 10.4±3.4 P<0.0001
1µg/ml CRP-XL 3.0±0.5 14.2±3.4 13.5±2.7 14.9±3.1 20.5±7.2 * 26.6±5.9 ** 36.2±4.7 *** 42.8±5.2 *** 6.0±0.5 10.2±3.9 P<0.0001
10μM U46619 3.9±1.0 7.2±1.6 8.0±1.7 12.7±1.4 15.1±1.9 23.7±5.8 * 27.5±4.6 ** 33.3±10.8 *** 6.8±2.2 7.1±0.5 P<0.001
100nM Rhodocytin 2.5±0.2 8.2±1.4 10.1±3.0 19.8±3.1 * 24.8±8.2 ** 42.9±5.4 *** 53.4±2.7 *** 58.0±2.6 *** 4.0±1.1 4.2±1.8 P<0.0001
50μg/ml oxLDL 3.7±5.1 7.7±1.6 8.7±2.2 9.0±2.3 9.2±2.7 10.2±3.0 10.1±2.2 19.9±10.7 6.6±1.5 8.8±1.9 ns
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5.3.2 Determining the level of accumulation of CD42b by monocytes in response to treatment 
with agonist reagents 
Having determined the accumulation of platelet specific CD42b by monocytes after 
treatment with TRAP and CTH previously, we wanted to repeat this analysis for other platelet 
agonists.  After treatment of whole blood with 30µM ADP and 100nM Rhodocytin followed by 
mixing at 37°C, the CD14+CD16- monocyte subset showed an increase in CD42b MFI in the 
microvesicle gate (Table 5-3).  Treatment with rhodocytin showed the greatest increase, 
followed by U46619 and then CRP-XL (Table 5-3).  An increase in percentage of events in the 
microvesicle gate over time was observed, following treatment with any of the agonists (Table 5-
4).  However, no change in CD42b MFI or percentage was detected for any of the untreated 
samples (Table 5-3, 5-4 ,5-5 and 5-6).  A possible explanation for the low level of accumulation of 
CD42b, by CD14+CD16- monocytes, is that following treatment with any of these platelet 
agonists they are accumulating PMV, generated upon platelet activation. However, when the 
CD42b MFI of resting platelets was surprisingly low then data should be interpreted with caution 
(Table 5-5 and 5-6).   
After treatment of whole blood with any of the agonists the CD14+CD16+ monocyte 
subset also showed an increase in CD42b MFI and percentage of events, over time, in the 
microvesicle gate (Table 5-7 and Table 5-8).  Treatment with rhodocytin produced the greatest 
increase in CD42b MFI, followed by ADP, U46619 and CRP-XL (Table 5-7).  Again indicating that 
under these conditions PMV may potentially be adhering to CD14+CD16+ monocytes. 
The data from the CD14+CD16+ monocyte subset suggested platelet adhesion may also 
be occurring after treatment with most platelet agonists.  After treatment with 1μg/ml CRP-XL 
the CD42b MFI in the platelet gate was higher than that of a resting platelet throughout the time 
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course (Table 5-9).  Treatment with U46619 produced the highest CD42b MFI (421.2) at 15 
minutes.    
This suggests that more than one platelet may be binding to the monocyte, however, the 
MFI reduced over time to lower than that of a platelet at 60 minutes (Table 5-9).  After 
treatment with 100nM rhodocytin the CD42b MFI in the platelet gate was roughly that of a 
resting platelet between 5-25mins (Table 5-9).  The percentage of events, which would be 
consistent with whole platelet binding, remained low for most agonists.  30μM ADP showed an 
increase in percentage, but data should be interpreted with caution, as the CD42b MFI of a 
resting platelet was surprisingly low (Table 5-10). 
5.3.3 The effect on MPA formation following treatment with lower concentrations of agonist 
reagents 
After finding that treatment with high concentrations of platelet agonists possibly leads 
to microvesicle generation by platelets, which in turn adhere to monocytes, we wanted to find 
out, what effect lower concentrations of ADP, U46619 and rhodocytin would have.  In order to 
achieve this whole blood was incubated and stirred at 37°C for up to 60 minutes after treatment 
with 3µM ADP, 3µM U46619 and 30nM rhodocytin. 
Of these three agonists rhodocytin was found to be the most effective with a maximum 
of ~65% and 60% MPA for the CD14+CD16- and CD14+CD16+ monocyte subsets respectively 
(Table 5-11 and 5-12).  The weaker agonists were 3µM U46619 and 3µM ADP both giving a 
maximum of roughly 30% MPA formation for the CD14+CD16- monocyte subset (Table 5-11).  
U46619 showed a maximum of 35% MPA on the CD14+CD16+ subset whereas ADP showed a 
maximum of 30% (Table 5-12).





Table 5-3: CD42b MFI on the CD14+CD16- monocyte subset in the microvesicle gate after treatment with high concentrations of agonist 
CD42b MFI in the microvesicle gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, incubated at 37°C with 
different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and 





Table 5-4: Percentage of the CD14+CD16- monocyte subset in the microvesicle gate after treatment with high concentrations of agonist 
CD42b positive percentage of events in the microvesicle gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, 
incubated at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min 
control is untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 4-7 experiments, CRP-XL 4 experiments, U46619 3 
experiments and rhodocytin 3 experiments.) 
 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 3.1 4.6 4.9 7.5 10.9 10.3 10.7 11.1 4.7 4.5
1μg/ml CRP-XL 2.2 2.8 3.0 3.1 4.0 4.4 5.4 6.1 2.5 2.9
10μM U46619 2.6 3.0 3.3 4.5 5.6 7.6 8.7 8.9 3.2 3.4
100nM Rhodocytin 2.1 2.5 2.8 4.4 5.7 10.0 12.1 14.0 2.2 2.3
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 56.9 74.1 80.0 78.6 83.1 79.0 77.1 82.4 71.1 69.5
1μg/ml CRP-XL 49.1 69.3 72.8 74.5 80.7 83.4 84.2 85.9 61.0 71.4
10μM U46619 48.6 61.0 77.0 79.8 85.2 90.3 91.3 93.4 69.9 76.9
100nM Rhodocytin 43.6 56.6 69.2 86.9 91.7 94.9 91.7 92.1 50.3 52.6





Table 5-5: CD42b MFI on the CD14+CD16- monocyte subset in the platelet gate after treatment with high concentrations of agonist 
CD42b MFI in the platelet gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, incubated at 37°C with different 
agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and fixed 





Table 5-6: Percentage of the CD14+CD16- monocyte subset in the platelet gate after treatment with high concentrations of agonist 
CD42b positive percentage of events in the platelet gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, incubated 
at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is 
untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 4-7 experiments, CRP-XL 4 experiments, U46619 3 experiments, 
rhodocytin 3 experiments.) 
 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con Platelet
Agonist
30μM ADP 92.1 84.6 94.4 79.2 68.6 66.6 70.0 71.6 68.1 52.2 194.0
1μg/ml CRP-XL 42.3 50.8 64.0 40.9 54.0 34.9 33.6 35.9 35.5 34.5 77.6
10μM U46619 75.8 121.2 107.7 112.2 124.2 84.1 81.4 72.7 75.1 76.3 157.7
100nM Rhodocytin 61.9 99.8 86.4 88.8 137.0 88.5 69.5 62.0 69.6 63.2 110.3
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 1.5 2.9 3.2 8.7 10.5 15.8 19.0 13.1 6.3 8.2
1μg/ml CRP-XL 1.0 1.2 0.7 0.8 1.7 2.3 5.9 6.4 3.8 3.2
10μM U46619 1.3 1.2 1.1 1.2 1.2 1.8 2.5 2.2 1.8 1.0
100nM Rhodocytin 0.6 1.8 0.7 0.7 1.0 2.1 6.3 7.0 0.7 0.4





Table 5-7: CD42b MFI on the CD14+CD16+ monocyte subset in the microvesicle gate after treatment with high concentrations of agonist 
 
CD42b MFI in the microvesicle gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, incubated at 37°C with 
different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and 





Table 5-8: Percentage of the CD14+CD16+ monocyte subset in the microvesicle gate after treatment with high concentrations of agonist 
CD42b positive percentage of events in the microvesicle gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, 
incubated at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min 
control is untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 4-7 experiments, CRP-XL 4 experiments, U46619 3 
experiments and rhodocytin 3 experiments.) 
 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 3.2 4.1 4.3 5.7 8.8 8.2 8.5 8.8 4.0 3.8
1μg/ml CRP-XL 2.2 2.8 3.0 3.2 4.0 4.6 5.6 6.5 2.4 2.7
10μM U46619 2.7 3.0 3.0 3.9 4.6 5.7 6.0 7.8 3.1 3.3
100nM Rhodocytin 2.1 2.4 2.7 4.2 5.0 8.9 10.6 12.6 2.3 2.3
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 61.8 67.0 73.2 77.1 77.4 75.7 74.6 78.3 69.9 69.4
1μg/ml CRP-XL 50.6 60.8 66.2 68.1 74.7 78.7 80.1 82.2 59.0 67.6
10μM U46619 48.6 54.6 54.1 62.2 69.7 76.3 77.6 83.5 67.3 75.3
100nM Rhodocytin 45.2 53.4 64.0 77.1 82.8 88.3 87.2 87.6 50.8 52.0





Table 5-9: CD42b MFI on the CD14+CD16+ monocyte subset in the platelet gate after treatment with high concentrations of agonist 
 
CD42b MFI in the platelet gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, incubated at 37°C with different 
agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and fixed 







5-10: Percentage of the CD14+CD16+ monocyte subset in the platelet gate after treatment with high concentrations of agonist 
CD42b positive percentage of events in the platelet gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, incubated 
at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is 
untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 4-7 experiments, CRP-XL 4 experiments, U46619 3 experiments 
and rhodocytin 3 experiments.)
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con Platelet
Agonist
30μM ADP 84.8 85.4 95.7 78.2 67.8 70.0 71.2 72.7 78.8 73.5 194.0
1μg/ml CRP-XL 41.8 149.9 156.5 210.3 169.8 175.9 91.6 46.1 39.6 35.4 77.6
10μM U46619 76.8 284.9 317.3 421.2 234.4 285.3 155.4 83.2 82.9 83.2 157.7
100nM Rhodocytin 59.1 116.8 135.5 144.4 167.4 101.6 63.5 75.3 76.4 59.6 110.3
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 1.8 2.7 2.6 7.6 8.4 12.8 16.2 12.9 3.9 8.0
1μg/ml CRP-XL 1.5 8.1 5.4 5.0 5.2 4.8 7.7 8.8 2.7 3.0
10μM U46619 1.6 3.9 4.7 4.7 1.8 2.1 2.4 2.0 1.6 1.2
100nM Rhodocytin 0.7 1.9 2.3 2.5 2.8 3.1 6.7 7.2 1.1 0.4




Table 5-11: MPA formation for the CD14+CD16- monocyte subset after treatment with low concentrations of various agonists 
Table 5-11 shows the mean percentage monocyte-platelet aggregate formation (CD14+CD16- monocyte subset) in stirred whole blood incubated at 
37°C in response to different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  *,** and 
*** indicate P<0.05, P<0.01 and P<0.001 respectively post hoc test (Dunnett’s) following a One-way ANOVA.  (Data are mean +/-SEM; ADP 5-6 
experiments, U46619 6-7 experiments and rhodocytin 4-5 experiments.) 
 
 
Table 5-12: MPA formation for the CD14+CD16+ monocyte subset after treatment with low concentrations of various agonists 
Table 5.12 shows the mean percentage monocyte-platelet aggregate formation (CD14+CD16+ monocyte subset) in stirred whole blood incubated at 
37°C in response to different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  *,** and 
*** indicate P<0.05, P<0.01 and P<0.001 respectively post hoc test (Dunnett’s) following a One-way ANOVA.  (Data are mean+/-SEM; ADP 5-6 
experiments, U46619 6-7 experiments and rhodocytin 4-5 experiments.) 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
3μM ADP 4.9±1.1 17.0±5.6 14.6±2.0 17.2±2.8 27.5±4.9 * 31.7±7.6 ** 31.2±8.2 ** 29.7±5.0 ** 6.5±1.8 6.67±1.8 P<0.0001
3μM U46619 5.3±0.9 12.1±6.2 13.3±4.8 20.6±3.9 37.3±3.8 *** 39.4±4.8 *** 43.3±5.9 *** 28.8±6.4 ** 7.2±2.7 10.1±2.7 P<0.0001
30nM Rhodocytin 4.9±0.9 8.9±1.5 6.3±1.9 7.8±2.5 16.3±1.3 44.5±1.7 *** 53.8±6.2 *** 65.8±7.5 *** 5.4±0.8 6.9±0.4 P<0.0001
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
3μM ADP 5.3±1.2 13.7±3.9 13.3±2.0 16.2±4.3 23.2±5.2 27.5±9.3 27.3±10.5 26.9±7.0 6.4±2.1 7.4±2.0 P<0.05
3μM U46619 6.1±1.1 10.7±2.9 13.8±3.1 19.8±3.0 32.0±4.9 *** 32.9±5.3 *** 35.9±5.7 *** 28.6±6.0 ** 7.1±2.5 10.4±3.3 P<0.0001
30nM Rhodocytin 5.5±0.7 13.1±2.6 11.3±1.7 12.6±1.1 29.3±3.3 *** 51.0±4.0 *** 55.5±5.7 *** 60.1±5.8 *** 4.9±0.8 6.8±0.6 P<0.0001
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5.3.4 Determining the level of platelet or PMV adhesion to monocytes in response to 
treatment with low concentrations of agonist reagents 
Having demonstrated that lower concentrations of platelet agonists are able to 
significantly increase the percentage of MPA, which formed in stirred whole blood.  We now 
wanted to assess the accumulation of CD42b, by monocytes, over time following treatment with 
a platelet agonist.  The CD14+CD16- monocyte subset had the highest CD42b MFI in the 
microvesicle gate after treatment with U46619 or rhodocytin (Table 5-13).  It was lower after 
treatment with ADP (Table 5-13).  There was an increase in the percentage of events in this gate 
over time (Table 5-14).  The data suggests that platelet derived microvesicles may possibly be 
adhering to monocytes upon activation with these agonists.  This monocyte subset never 
reached the MFI of a resting platelet after treatment with any of the agonists, this together with 
the percentage of events in this gate suggests that CD14+CD16- monocytes probably don’t bind 
to whole platelets (Table 5-15 and 5-16). 
Again an increase in CD42b MFI can be detected in the microvesicle gate for the 
CD14+CD16+ monocyte subset.  The highest CD42b MFI detected was again after treatment with 
rhodocytin, followed by treatment with U46619 and then 3µM ADP (Table 5-17).  There is an 
increase in percentage of events in the CD42b microvesicle gate over time except after 
treatment with 3µM ADP where it remains stable (Table 5-18). 
The CD42b in the platelet gate again suggests that in some instances whole platelets may 
be adhering to CD14+CD16+ monocytes.  After treatment with U46619 or rhodocytin the MFI of 
CD42b in the platelet gate is higher than that of a resting platelet (Table 5-19).  However, the 
low percentage of CD42b positive events in the platelet gate indicates that following U46619 
treatment this is only the case for a small number of monocytes (Table 5-20).  




Table 5-13: CD42b MFI on the CD14+CD16- monocyte subset in the microvesicle gate after treatment with low concentrations of agonist 
CD42b MFI in the microvesicle gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, incubated at 37°C with 
different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and 






Table 5-14: Percentage of the CD14+CD16- monocyte subset in the microvesicle gate after treatment with low concentrations of agonist 
CD42b positive percentage of events in the microvesicle gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, 
incubated at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min 
control is untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 5-6 experiments, U46619 6-7 experiments and 




Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
3μM ADP 2.9 4.2 4.7 4.7 5.7 5.9 5.5 6.2 3.5 3.6
3μM U46619 2.7 3.3 3.8 4.7 8.1 7.9 8.6 6.5 2.9 3.3
30nM Rhodocytin 2.4 2.9 2.7 3.1 4.8 7.9 8.9 10.4 2.4 2.6
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
3μM ADP 59.1 75.7 82.5 72.7 68.0 65.5 62.6 71.3 70.2 77.0
3μM U46619 58.3 65.7 72.9 82.3 85.7 85.5 82.7 86.5 66.9 74.4
30nM Rhodocytin 56.3 71.6 66.4 76.6 89.8 88.1 82.7 75.1 55.1 61.0





Table 5-15: CD42b MFI on the CD14+CD16- monocyte subset in the platelet gate after treatment with low concentrations of agonist 
CD42b MFI in the platelet gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, incubated at 37°C with different 
agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and fixed 
instantly prior to any incubation period.  (Data are mean; ADP 5-6 experiments, U46619 6-7 experiments and rhodocytin 4-5 experiments.) 
 
 
Table 5-16: Percentage of the CD14+CD16- monocyte subset in the platelet gate after treatment with low concentrations of agonist 
CD42b positive percentage of events in the platelet gate for the CD14+CD16- monocyte subset, following treatment of stirred whole blood, incubated 
at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is 
untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 5-6 experiments, U46619 6-7 experiments and rhodocytin 4-5 
experiments.) 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con Platelet
Agonist
3μM ADP 55.3 55.3 47.7 43.0 44.4 46.8 49.6 42.1 45.1 39.9 115.9
3μM U46619 63.8 111.9 105.9 77.5 69.9 69.1 73.9 75.5 68.9 64.2 146.6
30nM Rhodocytin 40.3 78.0 57.6 43.6 66.5 45.9 40.5 42.4 38.1 38.3 75.9
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
3μM ADP 4.2 9.9 8.1 10.0 17.1 21.2 21.9 17.6 4.7 5.0
3μM U46619 1.9 5.5 4.9 5.7 7.7 8.4 11.3 5.4 1.3 1.2
30nM Rhodocytin 2.1 3.3 1.8 1.4 2.1 8.3 14.5 23.3 2.1 1.8




Table 5-17: CD42b MFI on the CD14+CD16+ monocyte subset in the microvesicle gate after treatment with low concentrations of agonist 
CD42b MFI in the microvesicle gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, incubated at 37°C with 
different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and 





Table 5-18: Percentage of the CD14+CD16+ monocyte subset in the microvesicle gate after treatment with low concentrations of agonist 
CD42b positive percentage of events in the microvesicle gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, 
incubated at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min 
control is untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 5-6 experiments, U46619 6-7 experiments, rhodocytin 4-
5 experiments.) 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
3μM ADP 3.0 3.9 4.3 4.4 4.8 5.1 4.9 5.1 3.6 3.6
3μM U46619 2.7 2.8 3.1 3.7 5.8 5.6 6.2 5.5 2.7 3.1
30nM Rhodocytin 2.2 2.6 2.5 2.8 4.2 6.1 6.7 7.4 2.2 2.4
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
3μM ADP 61.5 76.4 79.9 69.3 67.3 63.5 60.4 68.0 70.7 77.7
3μM U46619 59.2 58.0 62.0 73.3 76.8 77.1 76.8 80.6 66.5 72.8
30nM Rhodocytin 54.2 63.4 58.2 68.0 77.1 76.8 71.8 72.7 52.8 58.7




Table 5-19: CD42b MFI on the CD14+CD16+ monocyte subset in the platelet gate after treatment with low concentrations of agonist 
CD42b MFI in the platelet gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, incubated at 37°C with different 
agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is untreated and fixed 






Table 5-20: Percentage of the CD14+CD16+ monocyte subset in the platelet gate after treatment with low concentrations of agonist  
CD42b positive percentage of events in the platelet gate for the CD14+CD16+ monocyte subset, following treatment of stirred whole blood, incubated 
at 37°C with different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  0 min control is 
untreated and fixed instantly prior to any incubation period.  (Data are mean; ADP 5-6 experiments, U46619 6-7 experiments and rhodocytin 4-5 
experiments.)
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con Platelet
Agonist
3μM ADP 60.5 57.1 49.3 44.8 45.7 51.5 60.0 45.5 47.6 42.7 107.0
3μM U46619 68.3 183.9 171.3 129.6 125.2 103.2 91.4 85.4 82.3 84.9 146.6
30nM Rhodocytin 52.2 124.0 124.5 146.0 165.3 71.5 72.3 50.9 41.5 45.0 75.9
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
3μM ADP 4.3 7.0 6.8 9.4 14.7 19.6 20.9 17.2 4.4 4.7
3μM U46619 2.1 6.3 7.6 6.5 6.4 6.5 7.5 3.7 1.5 1.5
30nM Rhodocytin 3.4 7.4 7.2 4.5 6.8 12.5 16.8 19.2 2.0 2.2




Upon addition of a known platelet agonist, either ADP, rhodocytin, U46619 or CRP-XL, to 
stirred whole blood incubated at 37°C, there was a significant increase in MPA formation.  
However, the data suggests no differences were observed between monocyte subsets in their 
ability to form MPA.  A previous study, has shown that blood from patients with coronary artery 
disease had increased MPA compared to controls, they also report that CD14+CD16+ monocyte 
subset showed no significant increase in MPA formation compared to the CD14+CD16- subset 
(Czepluch et al., 2014). 
The degree of MPA formation was time dependent and increased with the duration of 
incubation.  An increase in aggregate formation after treatment with a platelet agonist is to be 
expected, as previous data demonstrates that MPA formation increases upon platelet activation 
(Michelson et al., 2001; Jensen et al., 2001; Gkaliagkousi et al., 2007).  Interestingly, Xiao & 
Théroux, (2004), showed patients suffering from ACS have an increased propensity to form MPA 
after blood was treated with either ADP or TRAP ex vivo.   
However, addition of 50μg/ml oxLDL appeared to have little effect on MPA formation 
over time, with the exception of a small non significant increase seen after 60 minutes.  Others 
have shown that oxLDL can activate platelets, although the agonistic effect is not as dynamic as 
the classical routes of platelet activation (Chen et al., 2001; Korporaal et al., 2007).  It would be 
interesting in future experiments to determine whether increasing the incubation period, to 
more than 60 minutes results in a time dependent increase in MPA formation in response to this 
agonist, albeit with very different dynamics from the other agents tested. 
Here we observed no differences in maximum response for percentage MPA formation 
using lower concentrations of rhodocytin, ADP or U46619 compared to the higher 
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concentrations, indicating that these agonists are just as effective at lower concentrations.  
Previous aggregometry data using washed isolated platelets, stimulated with 30nM rhodocytin 
has shown that maximal platelet activation can be achieved with this concentration of agonist 
(Pollitt et al. 2010).  It has also been demonstrated that 1μM U46619 can cause platelet 
aggregation in PRP (Moraes et al., 2007).  If maximal response to the platelet agonist is also 
achieved in whole blood then it is likely that there will be no difference in MPA formation 
between concentrations.  The data showed an increase in donor variability at lower 
concentrations of all agonists, with some donors clearly more responsive than others at these 
marginal concentrations.  Future work should determine the sensitivity of MPA formation to 
platelet agonists, as the concentrations used currently represent robust stimulation and our data 
indicates that this may not be required to induce interactions between platelets and monocytes. 
Subtle differences between platelet agonists were observed; rhodocytin appeared to be 
the most potent agonist, whereas ADP, U46619 and CRP-XL showed a much lower maximum 
response.  The difference in maximum response of MPA formation between agonists may be due 
primarily to the agonists ability to activate platelets.  For example, ADP is recognised as a 
relatively weak platelet agonist (released by platelets themselves), which must signal through 
both P2Y1 and P2Y12 receptors in order to fully activate platelets, usually in a positive feedback 
loop to reinforce activation through other receptors.  Thromboxane, also synthesised by 
platelets is able to cause further activation through a positive feedback loop, in this instance by 
signalling through TP receptor (Paul et al., 1999).  It would be of interest to determine how much 
of the MPA formation in response to agonists such as CRP-XL were dependent upon these 
feedback loops, experiments could be readily conducted in the presence of specific receptor 
antagonists. 
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Further analysis revealed that the levels of CD42b on MPA rarely equalled that of a single 
resting platelet.  Indeed, our time course data suggested that monocytes accumulate CD42b in 
quanta that are significantly less than whole platelets.  It has been well documented that upon 
platelet activation CD42b positive PMV are generated (Flaumenhaft et al., 2009; Hargett and 
Bauer, 2013).  Increased levels of microvesicles have been found alongside increased levels of 
soluble P-selectin (a well known marker for inflammation) in patients with chronic inflammatory 
disease (Burton et al., 2013; Joseph et al., 2001).  Christersson et al, (2010) also demonstrated 
that the number of microvesicles in whole blood increased after treatment with ADP.  One 
explanation for MPA accumulation of CD42b in quanta less than a platelet, which was observed 
in this study, could be that monocytes may be accumulating platelet derived microvesicles over 
time, rather than binding to whole platelets.  A potential confounding issue with this analysis is 
the fact that CD42b is a ‘shedable’ marker (Michelson et al., 1994).  It is therefore possible that 
after platelet activation CD42b is shed, reducing the MFI of an activated platelet compared to a 
resting one.  Future studies should optimise the use of other markers such as CD41 or P-selectin. 
As well as appearing to possibly accumulate CD42b positive microvesicles, the 
CD14+CD16+ monocyte subset appears to bind whole platelets after treatment with U46619, 
rhodocytin and CRP-XL, at least through the early part of the time course.  Several studies have 
implied that upon platelet activation, MPA form (Jungi et al., 1986; Rinder et al., 1991; 
Christersson et al., 2010).  Very few studies have attempted to determine the number of 
platelets adhering.  Xiao and Théroux, (2004) used the MFI of CD42a to determine the number of 
platelets bound to monocytes.  They demonstrated that ~15% MPA formed in untreated control 
blood and these heterotypic aggregates had up to 3 platelets bound.  This is in contrast to the 
findings from our study where untreated whole blood, which was kept under conditions of low 
shear for up to one hour had ~4% MPA, which never reached the MFI of a resting platelet.  
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Whole blood treatment with ADP showed an increase to 45% with 4 platelets adhering per 
monocyte (Xiao and Théroux, 2004).  Again, this is in contrast to data from our study where the 
MFI never reaches that of a resting platelet after treatment with ADP.  The study by Xiao et al 
2004, was carried out with blood which had been incubated under static conditions rather than 
being kept under conditions of stirring, as was the case in the current study.  Incubating whole 
blood under static conditions may encourage MPA to form and could explain discrepancies in 
the data. 
This study also showed that after treatment with 3μM U46619 there appeared to be a 
decrease in CD42b accumulation on both monocyte subsets between 30-60 minutes.  It has 
again been documented that microvesicles can be internalised by monocytes, although it is not 
yet known whether this is through a process of receptor mediated endocytosis or through fusion 
of the plasma membranes (Del Conde et al., 2005; Hargett and Bauer, 2013; Yang et al., 2012).  
This uptake of vesicles is thought to have an important role in cell communication and be a key 
signalling process, which allows cross talk between platelets and monocytes. 
Conclusions 
In conclusion, we have demonstrated that upon platelet activation through TP, P2Y1, 
P2Y12, GPVI and CLEC-2 the formation of MPA increases over time.  The maximum percentage 
increase in MPA formation is dependent on the agonist used.  Lower concentrations of some 
agonists were found to be as effective as higher ones, indicating the need for further titration.  
Our data also suggests that PMV may be responsible for MPA formation rather than whole 
platelets.  Further work needs to be carried out to find out, which receptor platelets or PMV are 
using to bind to monocytes and whether their formation can be blocked.
 












6. Chapter 6- FORMATION OF LYMPHOCYTE-
PLATELET AND NEUTROPHIL-PLATELET 
AGGREGATES IN RESPONSE TO TREATMENT 
WITH DIFFERENT PLATELET AGONISTS  
  




Lymphocyte-platelet aggregates (LPA) have been reported to be at increased levels in 
patients with chronic inflammatory diseases such as (SLE) compared to healthy controls (Joseph 
et al., 2001).  It has also been suggested that the enhancement of lymphocyte capture by 
platelets may have a role in the recruitment of lymphocytes during the progression of 
atherosclerosis amongst other inflammatory diseases (Li, 2008). 
A Previous study from our lab has demonstrated that immobilised activated platelets are 
able to capture lymphocytes from flow (Lalor and Nash, 1995).  Experiments carried out both in 
vitro and in vivo demonstrate that activated platelets aid in leukocyte capture to endothelial 
cells, under proinflammatory conditions (Pitchford et al 2005; Diacovo et al. 1998; Diacovo et al. 
1996; Kuckleburg et al. 2011).  However, there is some debate in the literature as to whether 
levels of LPA increase upon platelet activation.  Rinder et al, (1991) and Jensen et al, (2001) both 
reported there was no change in levels of LPA after treatment of whole blood with a platelet 
agonist.  Other more recent studies do suggest that lymphocytes can bind to activated platelets, 
although some lymphocyte subsets are better adapted for this interaction than others (Li et al., 
2006; Pitchford et al., 2005; Kuckleburg et al., 2011; Diacovo et al., 1996). 
Neutrophil-platelet aggregates (NPA) are thought to have an important role in the 
progression of inflammatory diseases and increased circulating levels have been shown in 
connection with RA, SLE, ACS and ischaemic stroke (Ishikawa et al., 2012; Jensen et al., 2001; 
Joseph et al., 2001; Linden et al., 2007; Nijm et al., 2005).  Mickelson et al, (1996) demonstrated 
patients with progressive angina had a significant increase in NPA following angioplasty, where 
atherosclerotic plaques are disrupted; a greater increase in NPA was linked to a poor prognostic 
outcome.  Upon activation of platelets in whole blood, NPA have been shown to significantly 
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increase in number (Jungi et al., 1986; Klinkhardt et al., 2003; Rinder et al., 1991; Xiao and 
Théroux, 2004).  This phenomenon has been demonstrated in vivo using baboons; following 
transfusion with activated platelets (expressing P-selectin) there was a significant increase in 
NPA formation compared to transfusion with resting platelets (Michelson et al., 2001). 
However, there are several different signalling routes for platelet activation.  Including 
activation through GPVI after interaction with collagen, which could occur following 
atherosclerotic plaque rupture (amongst other forms of mechanical damage) (Libby, 2012).  This 
would trigger thrombosis and therefore thrombin generation, which would also lead to platelet 
activation (Coughlin, 2000).  When platelets become activated they release the contents of δ 
granules containing ADP and synthesise thromboxane, both of these can increase platelet 
activation through an autocrine and paracrine fashion (Jin and Kunapuli, 1998; Liu et al., 2012).  
Oxidised low-density lipoprotein is also present in atherosclerotic plaques and may be accessible 
to platelets upon plaque rupture and may also activate platelets (Chen et al., 2001, Libby, 2012).  
Damage to cells leads to the release of histones, which have been demonstrated to activate 
platelets through TLR2 and TLR4 (Semeraro et al., 2011).  All of these different platelet agonists 
have potential roles in platelet activation following vascular damage (such as atherosclerotic 
plaque rupture).  The route of platelet activation could have an effect on the ability of platelets 
to bind to lymphocytes or neutrophils.  Platelet activation has also been linked to an increase in 
platelet microvesicle (PMV) release (Chow et al., 2000).  This has also been detected in 
conjunction with inflammatory diseases (Beyer and Pisetsky, 2010; Burton et al., 2013).  It is has 
been demonstrated that PMV can bind to neutrophils and there is potential for them to also 
bind to lymphocytes, implicating this as a potential route for interaction during heterotypic 
aggregate formation (Forlow et al., 2000). 
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The aims for this chapter were; 
1) To find out if activation of platelets in whole blood activated with different agonists 
would lead to the formation of LPA and if the route of activation had any effect on the 
rate, or efficiency of LPA formation. 
2) To find out if NPA formed with different rates or efficiency in response to platelet 
activation through different receptor pathways. 
3) To specifically assess the level of CD42b accumulation by neutrophils following treatment 




6.2.1 Leukocyte-platelet aggregate formation in whole blood following treatment with 
different platelet agonists  
Briefly CPDA anti-coagulated whole blood, was gently stirred and incubated at 37°C with 
platelet agonists, including 100μM and 10μM TRAP, 10µM and 3µM thromboxane mimetic 
U46619, 100nM and 30nM rhodocytin, 30µM and 3µM ADP, 1µg/ml CRP-XL, 1mg/ml, calf 
thymus histones (CTH) or 50µg/ml oxLDL.  Analysis of NPA and LPA formed was determined 
using flow cytometry (Figure 6.1).  Statistical analysis was carried out using Graph Pad Prism 
version 5.0.  (For further detail see methods section 2.3.1-2.3.3.)  
 
 




6.3.1 The effect of PAR1 signalling on LPA formation in whole blood 
Our aim was to find out if platelet activation could lead to lymphocyte-platelet aggregate 
(LPA) formation in stirred whole blood incubated at 37°C.  First, we used the potent platelet 
agonist TRAP (Par1 peptide, SLFFRN), to assess the effect this had on LPA formation.  Whole 
blood was incubated with 100μM TRAP for up to 60 minutes, there was no significant increase in 
percentage LPA formation over time (Figure 6-1 and 6-2).  The maximum LPA formation was 
detected at 60 minutes with an average of ~5%, however, this was not a significant increase 
compared to the 0 minute control (Figure 6-2). 
6.3.2 The effect of other platelet agonists on LPA formation in whole blood 
Having determined that platelet activation using 100μM TRAP did not lead to any 
significant increase in LPA formation in whole blood, we wanted to find if activating platelets 
through different receptor pathways still showed no effect.  Treatment with a range of platelet 
agonists including thromboxane mimetic U46619, snake venom toxin rhodocytin, ADP, CRP-XL, 
CTH as well as oxLDL were compared.  After whole blood treatment for a period of up to 60 
minutes, table 6-1 demonstrates that there is no significant increase in LPA formation, except 
after treatment with ADP.  Indeed, after treatment with CRP-XL, rhodocytin or U46619 a 
significant decrease in percentage LPA formation could be detected (Table 6-1).  Although 
significant, these changes were not large, representing a 2-3 fold increase above a low 
background level of LPA in control samples.  There is no significant increase in LPA formation in 
untreated blood which has been incubated for up to 60 minutes (Table 6-1). 




Figure 6-1: Flow cytometry plots for LPA formation after treatment with 100µM TRAP 
Whole blood was incubated at 37°C with or without 100µM TRAP.  The control (0) was fixed 
prior to any treatment.  Lymphocyte platelet aggregates (LPA) were detected using flow 
cytometry with antibodies against the platelet marker CD42b and granularity (side scatter) of 
lymphocytes.  The flow cytometry plots demonstrate no change in LPA formation over time.  
(Representative experiment from data set of 3). 
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Figure 6-2: LPA formation in whole blood after addition of 100µM TRAP   
Whole blood was incubated and mixed at 37°C, with or without the addition of 100µM TRAP.  
The control (0) was fixed prior to any treatment.  Data were acquired using flow cytometry.  
There is no increase in lymphocyte-platelet aggregates over time (ANOVA ns).  *,** and *** 
indicate P<0.05, P<0.01 and P<0.001, respectively, post hoc test Dunnett’s.  Data are mean +/- 
SEM of 3 experiments.   




Table 6-1: Mean percentage LPA formation after treatment with high concentration of various agonists 
Table 6-1 shows the mean percentage lymphocyte-platelet aggregate formation, in stirred whole blood, incubated at 37°C, in response to treatment 
with different agonists.  30 Con and 60 Con are stirred and incubated at 37°C for 30 and 60 minutes without the addition of any agonist.  The control 
(0) was fixed prior to any treatment.  ANOVA indicates a significant increase in Lymphocyte-platelet aggregates (LPA) formation over time, after 
treatment with ADP.  ANOVA indicates a significant decrease in LPA occurs over time after treatment with CRP-XL, U46619 and rhodocytin.  Post-hoc 
test Dunnett’s ƚ indicates 0 minute control is significantly higher than after addition of agonist, ɸ indicates 0 min is significantly higher than after 10-
20 minute incubation with agonist.  Data are mean +/-SEM; ADP 4-7 experiments, CRP-XL 4 experiments, TRAP 3 experiments, U46619 3 experiments, 
Rhodocytin 3 experiments, oxLDL 5-6 experiments and CTH 3-4 experiments. 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
30μM ADP 1.9±0.4 0.9±0.1 0.9±0.1 1.6±0.3 2.2±0.5 2.1±0.3 2.8±0.5 1.8±0.2 1.6±0.4 1.8±0.3 P< 0.005
1μg/ml CRP-XL 2.3±0.2 ƚ 0.8±0.2 0.5±0.1 0.4±0.1 0.4±0.1 0.5±0.1 0.7±0.1 1.1±0.3 2.1±0.2 2.2±0.3 P<0.001
100μM TRAP 3.3±1.1 0.9±0.3 0.9±0.3 1.2±0.3 2.2±1.0 2.5±0.7 3.2±1.3 4.3±1.6 1.8±0.5 1.4±0.6 ns
10μM U46619 3.4±0.9ƚ 0.9±0.2 0.7±0.0 0.9±0.1 0.9±0.1 1.0±0.3 1.4±0.3 1.3±0.1 2.8±0.3 2.2±0.5 P<0.001
100nM Rhodocytin 2.2±0.2ɸ 1.5±0.5 0.6±0.1 0.6±0.1 0.8± 0.2 1.0±0.2 1.5±0.5 1.5±0.4 1.1±0.2 1.0±0.2 P<0.05
50μg/ml oxLDL 2.5±0.6 2.9±0.7 2.9±0.7 2.6±0.5 2.8±0.7 2.7±0.8 2.3±0.6 1.4±0.2 1.9±0.3 2.0±0.6 ns
1mg/ml CTH 1.9±0.4 1.2±0.2 1.3±0.3 1.2±0.4 1.5±0.2 1.5±0.1 1.4±0.2 1.3±0.2 1.6±0.5 1.6±0.2 ns
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6.3.3 The effect of PAR signalling on NPA formation in whole blood 
Having found 100μM TRAP has no effect on lymphocyte-platelet aggregate formation in 
stirred whole blood incubated at 37°C, we now wanted to assess if this agonist had any 
detectable effect on NPA formation under the same conditions.  A significant increase in 
percentage NPA formation can be detected after 20 minutes TRAP treatment (Figure 6-3 and 6-
4).  A maximum of ~45% NPA formation can be detected at 60 minutes (Figure 6-3 and 6-4).  
There is no significant increase in NPA formation in untreated whole blood incubated for up to 
60 minutes (Figure 6-3 and 6-4). 
6.3.4 The effect of other platelet agonists on NPA formation  
Having demonstrated that activation of platelets through the PAR1 pathway leads to a 
significant increase in NPA formation, we now wanted to find out if activation through other 
platelet receptor pathways would also lead to an increase in NPA over time.  The agonists used 
included thromboxane mimetic U46619, rhodocytin, ADP, CRP-XL, CTH as well as oxLDL.  After 
treatment of whole blood with ADP, TRAP, rhodocytin and U46619 a significant increase in NPA 
formation could be detected over time (Table 6-2).  A significant increase in percentage NPA 
formation can be detected at 20 minutes after treatment with ADP and TRAP and after 30 
minutes with U46619 and rhodocytin, compared to untreated, fixed blood (0 minute control) 
(Table 6-2).  The most effective agonist which showed maximum NPA formation of ~45% was 
TRAP, followed by rhodocytin (~25%), ADP (15%) and U46619 (9%), (Table 6-2).  No significant 
increase in NPA formation can be detected over time after treatment with oxLDL or CTH (Table 
6-2).  However, a small but significant increase of ~9% can be detected after 60 minute 
incubation with CRP-XL.  No significant increase in percentage NPA formation can be detected in 
unstimulated blood, which has been incubated at 37°C for up to 60 minutes (Table 6-2). 




Figure 6-3: Flow cytometry plots NPA formation after treatment with 100µM TRAP 
Whole blood was incubated at 37°C, with or without 100µM TRAP.  The control (0) was fixed 
prior to any treatment.  Neutrophil-platelet aggregates (NPA) were detected using flow 
cytometry with antibodies against the platelet marker CD42b and neutrophil marker CD16.  The 
data shows an increase in NPA formation over time.  (Representative experiment from data set 
of 3).  
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Figure 6-4: NPA formation in whole blood after addition of 100µM TRAP 
Whole blood was incubated and stirred at 37°C, with or without the addition of 100µM TRAP.  
The control (0) was fixed prior to any treatment.  Data were acquired using flow cytometry.  
ANOVA (P<0.001) reveals a significant increase in neutrophil-platelet aggregate formation over 
time.  There is a significant increase in NPA formation after 20 minute incubation with TRAP 
compared to 0.  (*,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, post hoc test 








Table 6-2: Mean percentage NPA formation after treatment with high concentration of various agonists 
Table 6-2 demonstrates the mean percentage neutrophil-platelet aggregate formation, in stirred whole blood, incubated at 37°C, in response to 
different agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  The control (0) was fixed prior 
to any treatment.  ANOVA indicates a significant increase in NPA formation over time, after treatment with either, ADP, TRAP, U46619 or rhodocytin.  
*,** and *** indicate P<0.05, P<0.01 and P<0.001, respectively, post hoc test (Dunnett’s) following a One-way ANOVA.  (Data are mean +/- SEM; ADP 
4-7 experiments, CRP-XL 4 experiments, TRAP 3 experiments, U46619 3 experiments, Rhodocytin 3 experiments, oxLDL 5-6 experiments and CTH 3-4 
experiments). 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
30μM ADP 1.9±0.4 2.8±1.1 2.8±0.3 7.9±2.0 13.8±5.0 ** 15.4±3.4 ** 17.2±2.4 *** 13.9±3.2 * 3.3±1.7 4.0±2.2 P<0.0001
1μg/ml CRP-XL 1.5±0.3 2.6±0.8 2.3±0.7 2.1±0.8 3.5±1.9 3.5±1.5 7.6±3.4 9.4±3.6 2.7±0.8 4.1±2.0 ns
100μM TRAP 2.6±0.8 2.4±0.4 5.9±1.3 11.5±0.6 21.1±3.4 ** 24.0±3.7 ** 27.5±4.6 *** 44.3±8.5 *** 2.5±0.2 1.7±0.5 P<0.0001
10μM U46619 2.9±1.0 2.5±0.4 2.2±0.5 2.8±0.7 3.5±0.9 5.6±0.5 7.6±2.1* 9.0±1.2 ** 3.3±1.2 2.3±0.6 P<0.001
100nM Rhodocytin 1.7±0.2 3.6±0.8 3.0±0.8 4.7±1.6 5.0±1.6 13.6±4.7 21.7±7.9 * 25.7±10.7 ** 1.6±0.5 1.4±0.5 P<0.01
50μg/ml oxLDL 2.2±0.4 3.9±1.0 3.5±0.7 3.8±0.9 3.3±0.7 3.3±0.6 2.9±0.3 3.0±1.1 2.9±0.8 2.4±0.6 ns
1mg/ml CTH 1.6±0.3 2.2±0.8 2.3±0.7 2.2±0.8 1.9±0.7 2.1±0.7 2.5±0.7 2.4±0.6 1.5±0.3 2.2±0.6 ns
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6.3.5 Determining the level of accumulation by neutrophils in response to PAR1 signalling 
Having identified the formation of NPA in response to platelet activation with 100µM 
TRAP we now wanted to determine the accumulation of platelet specific CD42b, by neutrophils, 
over time (see Methods chapter 2.3.3 for details).  Figure 6-5A suggests that very few cells of the 
neutrophil population have a CD42b MFI equivalent to that of a resting platelet at the 60 minute 
time point.  One explanation for the CD42b MFI being lower than that of a resting platelet is that 
neutrophils may be accumulating PMV over time, rather than adhering to whole platelets. 
A small increase in CD42b MFI in the microvesicle gate was observed, coupled with the 
increase in percentage of neutrophils in this gate, this suggests that neutrophils could possibly 
be adhering to PMV, at increasing levels, over time, after treatment with TRAP (Figure 6-5B, D 
and Tables 6-3 and 6-5).  The CD42b MFI of the neutrophil population between 5 and 60 
minutes in the platelet gate was shown to be almost equal to that of a resting platelet (Figure 6-
5C and Table 6-5).  There was an increase in percentage of neutrophils in this gate over time, 
suggesting that at least towards the end of the time course (20-60 minutes), whole platelets may 
also be adhering to neutrophils (Figure 6-5E and Table 6-6).  The CD42b MFI of untreated 
neutrophils at the 60 minute time point was also equal to that of a resting platelet but the 
percentage of events in this gate was low (there was also no significant increase in NPA 
formation at this time point) making it unlikely that platelets are binding in this instance (Figure 
6-5C, E, Table 6-5 and 6-6). 




Figure 6-5: CD42b expression on the neutrophil population after treatment with 100µM TRAP 
Whole blood was incubated and stirred at 37°C with or without the addition of 100μM TRAP.  
Control (0) was fixed prior to any treatment.  Data were acquired using flow cytometry. A) 
Demonstrates the gating strategy at the 60 minute time point.  B) and D) show an increase in the 
CD42b MFI and percent positive cells in the microvesicle gate, respectively, over time for the 
neutrophil population.  C) Shows the CD42b MFI of neutrophils in the platelet gate.  The MFI is 
close to that of a resting platelet throughout except at 0 minute and 30 minute control.  
However, E) demonstrates that the percentage of cells in the platelet gate remains low until 20 
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6.3.6 Determining the level of CD42b accumulation by neutrophils; other agonists 
The data suggests that neutrophils most likely bind PMV and whole platelets after 
treatment with 100µM TRAP, we then wanted to repeat this analysis for other platelet agonists.  
After treatment with 30μM ADP, 10μM U46619 and 100nM rhodocytin there was a small 
increase in the CD42b MFI of the neutrophils in the microvesicle gate, over time (Table 6-3).  
There was also an increase in the percentage of neutrophils in this gate over time (Table 6-4).  
The maximum increase in CD42b MFI (accumulation by neutrophils) in the microvesicle gate was 
seen after treatment with TRAP (~9), followed by rhodocytin and ADP (~5.5) then by U46619 
(~4.0) (Figure 6-5A and C Table 6-3).  Together, with the increase in percentage of neutrophils in 
the microvesicle gate (Table 6-4), this suggests that platelet activation with TRAP leads to the 
highest level of CD42b accumulation by neutrophils. 
After treatment with ADP the CD42b MFI never reaches that of a resting platelet, there 
was however, an increase in percentage of neutrophils in this gate (Table 6-5 and 6-6).  In this 
instance the resting platelet MFI is low, therefore, the data should be interpreted with caution.  
After treatment with TRAP or rhodocytin the CD42b MFI of neutrophils in the platelet gate was 
almost equal to that of a resting platelet between 5-60 minutes (Figure 6-5 B and Table 6-5).  
However, the percentage of neutrophils in this gate remained low (Table 6-6).  Together, the 
detection of a significant increase in NPA formation and a small increase in the percentage of 
neutrophils in the platelet gate after 20 minutes, following treatment with either agonist; 
suggests that up to one platelet may be adhering to a small population of neutrophils between 
20-60 minutes (Figure 6-4 and 6-5 and Table 6-2, 6-5 and 6-6).  Treatment with U46619 also 
yielded a high CD42b MFI in the platelet gate, but the percentage of neutrophils in this gate 
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remained stable throughout, suggesting that it is unlikely that platelets are adhering in this 
instance (Table 6-5 and 6-6). 
6.3.7 The effect of lower concentrations of agonists on NPA formation in whole blood 
Having found that treatment of whole blood with high concentrations of agonists TRAP, 
rhodocytin, U46619 and ADP, lead to CD42b accumulation by neutrophils, which suggested that 
PMV and platelets were adhering to neutrophils.  We decided to test the effect of using lower 
concentrations of these agonists.  The data indicates that 3μM ADP had no significant effect on 
NPA formation (Table 6-7).  The most effective agonist was 10μM TRAP which caused a 
significant increase in NPA formation after 10 minutes (compared to 0 minute control), with a 
maximum of 65% NPA formation being detected at 60 minutes (Table 6-7).  Treatment with both 
3μM U46619 and 30nM rhodocytin lead to a maximum increase of ~20% NPA, however, this 
increase was detected at 60 minutes with rhodocytin and after 30 minutes with U46619 (Table 
6-7).  After 60 minute treatment with U46619 percentage NPA formation decreased and was no 
longer significant compared to the 0 minute control (Table 6-7).  There was no significant 
increase in NPA formation in untreated blood, which had been incubated for up to 60 minutes 
(Table 6-7). 





Table 6-3: CD42b MFI on the neutrophil population in the microvesicle gate after treatment with high concentrations of agonist 
Table 6-3 shows CD42b MFI of neutrophil population in the microvesicle gate, following treatment of stirred whole blood, incubated at 37°C with 
different agonists.  Control (0) was fixed prior to any treatment. 30 Con and 60 Con are incubated and stirred at 37°C without the addition of any 
agonist.  Data were acquired using flow cytometry.  (Data are means of; ADP 4-7 experiments, TRAP 3 experiments, U46619 3 experiments and 




Table 6-4: Percentage of neutrophil population in the microvesicle gate after treatment with high concentrations of agonist 
Table 6-4 indicates percentage of neutrophils in the microvesicle gate, based on CD42b expression, following treatment of stirred whole blood, 
incubated at 37°C with different agonists.  Control (0) was fixed prior to any treatment.  30 Con and 60 Con are incubated at 37°C without the 
addition of any agonist. Data were acquired using flow cytometry.  (Data are means of; ADP 4-7 experiments, TRAP 3 experiments, U46619 3 
experiments and rhodocytin 3 experiments.) 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 3.4 3.7 3.9 4.5 5.5 5.4 5.4 5.6 3.6 3.7
100μM TRAP 2.2 2.3 2.8 3.6 5.2 5.8 6.6 8.9 2.3 2.3
10μM U46619 2.7 2.7 2.7 3.0 3.2 3.6 3.9 4.0 2.9 3.1
100nM Rhodocytin 2.1 2.2 2.3 2.5 2.7 3.6 4.6 5.5 2.1 2.1
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 59.6 63.7 67.7 72.1 73.7 74.1 74.8 78.2 64.3 66.4
100μM TRAP 46.4 44.3 60.1 69.2 79.7 80.3 82.1 85.7 53.0 49.5
10μM U46619 52.6 53.8 53.4 59.2 64.1 69.6 74.2 77.2 65.8 72.6
100nM Rhodocytin 45.3 46.8 52.3 58.0 60.6 72.1 77.0 84.6 47.2 47.4





Table 6-5:  CD42b MFI on the neutrophil population in the platelet gate after treatment with high concentrations of agonist 
Table 6-5 shows CD42b MFI of neutrophil population in the platelet gate, following treatment of stirred whole blood, incubated at 37°C with different 
agonists.  Control (0) was fixed prior to any treatment.  30 Con and 60 Con are stirred and incubated at 37°C without the addition of any agonist.  





Table 6-6:  Percentage of neutrophil population in the platelet gate after treatment with high concentrations of agonist 
Table 6-6 shows percentage of neutrophil population in the platelet gate, based on CD42b expression, following treatment of stirred whole blood, 
incubated at 37°C with different agonists.  Control (0) was fixed prior to any treatment.  30 Con and 60 Con are stirred and incubated at 37°C without 
the addition of any agonist.  Data were acquired using flow cytometry. (Data are means of; ADP 4-7 experiments, TRAP 3 experiments, U46619 3 
experiments and rhodocytin 3 experiments.) 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con Platelet
Agonist
30μM ADP 92.7 125.1 129.2 108.0 75.0 78.4 76.2 78.8 81.6 73.6 194.0
100μM TRAP 72.4 111.3 113.8 118.2 106.2 112.7 105.4 98.2 80.0 110.9 122.9
10μM U46619 80.8 129.0 139.0 143.0 139.1 125.5 105.5 92.1 82.1 91.9 157.7
100nM Rhodocytin 65.6 112.3 93.3 105.2 97.9 98.7 94.3 98.4 87.3 77.6 110.3
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
30μM ADP 1.3 1.4 1.6 4.2 5.4 7.8 9.4 5.5 2.2 2.6
100μM TRAP 0.6 0.9 1.0 1.3 1.8 2.5 3.0 5.6 0.4 0.3
10μM U46619 1.3 1.3 1.2 1.0 1.0 0.9 1.2 1.2 1.1 0.5
100nM Rhodocytin 0.5 1.7 1.0 1.2 0.9 1.6 1.8 1.2 0.4 0.3





Table 6-7: Mean percentage NPA formation after treatment with low concentrations of agonists 
Table 6-7 shows the mean percentage neutrophil-platelet aggregate formation, in stirred whole blood, incubated at 37°C in response to different 
agonists over time.  30 Con and 60 Con are stirred and incubated at 37°C, without the addition of any agonist.  The control (0) was fixed prior to any 
treatment.  ANOVA indicates a significant increase in NPA formation over time after treatment with either, TRAP, U46619 or rhodocytin.  *,** and 
*** indicate P<0.05, P<0.01 and P<0.001, respectively, post hoc test (Dunnett’s), following a One-way ANOVA.  (Data are mean +/- SEM; ADP 5-6 
experiments, TRAP 4 experiments, U46619 6-7 experiments, rhodocytin 4-5 experiments). 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes con ANOVA
Agonist
3μM ADP 4.2±1.1 7.8±2.7 5.3±1.1 5.5±0.8 8.9±2.1 10.5±2.8 10.8±4.1 6.3±2.0 3.4±1.2 2.6±0.9 ns
10μM TRAP 3.8±0.6 7.6±3.3 20.3±4.2 * 33.5±5.6 *** 49.0±7.1 *** 50.6±3.6 *** 61.0±2.9 *** 64.2±2.9 *** 3.7±0.7 3.9±0.7 P<0.0001
3μM U46619 5.0±0.8 4.7±2.7 5.8±2.1 8.9±1.7 14.2±2.1 * 14.8±2.6 ** 17.3±2.5 *** 10.4±2.9 3.2±1.0 4.0±1.0 P<0.0001
30nM Rhodocytin 2.9±0.5 4.5±1.3 2.3±0.4 2.8±0.7 4.1±0.5 8.8±1.6 11.5±2.3* 19.4±5.9** 1.7±0.2 2.6±0.5 P<0.0001
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6.3.8 Determining the level of CD42b accumulation by neutrophils in response to lower 
concentrations of platelet agonists 
Having demonstrated that neutrophil-platelet aggregates formed after treatment with 
3μM U46619, 10μM TRAP and 30nM rhodocytin we now wanted to assess the accumulation of 
CD42b by neutrophils over time.  The microvesicle gate showed a small increase in CD42b MFI 
for the neutrophil population after treatment with any agonist (Table 6-8).  There was an 
increase in the percentage of neutrophils in the microvesicle gate, over time (except after 
treatment with 10μM TRAP where the percentage of events decreased at 30 and 60 minutes 
after treatment with this agonist) (Table 6-9).  This data suggests that the neutrophils may be 
binding to platelet derived microvesicles after treatment with TRAP, U46619 or rhodocytin. 
After treatment with 10μM TRAP and 3μM U46619 the CD42b MFI of the neutrophils in 
the platelet gate never approaches that of a resting platelet (Table 6-10).  There was an increase 
in percentage of neutrophils in the platelet gate after treatment with 10μM TRAP.  However, 
with the low CD42b MFI observed in the platelet gate and the decrease in percentage of events 
in the microvesicle gate, this should be interpreted with caution (Table 6-9, 6-10 and 6-11).  
After treatment with rhodocytin or U46619 the CD42b MFI was roughly equal to that of a resting 
platelet between 5 and 15 minutes (Table 6-10).  However, the percentage of neutrophils in the 
platelet gate were low and there was no significant increase in NPA at this time point, making it 
unlikely that platelet adhesion to neutrophils was occurring (Table 6-7 and Table 6-11). 





Table 6-8: CD42b MFI on the neutrophil population in the microvesicle gate after treatment with low concentrations of agonist 
 
Table 6-8 indicates CD42b MFI of neutrophil population in the microvesicle gate, following treatment of stirred whole blood, incubated at 37°C with 
different agonists.  Control (0) was fixed prior to any treatment. 30 Con and 60 Con are stirred and incubated at 37°C without the addition of any 
agonist.  0 min control is untreated and fixed prior to any incubation period. Data were acquired using flow cytometry.  (Data are means; TRAP 4 






Table 6-9:  Percentage of neutrophil population in the microvesicle gate after treatment with low concentrations of agonist 
Table 6-9 shows percentage of neutrophil population in the microvesicle gate based on CD42b expression, following treatment of stirred whole 
blood, incubated at 37°C with different agonists.  Control (0) was fixed prior to any treatment.  30 Con and 60 Con are stirred and incubated at 37°C 
without the addition of any agonist.  0 min control is untreated and fixed prior to any incubation period.  Data were acquired using flow cytometry.  





Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
10μM TRAP 2.2 2.4 3.1 4.0 4.7 5.0 4.9 5.9 2.2 2.2
3μM U46619 2.6 2.6 2.7 3.1 3.7 3.5 3.8 3.5 2.6 2.8
30nM Rhodocytin 2.2 2.4 2.2 2.4 2.7 3.1 3.4 4.7 2.1 2.2
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
10μM TRAP 49.6 55.3 66.0 70.0 63.6 63.9 54.4 57.1 56.8 57.3
3μM U46619 56.7 53.6 56.6 66.5 70.0 69.1 71.7 70.2 61.5 68.2
30nM Rhodocytin 52.4 62.0 53.9 61.1 65.8 71.8 73.2 79.5 49.5 53.6





6-10: CD42b MFI on the neutrophil population in the platelet gate after treatment with low concentrations of agonist 
Table 6-10 indicates CD42b MFI of neutrophil population in the platelet gate, following treatment of stirred whole blood, incubated at 37°C with 
different agonists.  Control (0) was fixed prior to any treatment. 30 Con and 60 Con are stirred and incubated at 37°C without the addition of any 
agonist.  0 min control is untreated and fixed prior to any incubation period.  Data were acquired using flow cytometry.  (Data are means; TRAP 4 





6-11: Percentage of neutrophil population in the platelet gate after treatment with low concentrations of agonist 
Table 6-11 shows percentage of neutrophil population in the platelet gate based on CD42b expression following treatment of stirred whole blood 
incubated at 37°C with different agonists.  Control (0) was fixed prior to any treatment.  30 Con and 60 Con are stirred and incubated at 37°C without 
the addition of any agonist.  0 min control is untreated and fixed prior to any incubation period.  Data were acquired using flow cytometry.  (Data are 
means; TRAP 4 experiments, U46619 6-7 experiments, rhodocytin 4-5 experiments.) 
 
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con Platelet
Agonist
10μM TRAP 31.6 42.3 33.7 33.2 38.3 38.3 43.9 39.8 30.5 36.3 62.1
3μM U46619 67.9 118.6 119.7 117.1 89.5 84.6 90.9 99.4 73.4 77.6 146.6
30nM Rhodocytin 44.1 90.0 83.4 64.7 55.0 55.8 61.0 46.2 43.4 43.3 75.9
Time point 0 5 Minutes 10 Minutes 15 Minutes 20 Minutes 25 Minutes 30 Minutes 60 Minutes 30 Minutes con 60 Minutes Con
Agonist
10μM TRAP 1.7 10.7 7.5 14.0 27.6 27.4 41.2 39.8 1.6 1.7
3μM U46619 1.8 2.6 2.3 3.1 3.8 4.0 5.1 2.4 0.9 0.8
30nM Rhodocytin 1.5 1.6 1.1 1.1 1.2 2.6 3.4 5.0 0.7 0.8
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6.3.9 Monocytes form heterotypic aggregates with platelets and PMV with a greater 
propensity than neutrophils or lymphocytes 
The data from this study indicated that all leukocytes are able to form heterotypic 
aggregates with platelets or possibly PMV.  Under certain conditions (treatment with 30µM ADP) 
a very small increase in LPA formation could be detected in whole blood (Table 6-2).  A 
significant increase in NPA formation in whole blood could be detected after treatment with a 
platelet agonist such as ADP, U46619, rhodocytin or TRAP (Table 6-2).  Previous data from this 
study indicated that upon treatment with a platelet agonist MPA form in whole blood (Chapter 
4).  TRAP was indeed shown to be the most potent agonist, in terms of leukocyte-platelet 
aggregate formation for both monocyte subsets and neutrophils.  However, figure 6-6 
demonstrates that upon activation with TRAP, MPA formed with a far greater propensity than 
NPA.  Although here treatment of whole blood with TRAP has been used as an example to 
demonstrate the increased propensity of MPA formation compared to NPA formation this is 
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Figure 6-6: Monocytes show the greatest propensity to form aggregates with platelets and 
platelet derived microvesicles following treatment with 100µM TRAP 
Whole blood was incubated and stirred at 37°C, with or without the addition of 100µM TRAP.  
The control (0) was fixed prior to any treatment.  Data were acquired using flow cytometry.  
ANOVA (P<0.001 and P<0.001) reveals a significant increase in monocyte-platelet and 
neutrophil-platelet aggregate formation over time (respectively).  There is no significant increase 
in LPA formation (ANOVA ns).  Monocytes show a maximum of ~70% MPA formation whereas 
NPA show a maximum of only ~45%.  Data are mean +/-SEM of 3 experiments.




There was a very small, but significant increase in LPA formation (~2%) over time, after 
whole blood had been treated with 30µM ADP.  However, no significant increase was detected 
after treatment with any other agonist.  Rinder et al, (1991) demonstrated no significant 
increase in percentage LPA formation over time, after treatment of whole blood with thrombin, 
however, percentage LPA formation was found to be ~10% throughout the study. This is a higher 
baseline than the one observed in the present study.   
Blood which has been collected (by venepuncture) into CPDA and fixed within 10 
minutes prior to any treatment showed an average of ~3% NPA formation.  This was not 
significantly increased when untreated blood was incubated at 37°C for up to 60 minutes.  
However, after treatment with known platelet agonists 30μM ADP, 100μM TRAP 100nM 
rhodocytin and 10μM U46619 a significant increase in percentage NPA could be detected over 
time.  The data demonstrates that platelet activation is necessary for NPA to form.  This is in 
agreement with previous studies where an increase in NPA formation has been demonstrated 
after treatment of whole blood with ADP and TRAP (Rinder et al., 1991; Xiao and Théroux, 2004).  
The study carried out by Xiao and Théroux, (2004), under static conditions showed a baseline of 
~8% NPA formation in healthy controls.  Our data implies that under low shear NPA do not 
significantly increase compared to untreated controls, for a period of up to 60 minutes.  The data 
from these studies implies that neutrophils and platelets have a propensity to aggregate readily 
under static conditions.  This leads us to believe that the high baseline observed under static 
conditions is an artefact of the experimental procedure rather than a true physiological 
representation of NPA, which have formed in the circulation. 
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It was however surprising, that no significant increase in NPA formation could be 
detected after treatment with CTH.  As histones have a key role in activation of both innate 
immune cells and platelets (Huang et al., 2011; Carestia et al., 2013; Semeraro et al., 2011).  
Histones also account for an essential part of neutrophil NETS (Carestia et al., 2013). NETS are 
able to provide a scaffold for thrombus formation (Fuchs et al., 2010).  This provides a clear link 
for histones in inflammation and thrombosis (Xu et al., 2009; Brill et al., 2012).  No significant 
increase in NPA formation being detected during this study could be due to activation of 
neutrophils and subsequent degranulation, or even formation of very large aggregates with 
platelets, making it difficult to detect them using flow cytometry. 
There were differences in the total percentage NPA formation after treatment with 
different agonists.  Platelet activation through the PAR1 pathway using 100μM TRAP was shown 
to be the most potent as this lead to ~45% NPA formation, this was followed by activation 
through CLEC-2 signalling pathway using rhodocytin (~25%), P2Y1, P2Y12 activation through ADP 
~(15%) and activation through TP using U46619 (~10%).  It is however surprising, that treatment 
of whole blood with CRP-XL a potent platelet agonist yielded very little NPA formation (only 9% 
maximum).  ADP and thromboxane are released from platelets themselves upon activation and 
are known to enhance platelet activation (Jin et al., 2002; Paul et al., 1999; Xiao and Théroux, 
2004).  Whereas activation through PAR-1 and CLEC-2 result in irreversible platelet signalling 
(Coughlin, 2000; Suzuki-Inoue et al., 2006).  
A lower concentration of both 10μM TRAP and 3μM U46619 seemed slightly more 
effective at inducing NPA formation than higher concentrations.  Rhodocytin appeared to be 
equally as effective at a lower concentration.  Previous data has demonstrated that full platelet 
activation can be achieved using these concentrations of TRAP, rhodocytin and U46619 (Moraes 
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et al., 2007; Pollitt et al., 2010; Stephens et al., 2005).  It is therefore not surprising that they are 
equally as potent as lower concentrations of these agonists.  There was however, an increase in 
donor variability at low concentrations of agonist.  Treatment with a lower concentration of ADP 
(3μM) showed no significant effect on NPA formation.  This indicates that NPA formation 
responds in a dose dependent manner to ADP.  Future work should determine sensitivity of NPA 
formation to other agonists as the data implies that it may not be necessary for full platelet 
activation to be achieved for NPA formation to occur in whole blood. 
Having demonstrated that in response to platelet activation there is an increase in NPA 
formation in stirred whole blood.  Further analysis of NPA showed that neutrophils accumulate 
CD42b at lower levels than that observed on a resting platelet.  One explanation for this is that 
neutrophils accumulate PMV, generated upon platelet activation with high concentrations of 
ADP, TRAP, rhodocytin and U46619.  This was also seen after treatment with lower 
concentrations of U46619, TRAP and rhodocytin. Previous data indicates that activation of 
platelets through PAR-1 signalling pathway leads to the generation of platelet derived 
microvesicle (Heijnen et al., 1999; Nygaard et al., 2014).  Whole blood sheared at (10,000S-1) and 
treated with TRAP peptide was found to have significantly more microvesicles compare to 
untreated sheared blood, however, the same study showed that ADP and U46619 had no effect 
(Chow et al., 2000).  This study used flow cytometry to assess microvesicle number, which is not 
a very accurate way of counting microvesicles as most will be too small to be detected.  In 
agreement with data shown in the current study suggesting that PMV are adhering to 
neutrophils Forlow et al., (2000) demonstrated that PMV could adhere to isolated neutrophils 
under conditions of low shear.  
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After 20 minute treatment with 100μM TRAP or 30 minute treatment with 100nM 
rhodocytin the data suggests that neutrophils may be binding to platelets in this instance.  
Although many studies have been carried out to assess the percentage of NPA, which form in 
whole blood in response to treatment with platelet agonists, very few have assessed the number 
of platelets adhering per neutrophil.  One such study was carried out by Xiao and Théroux, 
(2004) used the MFI of CD42A to assess the number of platelets adhering to neutrophils.  This 
showed that up to ~8% NPA formed at baseline with up to 2 platelets adhering per neutrophil.  
This was increased to ~20% with 3 platelets per neutrophil upon treatment with ADP and up to 
~70% with 5 platelets per neutrophil upon treatment with TRAP.  However, this study was 
carried out under static conditions, which the data from the current study suggests encourages 
NPA formation.  We would therefore interpret the high level of platelet adhesion which occurs 
during NPA formation in the study by Xiao and Théroux (2004) as an artefact of the experimental 
conditions. 
In this study we measured CD42b as a platelet marker on neutrophils.  Upon platelet 
activation with thrombin surface expression of CD42b has been shown to decrease (Hourdillé et 
al., 1992; Schmitz et al., 1998; Hourdillé et al., 1990).  This may be indicative of shedding of the 
receptor on MV after activation.  Future studies of NPA formation in whole blood should 
optimise the use of other markers such as CD41 and/or P-selectin in conjunction with CD42b to 
determine which of these is the most robust marker of NPA formation. 
The data from this study demonstrates that very few LPA form in whole blood in 
response to platelet activation.  However both NPA and MPA form under these conditions, but 
MPA form with far greater propensity.  This is in agreement with several studies which indicate 
that MPA and NPA formation in patients with chronic inflammatory diseases is increased, but 
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with higher levels of MPA (Jensen et al., 2001; Joseph E Italiano Jr, Mairuhu Albert T.A., 2010; 
Michelson et al., 2001; Mickelson et al., 1996; Xiao and Théroux, 2004).  It is also in agreement 
with data where whole blood has been treated with a platelet agonist such as ADP or TRAP (or 
thrombin) ex vivo, treatment with an agonist leads to increased levels of both MPA and NPA but 
a greater increase in MPA was always observed (Jensen et al., 2001; Jungi et al., 1986; Rinder et 
al., 1991; Xiao and Théroux, 2004). 
Conclusions 
We have demonstrated that upon platelet activation through PAR1, TP, P2Y1, P2Y12, 
GPVI and CLEC-2, NPA form, but with a lower propensity than MPA, however, LPA do not.  The 
maximum increase in NPA formed is dependent upon the agonist used.  The data suggests that 
platelet derived microvesicles are binding to neutrophils, although, in some instances whole 
platelets were thought to adhere as well.  Further work needs to be carried out to find out what 
receptor these platelet derived microvesicles, or platelets, are using to bind to neutrophils and if 



















7. Chapter 7- THE ROLE OF P-SELECTIN IN 
LEUKOCYTE-PLATELET AGGREGATE FORMATION 
  




Elevated levels of leukocyte-platelet aggregates have been associated with various 
chronic inflammatory diseases including atherosclerosis (Harding et al., 2004; Htun et al., 2006; 
Joseph et al., 2001; Shantsila and Lip, 2009; Nijm et al., 2005).  The increase in leukocyte-platelet 
aggregates is often accompanied by an increase in soluble P-selectin levels (Ridker et al., 2001; 
Xiao and Théroux, 2004).  P-selectin is released from activated endothelial cells and activated 
platelets.  Administering anti-platelet therapy, which reduces activation of platelets, significantly 
reduces levels of soluble P-selectin and levels of MPA in acute coronary syndrome (ACS) patients 
(Xiao & Théroux 2004).  This reduction in platelet activation and P-selectin levels leading to a 
subsequent reduction in the levels of circulating MPA, implies that this receptor has a role in 
leukocyte-platelet aggregate formation.  
P-selectin is only expressed on the platelet surface upon platelet activation and evidence 
for its potential role in MPA and NPA formation has been previously demonstrated both in vivo 
and in vitro.   Upon activation of platelets in whole blood, significantly increased surface 
expression of platelet P-selectin has been detected along with an increase in MPA and NPA 
(Jungi et al., 1986; Rinder et al., 1991).  Michelson et al, (2001) showed that infusion of thrombin 
activated platelets (assessed by P-selectin expression) into baboons resulted in an increase in 
both MPA and NPA compared to control animals infused with resting platelets.  Interestingly, the 
MPA formed upon infusion of thrombin stimulated platelets were detectable in vivo, above 
baseline for up to 2 hours, they were stable for a longer time period than NPA (Michelson et al., 
2001).  In patients undergoing angioplasty, increased levels of platelet surface P-selectin, MPA 
and NPA can be detected immediately following plaque rupture, when compared to 
preoperative levels (Mickelson et al., 1996).   
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Leukocytes possess the necessary ligand with the highest affinity for interacting with P-
selectin, P-selectin glycoprotein ligand-1 (PSGL-1) (Mehta, P. Cummings, 1998).  Previous studies 
have demonstrated that leukocyte PSGL-1 plays an important role in leukocyte-platelet 
aggregate formation (Théorêt et al., 2001).  As activated platelets are known to shed P-selectin 
positive platelet microvesicles (PMV) from their plasma membrane (Hargett & Bauer 2013; 
Flaumenhaft et al. 2009).  It is possible that these also adhere to leukocytes using P-selectin and 
PSGL-1 interaction.  Evidence to further support this comes from a study which indicated that 
PSGL-1 positive monocyte derived microvesicles are able to bind to activated platelets (Del 
Conde et al., 2005).  We hypothesised that PMV will bind to leukocytes using surface P-selectin.    
Aims 
The aims for this chapter were; 
1) To find out if LPA, NPA and MPA could be detected using P-selectin as a platelet marker 
and find both the percentage of aggregates formed, as well as the CD62P MFI of the 
aggregates. 
 
2) To measure surface expression of PSGL-1 on monocytes, neutrophils and Lymphocytes, 
including after treatment with the platelet agonists CRP-XL and TRAP. 
 
3) To find out if blocking P-selectin interactions prevents NPA and MPA formation in 
response to treatment with various agonists. 
 
 




7.2.1 Heterotypic aggregate formation using P-selectin as a platelet marker 
Briefly, whole blood was collected into CPDA.  Blood was either fixed within 10 minutes 
(0 minute control) or incubated for 30 minutes, with or without the addition of 30μM ADP, 
1μg/ml CRP-XL or 100μM TRAP, at 37°C, on a roller mixer. Whole blood was fixed and incubated 
with antibodies against monocyte markers CD14, CD16 (also a neutrophil marker) and platelet 
markers CD42b and CD62P.  Red cells were lysed and data were acquired using flow cytometry.  
(For further details see methods section 2.3.6) 
7.2.2 PSGL-1 expression by lymphocytes, neutrophils and monocytes 
Briefly, whole blood was collected into CPDA.  Blood was either fixed within 10 minutes 
(0 minute control) or incubated for 30 minutes, at 37°C, on a roller mixer, with or without the 
addition of 1μg/ml CRP-XL or 100μM TRAP.  Blood was fixed and incubated with antibodies 
against a) CD3, CD20 and PSGL-1, or b) CD14, CD16 and PSGL-1, red cells were lysed and data 
was acquired using flow cytometry.  (For further details see method section 2.3.7) 
7.2.3 Heterotypic aggregate formation in the presence of P-selectin blocking antibody 
Briefly, Whole blood was collected into CPDA.  20μg/ml of P-selectin blocking antibody 
(G1) or relevant isotype control was added to aliquots of whole blood some were left untreated 
at this stage.  This was followed by the addition of 30μM ADP, 1μg/ml CRP-XL, 100μM TRAP or 
100μg/ml recombinant human histone H4 and 30 minutes incubation at 37°C, on a roller mixer. 
Blood was fixed and incubated with antibodies against monocyte markers CD14, CD16 (also a 
neutrophil marker) and platelet marker CD42b.  Red cells were lysed and data was acquired 
using flow cytometry.  (For further details see section 2.3.8.) 




7.3.1 LPA detection using platelet P-selectin as a marker 
Lymphocytes are defined in this protocol based only on their size and granularity.  It was 
apparent when using the constitutively expressed platelet marker CD42b, that due to their size 
some resting platelets were being detected in the lymphocyte gate.  To avoid this problem 
platelets can be identified using a marker which is only expressed upon activation; P-selectin.  
Untreated blood either fixed within 10 minutes of aliquoting into CPDA or incubated at 37°C for 
30 minutes before fixing, showed less than 1% LPA formation (Figure 7-1).  As previous data has 
demonstrated that platelet activation is necessary for a significant number of leukocyte-platelet 
aggregates to form, this suggests that platelets are in their resting state.  There was a significant 
increase in LPA formation, based on the platelet marker P-selectin after whole blood was 
incubated for 30 minutes with 30μM ADP, 100μM TRAP or 1mg/ml CRP-XL compared to fixed 
untreated control (0 minute). Although significant increases were observed, these still represent 
exceedingly modest changes in the percentage of lymphocytes forming LPA, as treatment with 
any of these agonists does not induce more than a 3% increase in LPA formation (Figure 7-1). 
7.3.2 PSGL-1 expression - lymphocytes  
As the main interaction between leukocytes and platelets has been well documented to 
be between platelet P-selectin and leukocyte PSGL-1, we decided to measure the PSGL-1 
expression on different leukocyte subsets in whole blood using flow cytometry.  Figure 7-2 
shows the expression of PSGL-1 on lymphocytes. Identified through their size, granularity and 
CD3 expression, T lymphocytes were found to express PSGL-1 (Figure 7-2A).  This remained the 
same even after 30 minutes incubation at 37°C (stirred), either with or without 100μM TRAP or 
1μg/ml CRP-XL (Figure 7-2A).  The MFI of PSGL-1 remains ~300 and is not significantly different 
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after treatment with either TRAP or CRP-XL showing that the surface expression of this marker is 
not affected by the addition of these platelet agonists (Figure 7-2B). However, figure 7-2 C and D 
clearly demonstrate that less than 10% of B lymphocytes (identified through size, granularity and 





















Figure 7-1: LPA formation using P-selectin as a marker  
Whole blood was incubated at 37°C with 30μM ADP, 100μM TRAP or 1μg/ml CRP-XL or left 
untreated. As a control untreated whole blood was fixed within 10 minutes of being taken, prior 
to any treatment (0 minute control). Lymphocyte platelet aggregates (LPA) were detected using 
flow cytometry against the platelet marker CD62P.  Less than 1% LPA form without the addition 
of an agonist, but a significant increase can be detected after treatment with TRAP, ADP and 
CRP-XL, although the total percentage LPA formed never goes above 3%.  ANOVA (P<0.0001) 
indicates that there is a significant increase in LPA formation after treatment with an agonist.  
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Figure 7-2: PSGL-1 expression on T and B lymphocytes 
Figure 7-2 shows surface expression of PSGL-1 by lymphocytes in whole blood, which has been 
fixed prior to any treatment (0 minute control) or incubated at 37°C, following treatment with 
100μM TRAP, 1μg/ml CRP-XL or left untreated. Data acquired using flow cytometry.   A) 
Demonstrates that all T-lymphocytes, based on size, granularity and CD3 expression express 
PSGL-1.  B) The high MFI indicates a high level of expression of PSGL-1 per cell. C) Shows that 
only ~10% of B-lymphocytes (depicted based on their size, granularity and CD20) express PSGL-1 








CRP-XL -         -       +         -





















CRP-XL -         -       +         -





























CRP-XL -         -       +         -



























CRP-XL -         -       +         -














Chapter 7                                           The role of P-selectin in leukocyte-Platelet aggregate formation 
238 
 
7.3.3 NPA detection using P-selectin as a platelet marker 
Previous data has demonstrated that upon platelet activation NPA form in whole blood.  
As P-selectin interaction with PSGL-1 has a potentially important role in NPA formation, we 
thought it important to measure the percentage NPA based on P-selectin expression after 30 
minute treatment with 30μM ADP, 100μM TRAP and 1μg/ml CRP-XL. 
Untreated blood either fixed within 10 minutes of aliquoting into CPDA or incubated at 
37°C for 30 minutes, before fixing showed less than 1% NPA formation (Figure 7-3).  As previous 
data has demonstrated that platelet activation is necessary for a significant number of NPA to 
form this suggests that platelets were in their resting state.  There was a significant increase in 
percentage NPA formation in whole blood after 30 minute incubation with ADP, TRAP or CRP-XL 
compared to fixed, untreated control (0 minute) (Figure 7-3A).  The maximum increase in 
percentage NPA formation reached 55% after treatment with TRAP (Figure 7-3A).  However, the 
P-selectin MFI of these NPA remained low reaching a maximum of ~15 after treatment with 
TRAP or CRP-XL, indicating that the amount of P-selectin expression per NPA was low (Figure 7-
3B).   
The percentage of NPA formation based on CD42b expression from the same samples is 
shown in figure 7-3C.  There was ~5% NPA formation observed for untreated whole blood, which 
had been fixed prior to treatment (0 minute) or incubated at 37°C without the addition of 
agonist (Figure 7-3C).  There was a significant increase in percentage NPA formation after 
treatment with ADP and TRAP (Figure 7-3C).  However, treatment with CRP-XL did not show any 
significant increase in NPA compared to the control using CD42b as a marker (Figure 7-3C). This 
is noteworthy, as P-selectin and CD42b are delivering different information about the formation 
of NPA in response to this agonist.  
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7.3.4 PSGL-1 expression - neutrophils 
 PSGL-1 expression by neutrophils was also demonstrated in this study.  The data 
suggests that all neutrophils express surface PSGL-1 (Figure 7-4A).  However, the PSGL-1 MFI is ~ 
150 which indicated that surface expression by neutrophils is lower than T-lymphocytes (MFI 
~300) (Figure 7-2B and 7-4B).  Neutrophils also showed a significant reduction in surface PSGL-1 
expression, after treatment with either 100μM TRAP or 1μg/ml CRP-XL compared to whole blood 
fixed prior to any treatment (Figure 7-4B).  This reduction was not detected in blood, which was 
incubated without the addition of any platelet agonist (Figure 7-4B). 
7.3.5 The effect of P-selectin blocking antibody on NPA formation 
Having determined that neutrophils express PSGL-1, we decided to block its interaction 
with P-selectin (using P-selectin blocking antibody, G1) in whole blood, prior to any treatment 
with platelet agonist to see if this reduced the percentage of NPA which formed.  As a control, 
samples were also incubated with relevant (non-blocking) IgG, and formation of NPA was 
assessed using flow cytometry where NPA formation was based on platelet CD42b expression. 
In the presence of control IgG antibody, blood treated with 30μM ADP, 100μM TRAP and 
1μg/ml CRP-XL still supported the formation of NPA (Figure 7-5). However, NPA formation was 
decreased in the absence of IgG control antibody, after treatment with TRAP and CRP-XL, this 
was not significant (compared to IgG normalised control) (Figure 7-5).  There was a significant 
decrease in percentage NPA formation after treatment with ADP, TRAP and CRP-XL in the 
presence of P-selectin (G1) blocking antibody (Figure 7-5).  This demonstrates that P-selectin is 
important for the formation of these aggregates. 
 





Figure 7-3: NPA formation based on platelet P-selectin or CD42b expression  
Whole blood was incubated at 37°C with 100µM TRAP, 30μM ADP, 1μg/ml CRP-XL or was left 
untreated.  For a control whole blood was fixed within 10 minutes of aliquoting into CPDA (0 
minute control). NPA were detected using flow cytometry against the neutrophil marker CD16 
and the platelet marker CD62P (A and B) or CD42b C).  A) Indicates there is ~1% NPA formed in 
untreated whole blood, a significant increase is observed after treatment with TRAP, ADP and 
CRP-XL compared to 0 minute control.  ANOVA (P<0.0001) suggests there is a significant increase 
in percentage NPA formation after treatment with an agonist.  B) Shows a significant increase in 
surface expression of P-selectin indicated by the MFI after treatment with TRAP or CRP-XL, 
ANOVA (P<0.005). C) There is a significant increase in percentage NPA formation based on 
CD42b expression after treatment with ADP or TRAP compared to 0 minute control (ANOVA 
P<0.0001).   (*,** and *** indicate P<0.05, P<0.01 and P<0.001, respectively, post hoc test 











ADP   -          -        +        -        -
TRAP -          -        -        +        -







































ADP   -          -        +        -        -
TRAP -          -        -        +        -

































ADP   -          -        +        -        -
TRAP -          -        -        +        -



































Figure 7-4: PSGL-1 expression on neutrophils 
Figure 7-4 shows surface expression of PSGL-1 by neutrophils in whole blood, which has been fixed prior to any treatment (0 minute control) or 
incubated at 37°C, following treatment with 100μM TRAP, 1μg/ml CRP-XL or left untreated. Data were acquired using flow cytometry.  A) 
Demonstrates that neutrophils based on their size, granularity and CD16 expression, express surface PSGL-1. B) Indicates that surface expression of 
PSGL-1 is significantly reduced after 30 minute treatment with CRP-XL or TRAP compared 0 minute control.  30 minute incubation alone showed no 
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Figure 7-5: NPA formation in whole blood after pre-treatment with P-selectin blocking 
antibody 
Whole blood was pre-treated with 20μg/ml of P-selectin blocking antibody (G1) or (non-
blocking) unlabelled mouse IgG, or treated with agonist alone.  Samples were incubated at 37°C 
with 100µM TRAP, 30μM ADP, 1μg/ml CRP-XL, NPA were detected using flow cytometry against 
the neutrophil marker CD16 and the platelet marker CD42b.  Data was normalised to the IgG 
control.  Pre-treatment with P-selectin blocking antibody shows a significant decrease in NPA 
formation after treatment with ADP, TRAP or CRP-XL compared to normalised IgG control 
(ANOVA (P<0.005). (*,** and *** indicate P<0.05, P<0.01 and P<0.001, respectively, post hoc 
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7.3.6 MPA detection using P-selectin as a platelet marker. 
Platelets are known to express P-selectin upon activation with an agonist.  This ligand is 
thought to be important for MPA formation.  Untreated blood either fixed within 10 minutes of 
aliquoting into CPDA or incubated at 37°C for 30 minutes before fixing showed ~5% MPA 
formation (Figure 7-6A and B).  This suggests that platelets were in their resting state.  Figure 7-
6A and B demonstrated that whole blood treated with ADP, TRAP and CRP-XL significantly 
increase MPA formation, using P-selectin as a platelet marker, compared to blood fixed prior to 
any treatment (0 minute).  This occurred for both the monocyte subsets and both subsets 
showed nearly all of the monocytes were positive for P-selectin (Figure 7-6A and B).  The MFI for 
P-selectin on both subsets reached a maximum of 60 with TRAP and CRP-XL, although ADP is a 
lesser agonist in this respect.  For comparison we include the levels of MPA formation measured 
using CD42b as a platelet marker (Figures 7-6E and F).  Interestingly, there is a large discrepancy 
in the reported formation of MPA using this marker compared to P-selectin, with the later 
indicating far more robust MPA formation than our previous data indicated.  
7.3.7 PSGL-1 expression - monocytes 
Monocytes are known to express PSGL-1 the highest affinity ligand for platelet P-selectin.  
However, flow cytometry data from whole blood demonstrates that differences occur between 
monocyte subsets.  Figure 7-7A and B demonstrate that both monocyte subsets express surface 
PSGL-1.  However, monocytes in untreated blood, either instantly fixed (0 minute) or incubated 
for 30 minutes at 37°C showed differences in the levels of surface expression of PSGL-1; with the 
CD14+CD16- subset showing a higher level of surface expression (MFI ~450) than the CD14+CD16+ 
subset (MFI ~350) (figure 7-7C and D).  Figure 7-7C also indicates that PSGL-1 may be shed from 
the CD14+CD16- monocyte surface after whole blood has been treated with TRAP or CRP-XL. 
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Interestingly however, the CD14+CD16+ subset do not demonstrate such a response (Figure 7-
7D). 
7.3.8 The effect of P-selectin blocking antibody on MPA formation 
Having determined that monocytes express the ligand PSGL-1, we decided to block the 
interaction with P-selectin (using P-selectin blocking antibody, G1) prior to any treatment with 
platelet agonist. As a control, samples were also incubated with (non blocking) IgG and 
formation of MPA was assessed using flow cytometry with CD42b as a platelet marker. 
Figure 7-8A and B shows a significant reduction in MPA formation in the presence of an 
anti-P-selectin blocking antibody, after treatment with; ADP, TRAP, CRP-XL or histone H4 for 
both monocyte subsets.  A decrease in MPA formation is detected with agonist treatment alone 
compared to IgG control, however, this is not statistically significant with the exception of the 
effect of TRAP treatment on the CD14+CD16- subset (Figure 7-8A).  In this instance there is a 








Figure 7-6: MPA formation based on platelet P-selectin or CD42b expression 
Whole blood was incubated at 37°C with 100µM TRAP, 30μM ADP, 1μg/ml CRP-XL or untreated.  
For a control whole blood was fixed within 10 minutes of aliquoting into CPDA (0 minute 
control).  Monocyte-platelet aggregate (MPA) were detected using flow cytometry against the 
monocyte markers CD14 and CD16 and the platelet marker CD62P (A, B, C and D) or CD42b (E 
and F).  A, C and E show the monocyte subset CD14+CD16- and B, D and F show the CD14+CD16+ 
monocyte subset.  A and B) Demonstrate that MPA formation for both monocyte subsets is 
significantly increased, upon addition of a platelet agonist (ANOVA P<0.001).  C) indicates that 
surface expression of P-selectin is significantly increased on CD14+CD16- MPA compared to 0 
minute control after treatment with all agonists (ANOVA P<0.001). D) shows surface expression 
of P-selectin CD14+CD16+ monocyte subset is significantly increased after treatment with TRAP 
and CRP-XL (ANOVA P<0.001).  E) and F) demonstrate a significant increase in percentage MPA 
formation based on the platelet marker CD42b, after treatment with any agonist, compared to 0 
minute control, (ANOVA P<0.01 and P<0.001, for E and F, respectively).  *,** and *** indicate 
P<0.05, P<0.01 and P<0.001, respectively, compared to 0 minute control, blood fixed prior to 
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Figure 7-7: PSGL-1 expression on monocyte subsets 
Figure 7-7 shows surface expression of PSGL-1 by monocytes in whole blood, which has been 
fixed prior to any treatment (0 minute control) or incubated at 37°C following treatment with 
100μM TRAP, 1μg/ml CRP-XL or left untreated. Data were acquired using flow cytometry.  A) and 
B) demonstrates that PSGL-1 is expressed by both CD14+CD16- and CD14+CD16+ monocytes, 
respectively. C) Demonstrates CD14+CD16- subset in untreated blood has a high surface 
expression of PSGL-1 (MFI ~500), which is significantly reduced upon addition of a platelet 
agonist (MFI ~250) (ANOVA P<0.001).  D) Demonstrates CD14+CD16+ subset also express high 
levels of surface PSGL-1 (~300).  *,** and *** indicate P<0.05, P<0.01 and P<0.001, respectively, 
compared to 0 minute, blood fixed prior to treatment, post hoc test Dunnett’s.) Data are mean 
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Figure 7-8: Reduction in MPA formation in whole blood after pre-treatment with P-selectin blocking antibody 
Whole blood was pre-treated with 20μg/ml of P-selectin blocking antibody (G1), unlabelled mouse IgG or agonist alone.  Samples were then 
incubated at 37°C with 100µM TRAP, 30μM ADP, 1μg/ml CRP-XL or 100μg/ml H4. Monocyte-platelet aggregates were detected using flow cytometry 
against the monocyte markers CD14, CD16 and the platelet marker CD42b.  Data was normalised to the IgG control.  A) Shows MPA formation for the 
CD14+CD16- monocyte subset is significantly reduced after pre-treatment with P-selectin blocking antibody (ANOVA P<0.001). B) shows MPA 
formation for the CD14+CD16+ monocyte subset is significantly reduced after pre-treatment with P-selectin blocking antibody (ANOVA P<0.001). *,** 
and *** indicate P<0.05, P<0.01 and P<0.001, respectively, compared to normalised IgG control for each agonist, post hoc test Bonferroni).




A small but significant increase (<3%) in LPA formation was detected (using P-selectin as 
a platelet marker) in whole blood after 30 minute treatment with ADP, CRP-XL and TRAP 
compared to blood fixed prior to treatment (0 minute control).  Incubation at 37°C alone had no 
significant effect on LPA formation.  This demonstrates that platelet activation is necessary for a 
significant level of LPA to form.  This small increase is in agreement with data showing little to no 
change in LPA formation using the platelet marker CD42b (Chapter 6).  The data is also in 
agreement with several previous studies.  Rinder et al, (1991) demonstrated no significant 
increase in percentage LPA formation over time after platelet activation with thrombin, 
however, the baseline percentage LPA formation was found to be ~10% throughout the study.  
Another study investigated LPA formation by individual lymphocyte subsets after platelet 
activation in whole blood incubated at 37°C (Li et al., 2006).  This study demonstrated that 
untreated NK, T-lymphocytes and B-lymphocytes had a baseline ~3% LPA. After treatment with 
10μM ADP, the percentage of LPA for the NK subset significantly increased to ~10%, while T- 
lymphocyte subset significantly increased to 5% and B-lymphocytes showed no change (Li et al., 
2006).  The differences between subsets would not be detected in our study. 
The leukocyte ligand with the highest affinity for P-selectin is PSGL-1.  This is thought to 
be the most important initial interaction in the formation of leukocyte-platelet aggregates.  This 
is in agreement with a previous study; Moore & Thompson, (1992) demonstrated that <2% 
isolated B lymphocytes were able to bind to purified P-selectin, this data further implies a lack of 
PSGL-1 expression by this lymphocyte subset.  Our data also demonstrates that T-lymphocytes 
express very high levels of PSGL-1, but paradoxically form very few LPA under the conditions of 
shear imposed by our assay.  A previous study demonstrated that 16.4± 10.4% and 6.0± 5.0% 
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isolated NK and T lymphocytes bound purified P-selectin respectively (Moore and Thompson, 
1992).  Indeed, it has been suggested that  PSGL-1 needs to undergo post translational 
modifications before it is able to bind to P-selectin (Ley, 2003).  Fucosyltransferase VII (FucT-VII) 
and Core 2 N-acetylglucosamine transferase (C2GnT) are enzymes, which mediate post 
translational modifications necessary for PSGL-1 binding to P-selectin (McEver and Cummings, 
1997).  Only CD4+ and CD8+ Th1 cells have been demonstrated to have these enzymes and bind 
P-selectin in a PSGL-1 dependent manner (White et al., 2001; Erdmann et al., 2002; Lim et al., 
1999; McEver and Cummings, 1997).  Data from other studies has indicated that upon T-cell 
activation there is an increase in expression of both of these enzymes (Erdmann et al., 2002; 
Vachino et al., 1995). 
Thus it may be that PSGL-1 on lymphocytes is not binding to P-selectin, possibly due to 
inappropriate localisation on the cell surface or lack of appropriate posttranslational processing. 
Alternatively, P-selectin-PSGL-1 interactions may be transient, with the formation of stable 
aggregates in other leukocyte subsets dependent upon additional adhesive pathways, which are 
lacking in lymphocytes.  Any interaction between platelet P-selectin and lymphocytes may be 
through another lymphocyte receptor which binds P-selectin with a lower affinity (Mehta, P. 
Cummings, 1998). 
Lymphocytes  are part of the acquired immune system and have a longer half life over 2 
months (compared to 6-8 hour half life for neutrophils), (Hellerstein et al., 1999).  Although 
lymphocytes are recruited to sites of inflammation this largely happens at a later stage than 
recruitment of innate immune cells (Ley et al., 2007).  Lymphocytes have been shown to have a 
role in atherogenesis, however, their recruitment is thought to occur later in plaque 
development, mainly through interactions with APC such as monocytes and macrophages 
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(Woollard, 2013).  It is possible that the differences in biological function of lymphocytes 
compared to leukocytes of the innate immune system means they have not evolved to interact 
with platelets to the same extent. 
Data from this study indicates that MPA and NPA both form in whole blood upon 
addition of a platelet agonist and this is mainly due to platelet derived microvesicles adhering to 
monocytes or neutrophils, with platelet adhesion to leukocytes being rare events.  The incidence 
of these heterotypic aggregates increases in a time dependent manner.  Whole blood incubated 
without the addition of any agonist showed no significant increase in either NPA or MPA over 
time.  This data strongly suggests that platelet activation is important for these heterotypic 
aggregates to occur.  Upon platelet activation P-selectin is released from α granules and is 
trafficked to the platelet surface (Rinder et al., 1993).  Platelet surface P-selectin interaction with 
PSGL-1 is thought to have an important role in initial platelet adhesion to leukocytes (Evangelista 
et al., 2003, 1999; McEver and Cummings, 1997; Théorêt et al., 2001; Zarbock et al., 2007b; 
Jensen et al., 2001).  Platelet derived microvesicles have also been demonstrated to express P-
selectin, (Hargett and Bauer, 2013) and so could potentially interact with monocyte or 
neutrophil PSGL-1. 
It was possible to measure percentage MPA and NPA formation in whole blood after 
treatment with a platelet agonist using platelet P-selectin as a platelet marker.  Very few MPA or 
NPA could be detected in whole blood, which had been fixed shortly after phlebotomy (0 minute 
control) or in blood which had been incubated for up to 30 minutes, without the addition of any 
agonist.  As data from this study and others have indicated that platelet activation is necessary 
for a significant increase in either of these leukocyte-platelet aggregates to occur, this implies 
that platelets are in their resting state (Michelson et al., 2001; Rinder et al., 1991). 
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However, after incubation with 30μM ADP, 100μM TRAP or 1μg/ml CRP-XL there is a 
significant increase in NPA and MPA formation compared to untreated controls (using P-selectin 
as a platelet marker).  The increase in percentage MPA formation is greater for both subsets of 
monocytes (~95% after treatment with TRAP) compared to percentage NPA formation (~50% 
after treatment with TRAP).  The P-selectin MFI also suggested a higher surface expression of P-
selectin per MPA compared to NPA.  This is in agreement with previous studies where a greater 
increase in MPA formation compared to NPA formation has been previously demonstrated upon 
platelet activation both in vivo and in vitro (Michelson et al., 2001; Rinder et al., 1991).  MPA 
have also been found to be more prominent than NPA in a chronic inflammatory disease setting 
(such as atherosclerosis), (Joseph et al., 2001; Mickelson et al., 1996).  Over all, the most potent 
agonist which induced the most MPA and NPA was shown to be TRAP.  However, for this part of 
the study a new batch of TRAP was used which did not appear to be as potent as the batch used 
previously. 
Although P-selectin may be a more sensitive marker for both percentage MPA and NPA 
formation it would be difficult to use the MFI to assess whether platelet or platelet derived 
microvesicles are binding to platelets.  As P-selectin is not expressed on the resting platelet 
surface, the MFI would be very low and it could not be used to differentiate between platelets 
and platelet microvesicles.  Once an agonist is added and the platelets become activated they 
undergo shape change, aggregate and release granules making it difficult to identify them in a 
whole blood sample based on their size and granularity; making a comparison using activated 
platelets difficult. 
Monocytes and neutrophils in untreated, CRP-XL or TRAP treated whole blood were 
shown to express PSGL-1.  Surface expression of CD14+CD16- monocyte subset in untreated 
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whole blood was highest (MFI~450), followed by CD14+CD16+ monocytes (MFI ~350). 
Neutrophils had a far lower surface expression of PSGL-1 (MFI ~150).  Upon treatment of whole 
blood with the platelet agonist TRAP or CRP-XL there is a significant reduction in surface PSGL-1 
expression for both CD14+CD16- monocytes (~250) and neutrophils (~100).  This may be due to 
masking of the PSGL-1 antigen by bound platelets or PMV.  However, PSGL-1 can also be shed 
(proteolytically or on microvesicles).  For example, monocyte microvesicles with high 
concentration of tissue factor have been shown to be positive for PSGL-1 (Del Conde et al., 
2005), thus, we cannot exclude that shedding of PSGL-1 plays some role in this reduction. 
It has been demonstrated that neutrophils and monocytes possess the enzymes 
necessary to carry out post translational modifications to PSGL-1 so it is known to be expressed 
in its active form (McEver & Cummings 1997; Mehta, P. et al 1998).  A previous study, in which, 
isolated platelets and neutrophils (mixed at a 1:2 ratio) infused over intact or damaged 
endothelium in vitro, showed that platelets were activated (P-selectin was expressed) when 
flowed across a damaged surface and NPA formed (Théorêt et al., 2001).  However, pre 
treatment of isolated platelets (before the addition of neutrophils) with PSGL-1 blocking 
antibody or P-selectin blocking antibody showed a significant reduction in NPA formation 
(Théorêt et al., 2001).  Konstantopoulos et al, (1998) demonstrated that blocking antibodies 
against either P-selectin or PSGL-1 decreased NPA formation in sheared (100S-1) whole blood.  
Kuckleburg et al. (2011) demonstrated that platelets adherent to activated EC preferentially 
recruited monocytes and P-selectin blocking antibody significantly reduced this.  This data 
suggests that neutrophil and monocyte PSGL-1 in its active form plays an important role in NPA 
and MPA formation. 
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So far we have demonstrated that upon activation with a platelet agonist MPA and NPA 
form in whole blood and the increase in these heterotypic aggregates observed after 30 minutes 
is possibly due to PMV adhesion to these leukocytes.  We have also demonstrated the 
expression of PSGL-1 by both monocytes and neutrophils, which is known to be in its active 
form.  To find out if P-selectin is important for PMV adhesion to monocytes and neutrophils we 
blocked this interaction using a P-selectin blocking antibody, before activating platelets in whole 
blood with 30μM ADP, 100μM TRAP or 1μg/ml CRP-XL (or H4 monocytes only).  A significant 
reduction in NPA and MPA formation (for both monocyte subsets) was observed when samples 
were pre-treated with P-selectin blocking antibody compared to pre-treatment with non-
blocking IgG control antibody.  This demonstrates that P-selectin is important in MPA and NPA 
formation.  It suggests that platelets (and possibly platelet derived microvesicles) are adhering to 
monocyte and neutrophils through an interaction involving their P-selectin expression and the 
leukocyte PSGL-1. 
As the data suggests that the initial interaction between the leukocytes and platelets (or 
PMV) is highly dependent on P-selectin and leukocyte PSGL-1 interaction, this could give a 
possible explanation as to why monocytes preferentially adhere to PMV rather than neutrophils.  
Monocytes have much higher surface expression of PSGL-1 than neutrophils, making them more 
likely to bind to PMV and platelets.  However, P-selectin blocking antibody does not completely 
block either NPA or MPA formation.  This may be because other interactions also have a role in 
heterotypic aggregate formation.  The interaction between platelet P-selectin and PSGL-1 has 
been suggested to activate monocytes and neutrophils (Christersson et al., 2008; Weber and 
Springer, 1997).  Weber and Springer, (1997) demonstrated using neutrophils that an increased 
expression of CD11b/CD18 occurred in response to PSGL-1 interaction with P-selectin.  
Evangelista et al, (1999) then demonstrated neutrophils bind to activated platelets using both 
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PSGL-1 and CD11b/CD18 (MAC-1).  It is thought that stable adhesion takes place when active 
platelet αIIbβ3 integrin binds neutrophil CD11b/CD18 (Neumann et al., 1999; Furman et al., 2001; 
Brown et al., 1998).  As PMV have been reported to express CD41 and CD61 (which together 
form the αIIbβ3) integrin it is also possible they are adhering to monocytes or neutrophils through 
this mechanism (Beyer and Pisetsky, 2010), future experiments blocking this interaction should 
be carried out to investigate this. 
Conclusions 
We have demonstrated that upon platelet activation, platelets (and possibly platelet 
microvesicles) are released and these are able to adhere to monocytes and neutrophils and at 
very low levels to lymphocytes.  Lymphocytes express high levels of PSGL-1 although do not 
possess the enzymes to carry out post translational modifications, which allow binding to P-
selectin.  Neutrophils and monocytes, however, express PSGL-1.  Data indicates that monocytes 
express the highest levels of PSGL-1 and form heterotypic aggregates more readily than 
neutrophils or lymphocytes.  Blocking P-selectin significantly reduces platelet (and PMV) 
















8. Chapter 8- RECRUITMENT OF MONOCYTE-










Platelet adhesion to activated endothelium before the appearance of atherosclerotic 
plaques has been demonstrated in APOE-/- mice (Burger and Wagner, 2003; Massberg et al., 
2002).  This is thought to be one of the first stages of the disease, preceding leukocyte 
infiltration of the artery wall (Ross, 1999).  Using in vitro flow assays, we have previously 
demonstrated one of the mechanisms, through which platelets may be captured during the 
atherosclerotic process.  Secretory phenotype SMC, found in atherosclerotic conditions, release 
plasmin, which is able to cleave TGF-β into its active form by removing the latency associated 
peptide.  Active TGF-β stimulates HUVEC to express vWf on the cell surface (Tull et al., 2006).  
Von Willebrand factor is able to capture platelets, initially through interactions with CD42b 
(GPIb), before they become activated in an ADP dependent manner and bind to vWf through 
αIIbβ3 integrin (Tull et al., 2006).  Activated platelets express P-selectin and are able to aid in 
initial leukocyte capture through classic selectin based interactions (Kuckleburg et al., 2011). 
Other studies have suggested that blocking platelet adhesion or platelet P-selectin 
expression reduces infiltration of leukocytes into the artery wall, in vivo (Massberg et al., 2002; 
Burger and Wagner, 2003).  Kuckleburg et al., (2011) revealed that these platelet-born P-selectin 
bridges preferentially recruited monocytes rather than other leukocyte subsets.  Platelets are 
known to release RANTES and CXCL4, both have been demonstrated to aid in monocyte 
activation and subsequent transmigration (von Hundelshausen et al., 2001, 2005; Kuckleburg et 
al., 2011).  As monocytes are amongst the first leukocyte subsets to infiltrate the damaged artery 
wall during the atherosclerotic disease process (Ross, 1999), the identification of a potential role 
for platelets in their specific recruitment may be  important for developing future treatments. 
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However, it is also worth noting that under static conditions, cultured endothelial cells 
have been demonstrated to bind PMV and this is associated with an increase in EC ICAM-1 
expression (Barry et al., 1998).  This was accompanied by monocyte adhesion, which increased 
with longer incubation periods (Barry et al., 1998).  Another study has suggested that PMV are 
able to mediate interactions between leukocytes (Forlow et al., 2000).  After incubation with an 
L-selectin blocking antibody to inhibit leukocyte-leukocyte secondary adhesion events, PMV 
could restore neutrophil capture by other neutrophils under low shear stresses.  Importantly, 
this was reduced in the presence of P-selectin blocking antibody (Forlow et al., 2000).  The 
authors suggest that in this case, the P-selectin on PMV is interacting with leukocyte PSGL-1 to 
achieve neutrophil recruitment.  It has also been suggested that PMV are able to deliver RANTES 
to the endothelium and aid in monocyte arrest (Mause et al., 2005).  Together, these 
observations indicate that PMV may provide both an adhesive platform and activating stimuli, 
which could support leukocyte capture in the absence of endothelial expression of these agents.  
Aims 
1) To find out if activating isolated washed platelets leads to a significant increase in 
PMV, and which is the most potent agonist in this context. 
 
2) To find out if isolated PMV are able to form aggregates with isolated monocytes and 
whether the route of platelet activation, through which the PMV are generated 
effects the final number of PMV-monocyte aggregates. 
 
3) To determine whether monocyte-PMV aggregates can be captured by vWf under 
conditions of low shear stress. 




8.2.1 Generating platelet derived microvesicles 
Briefly, blood was collected into CPDA and platelets were isolated using theophylline. 
2.5ml of 0.15% (w/v) PBSA containing platelets at a concentration of 8x108/ml were incubated at 
37°C for 30 minutes either without the addition of any agonist (control) or in the presence of 
100μM TRAP, 1μg/ml CRP-XL or 10μM U46619 or both CRP-XL and U46619.  Supernatants were 
collected following centrifugation at 200G for 20 minutes and 13000G for 2 minutes.  PMV were 
collected, 1ml was stored at -80°C (to be incubated with isolated monocytes at a later date) and 
1ml was used for determining the concentration and size distribution using the Nanosight.  (For 
further details see methods section 2.4.1 and 2.4.3.) 
 8.2.2 Generating monocyte-PMV aggregates 
Blood was collected into EDTA and monocytes were isolated using a histopaque density 
gradient followed by incubation with CD14 positive magnetic beads.  Monocytes were separated 
using a magnetic column.  1x106 isolated (mixed) monocytes were incubated at 37°C for 30 
minutes in 0.15% (w/v) PBSA or in a previously prepared aliquot of platelet derived microvesicles 
(which had been stored at -80°C).  At the end of the 30 minute incubation period, samples were 
fixed using 1% (w/v) FA and then incubated with antibodies against CD14, CD16 and CD42b.  
Data were acquired using flow cytometry.  (For further details see methods section 2.4.4 and 
2.4.5) 
8.2.3 Flow based adhesion assay; monocyte-PMV recruitment to vWf 
Platelet derived microvesicles were isolated (as above) using 1μg/ml CRP-XL as a platelet 
agonist and were stored at -80°C.  Monocytes were isolated (as above) and 5x105 monocytes 
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were incubated with 0.5ml CRP-XL derived PMV or 0.15% (w/v) PBSA for 30 minutes at 37°C 
before being used in the flow assay. 
1mm x 10mm x 0.1mm (width, x length, x height) APES coated, glass microslides were 
incubated for 2 hours with 100μg/ml vWf, followed by 1 hour with 1% (w/v) BSA (at 37°C).  Or 
for BSA controls, slides were incubated with 1% (w/v) BSA at 37°C for a minimum of 1 hour.  In 
some experiments, slides were incubated with P-selectin blocking antibody (G1) or IgG control 
for 30 minutes.  Monocyte or monocyte-PMV aggregate samples were flowed at 0.1Pa for a total 
of 3.5 minutes.  After 1 minute of initiating perfusion, digital images of the experiment were 
collected every 340ms over a 17s period, for 6 different fields of view on the slide.  Videos were 
analysed using image pro software.  (For further details see method section 2.4.4, 2.4.5 and 
2.4.7-2.4.9.) 
8.2.4 Western blot for the detection of P-selectin 
100µg/ml recombinant human P-selectin and 250µg/ml human vWf (vWf used for flow 
adhesion assays) were heated to 70°C in Laemmli buffer for 10 minutes before being loaded on 
to a 8% SDS page gel.  Following electrophoresis at 200V for 45 minutes, gels were removed 
from tanks and either stained with coomassie blue, or transferred to PVDF membranes 
(electrophoresis at 100V for was carried out for 1hour).  Membranes were incubated at 4°C 
overnight in PBS- tween either with or without 0.1µg/ml sheep anti-human P-selectin antibody.  
The following day, membranes were incubated with donkey anti-sheep HRP conjugated 
secondary antibody for 1 hour.  Membranes were covered with ECL detection mixture and 
incubated for 5 minutes at RT.  Chemiluminescence was detected using photographic film (10s 
exposure).  (For further details see method section 2.5.0.) 
 




8.3.1 Measuring PMV production after incubation of isolated washed platelets with a platelet 
agonist 
Before monocyte-microvesicle aggregates could be used in flow assays, it was important 
to determine if PMV could be generated and isolated following treatment of platelets with an 
agonist.  Also, whether treatment with any particular agonist was more effective in this context.  
To prevent samples being contaminated with leukocyte microvesicles, platelets were isolated 
prior to any treatment with an agonist.  Washed isolated platelets suspended at a concentration 
of 8x108/ml showed a significant increase in microvesicle production, following 30 minutes 
incubation at 37°C with either 1μg/ml CRP-XL or 10μM U46619 compared to untreated controls.  
CRP-XL was found to be the most potent agonist for PMV production, with an average of 
~1.25x109/ml vesicles produced (Figure 8-1A).  The weakest agonist in this system was 
surprisingly 100μM TRAP, showing an average of ~5x108/ml vesicles produced (Figure 8-1A).  A 
combination of both CRP-XL and U46619 did not lead to a further increase in PMV production 
(Figure 8-1A).  The PMV produced were also shown to be significantly bigger following treatment 
with CRP-XL, U46619 or a combination of both compared to the untreated control (Figure 8-1B). 
The size distribution indicates that the majority of PMV produced either from untreated 
platelets or following treatment with an agonist were between 100-399nm in diameter (Figure 
8-2A-E).  However, after treatment with 1μg/ml CRP-XL or a combination of 10μM U46619 and 
1μg/ml CRP-XL there appears to be more PMV produced with a diameter between 400-599nm 
compared to the controls or treatment with other agonists (Figure 8-2A-E).
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Figure 8-1: Microvesicle production following stimulation of washed isolated platelets with various agonists 
Washed isolated platelets suspended at 8x108 platelets/ml were incubated for 30 minutes at 37°C, either as untreated (con) or with 100μM TRAP, 
1μg/ml CRP-XL or 10μM U46619.  Microvesicles were isolated from supernatants following centrifugation for 20 minutes at 2000G and 2 minutes at 
13000G, data were acquired using the Nanosight.  A) Indicates a significant increase in the number of microvesicles released following treatment with 
a platelet agonist (ANOVA P<0.01).  B) shows a significant increase in the size of the microvesicles following treatment with a platelet agonist (ANOVA 
P<0.01)  *,** and *** indicate P<0.05, P<0.01 and P<0.001 respectively, post hoc test Dunnett’s.  Data are means of 3-5 experiments. 















































































































































































































































































































































































































































































































































































































































































































































D E Figure 8-2: Size distribution of platelet microvesicles  
Washed isolated platelets suspended at 8x108/ml and 
incubated for 30 minutes at 37°C with or without 
platelet agonist.  Microvesicles were isolated following 
centrifugation for 20 minutes at 2000G and 2 minutes 
at 13000G, data were acquired using Nanosight.  Data 
shows size distribution of platelet microvesicles for A) 
untreated platelets (7 experiments), or following 
treatment with B) 100μM TRAP (4 experiments), C) 
1μg/ml CRP-XL (4 experiments), D) 10μM U46619 (4 
experiments) and E) 1μg/ml CRP-XL and 10μM U46619 
(3 experiments).  Data are mean +/- SEM. 
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8.3.2 Generating monocyte-PMV aggregates through incubation of isolated monocytes with 
platelet derived microvesicles 
 Having determined that washed, isolated platelets incubated with an agonist 
produce PMV we wanted to find out if they would adhere to monocytes when incubated at 37°C 
under stirred conditions (samples on a roller mixer).  1x106 (mixed) monocytes were incubated 
with a 1ml aliquot of microvesicles of varying concentrations (Figure 8-1A).  Using the monocyte 
markers CD14 and CD16 and the platelet marker CD42b for identification, we demonstrate that 
up to 75% monocyte-PMV aggregates form for both monocyte subsets after incubation with 
CRP-XL generated PMV (Figure 8-3A and B).  The lowest percentage increase in monocyte-PMV 
formation was seen after incubation with TRAP generated PMV (~60% with both monocyte 
subsets) (Figure 8-3A and B).  The ~5% of MPA formed when monocytes are incubated in PBSA 
control is similar to previously observed data for percentage MPA formed in fixed whole blood. 
Figure 8-4A and B demonstrate that the CD42b MFI of the monocyte-PMV aggregates 
remains low for both monocyte subsets, relative to the CD42b MFI of resting platelets previously 
observed in whole blood.  Monocyte-PMV formed following incubation with PMV, generated 
using CRP-XL had the highest CD42b MFI, (~30 CD14+CD16- subset and ~35 CD14+CD16+ subset), 
Monocyte-PMV formed using TRAP generated PMV, had the lowest MFI (~20 both subsets).
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Figure 8-3: Isolated monocytes incubated with isolated platelet microvesicles  
One million monocytes (mixed subsets) were incubated for 30 minutes at 37°C, either in 1ml 0.15% (w/v) PBSA (control) or in 1ml PBSA containing 
platelet microvesicles produced from 8x108 platelets, following treatment with 100μM TRAP, 1μg/ml CRP-XL or 10μM U46619 (or both of these 
agonists together).  Samples were fixed and incubated with antibodies against CD14, CD16 and CD42b.  Data were acquired using flow cytometry.  A) 
Demonstrates a significant increase in percentage monocyte-PMV formation for the CD14+CD16- monocyte subset when monocytes are incubated 
with platelet microvesicles compared to PBSA control (ANOVA P<0.001).  B) Indicates this is also the case for the CD14+CD16+ monocyte subset 
(ANOVA P<0.0001).   *,** and *** indicate P<0.05, P<0.01 and P<0.001, respectively, post hoc test Dunnett’s.  Data are means for 3-4 experiments. 
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Figure 8-4: Monocyte-microvesicle aggregates; microvesicle coverage per cell  
One million monocytes (mixed subsets) were incubated for 30 minutes at 37°C either in 1ml 0.15% (w/v) PBSA (control) or in 1ml PBSA containing 
platelet microvesicles produced from 8x108 platelets, following treatment with 100μM TRAP, 1μg/ml CRP-XL and 10μM U46619 (or both of these 
agonists together).  Samples were fixed and incubated with antibodies against CD14, CD16 and CD42b.  Data were acquired using flow cytometry.  A) 
shows a significant increase in platelet marker expression on the CD14+CD16- monocyte-PMV aggregates, after treatment with either CRP-XL or 
U46619 compared to PBSA control, demonstrating more microvesicles are accumulated per monocyte (ANOVA P<0.001).  B) Indicates this is also the 
case for the CD14+CD16+ monocyte subset (ANOVA P<0.0001).  Data are means for 3-4 experiments. 
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8.3.3 Monocytes roll on vWf under conditions of low shear stress 
 Flow assays were carried out using APES coated glass microslides, which have 
been further coated with 100μg/ml vWf and blocked with 1% (w/v) BSA, or for a control, just 
blocked with 1% (w/v) BSA.  Isolated monocytes (mixed subsets) were incubated for 30 minutes 
at 37°C and flowed across the vWf substrate at a wall shear stress of 0.1Pa.  The 30 minute 
incubation of monocytes without PMV was necessary as in later experiments, where monocyte-
PMV aggregates will be used, the cells will be treated thus.  Any brief interaction (≥340ms) with 
the substrate was termed ‘rolling’, ‘stationary adherent’ cells were stationary for the full 17s 
period.  The data revealed that there is a significant increase in total monocyte adhesion to vWf 
compared to BSA control (Figure 8-5A).  The majority of monocytes were rolling along the vWf 
(Figure 8-5B). 
8.3.4 P-selectin blocking antibody prevents monocyte adhesion to the vWf substrate 
The vWf used for these experiments has been isolated from human plasma.  It is well 
known that soluble P-selectin is present in the plasma as well.  The monocyte rolling phenotype 
observed in the previous experiments lead us to believe that there may be P-selectin 
contamination of the vWf.  Therefore, vWf coated slides were further treated with P-selectin 
blocking antibody (G1) or non-blocking IgG control.  Monocytes were incubated at 37°C for 30 
minutes either in (0.15% w/v) PBSA or with PMV generated using CRP-XL.  CRP-XL was used as 
this lead to the highest number of vesicles being produced in isolated platelets; also when 
incubated with isolated monocytes, the highest number of CD42b positive, monocyte-PMV 
aggregates.  Although the CRP-XL was still present during the experiment, as monocytes do not 
express GPVI receptor this agonist should not directly affect them. 
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There was a significant increase in total monocyte adhesion to vWf treated with (non-
blocking) IgG antibody, however, treatment with P-selectin blocking antibody (G1) diminished 
this (Figure 8-6A).  This suggests that the vWf was contaminated with P-selectin and that it was 
this P-selectin interaction with monocytes, which lead to monocyte rolling observed throughout 
these experiments (Figure 8-6A and B).  Pre-incubating monocytes with CRP-XL derived PMV 
perfused across either P-selectin blocked or IgG treated vWf substrate, did not lead to a 
significant increase in monocyte capture compared to BSA control (Figure 8-6A and B). 
Figure 8-7A demonstrates that the PMV aliquots used in this study were of similar 
concentrations (~5x109/ml).  Therefore, similar numbers of PMV were added to 5x105 
monocytes for each sample used in this study.  Figure 8-7B again, indicates that treatment with 
CRP-XL lead to an increase in PMV size.  The majority of PMV were found to be between 100-
399nm in diameter, however, there are more PMV between 400-599 after treatment with CRP-
XL (Figure 8-8A and B). 
 On completion of the flow assay, samples were fixed and stained with the 
monocyte markers CD14, CD16 and platelet marker CD42b.  CD42b has been well documented 
to interact with vWf and therefore it was important to determine its presence on PMV.  Figure 8-
10A and B demonstrate that after 30 minutes incubation at 37°C, monocytes and CRP-XL PMV 
form monocyte-PMV aggregates, which express CD42b, effectively. 
 








































Figure 8-5: Monocyte capture by vWf substrate compared to BSA control at a wall shear stress of 0.1Pa. 
Isolated monocytes (mixed subsets) incubated for 30 minutes at 37°C (in the absence of PMV) were perfused across either 1% (w/v) BSA or 100μg/ml 
vWf substrate at a wall shear stress of 0.1Pa.  A) There was a significant increase in monocyte capture by vWf compared to BSA control (Unpaired t-
test P=0.0028).  B) ‘Rolling’ was defined as interaction with the substrate for at least 1 frame (340ms).  (‘Stationary adherent’ were stationary 
throughout the 17s period.) The majority (>95%) of monocytes that interacted with either BSA or Vwf ‘rolled’ along the substrate.  Data are mean +/- 
SEM for 5 experiments.











































Figure 8-6:  Monocyte capture by Vwf substrate in the presence of P-selectin blocking antibody at a wall shear stress of 0.1Pa 
Isolated monocytes (mixed subsets) were incubated for 30 minutes at 37°C in (0.15% w/v) PBSA or in the presence of platelet microvesicles, which 
had been previously isolated from 8x108 platelets treated with 1μg/ml CRP-XL and stored (-80°C).  Substrates were either 1% BSA controls or 
100μg/ml vWf substrate, which had been incubated for 30 minutes at 37°C with P-selectin blocking antibody (G1) or (non-blocking) IgG control.  
Samples were perfused across substrate at a wall shear stress of 0.1Pa.  A) A significant increase can be detected in monocyte capture by vWf 
incubated with IgG control compared to BSA control.  Treatment of vWf with P-selectin blocking antibody (G1) prevents this increase from occurring 
as does, pre-incubation of monocytes with platelet microvesicles. (ANOVA P<0.05), *,** and *** indicate P<0.05, P<0.01 and P<0.001, respectively, 
post hoc test Tukey’s multiple comparison test.  B) ‘Rolling’ was defined as interaction with the substrate for at least 1 frame (340ms).  (‘Stationary 
adherent’ were stationary throughout the 17s period.)  The majority (>95%) of monocytes or monocyte-microvesicle aggregates that interacted with 
vWf ‘rolled’ along the substrate.  Data are mean +/-SEM 4-5 experiments.










































Figure 8-7: Concentration and size of microvesicles after treatment with 1μg/ml CRP-XL 
Washed isolated platelets were suspended at 8x108/ml and incubated for 30 minutes at 37°C as either untreated (con) or with 1μg/ml CRP-XL.  
Microvesicles were isolated in supernatants following centrifugation 20 minutes at 2000G and 2 minutes at 13000G.  Data were acquired using the 
Nanosight.  A) Indicates a significant increase in the number of platelet microvesicles following treatment with CRP-XL.  B) Shows a significant 
increase in the size of the microvesicles following treatment with CRP-XL.  *,** and *** indicate P<0.05, P<0.01 and P<0.001, paired t-test.  Data are 
mean +/-SEM of 5 experiments. 


























































































































































































































































































Figure 8-8: The sized distribution of platelet microvesicles following treatment with 1μg/ml CRP-XL 
Washed isolated platelets suspended at 8x108/ml were incubated for 30 minutes at 37°C with or without platelet agonist. Platelet microvesicles were 
isolated in supernatants following centrifugation for 20 minutes at 2000G and 2 minutes at 13000G.  Data were acquired using the Nanosight.  Data 
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Figure 8-9: Monocyte-microvesicle aggregates formed for use in flow assays 
5x105 monocytes (mixed subsets) were incubated for 30 minutes at 37°C either in 0.5ml of 0.15% (w/v) PBSA (control) or 0.5ml PBSA, containing 
platelet microvesicles produced from isolated washed platelets (8x108/ml), following treatment with 1μg/ml CRP-XL.  Samples were used in flow 
assays.  At the end of the flow assay experiment samples were fixed and incubated with antibodies against CD14, CD16 and CD42b.  Data were 
acquired using flow cytometry.  A) Demonstrates a significant increase in percentage monocyte-microvesicle formation for monocytes (mixed 
subsets) when incubated with platelet microvesicles compared to PBSA control B) shows a significant increase in platelet marker expression on 
monocytes incubated with platelet microvesicles compared to PBSA control.  *,** and *** indicate P<0.05, P<0.01 and P<0.001 paired t-test (pairing 
not significant).  Data are mean +/- 5 experiments.  
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8.3.5 Confirming P-selectin contamination of vWf 
 Monocyte ‘rolling’ on vWf was significantly reduced in the presence of P-selectin 
blocking antibody.  This lead us to believe that soluble P-selectin may be contaminating the vWf, 
which was used as a substrate for flow based adhesion assays, designed to detect monocyte-
PMV capture by vWf.  To confirm this, a western blot was carried out using an anti-P-selectin 
antibody.  Recombinant P-selectin was used as a positive control.  The western blot shows a 
band between 100 and 150Kda which represents P-selectin, in the recombinant P-selectin lane 
confirming that the antibody recognises this ligand (Figure 8-11).  A band of a similar size can 
also be seen in the vWf lane, confirming the vWf is indeed contaminated with P-selectin (Figure 
8-11).  The coomassie stained gel confirms the presence of both P-selectin and vWf proteins 
(Figure 8-10). 




Figure 8-10: Coomassie blue stained gel showing P-selectin and vWf 
Recombinant P-selectin (100µg/ml) and human vWf (250µg/ml) were incubated at 70°C for 10 
minutes in Laemmli buffer and loaded on to an 8% SDS page gel.  Electrophoresis was carried out 
at 200V for 45 minutes.  Gel stained with coomassie blue.  Von Willebrand factor (monomers 
260KDa), a band can be detected in the vWf lane above 250KDa.  A faint band can also be seen in 
this lane between 100-150KDa, which could represent the presence of P-selectin. P-selectin 












Figure 8-11: Confirmation of P-selectin contamination of vWf 
Recombinant P-selectin (100µg/ml) and human vWf (250µg/ml) were incubated at 70°C for 10 
minutes in Lammeli buffer and loaded on to an 8% SDS page gel.  Bands were transferred on to 
membranes.  Membranes were subsequently incubated in PBS-tween overnight, either A) with 
or B) without the addition of sheep anti-human P-selectin antibody.  The following day, 
membranes were washed and incubated with donkey anti-sheep HRP conjugated antibody.  
Images are from a 10s exposure of chemiluminescent substrate on photographic film.  A) A band 
can be detected between 100-150KDa in the P-selectin lane, confirming that the antibody 
detects P-selectin.  A faint band (inside red circle) can be detected in the vWf lane between 100-
150KDa confirming P-selectin contamination of vWf.  B) Confirms there is no non-specific binding 





















Here we demonstrate that upon activation through either, PAR-1, GPVI or TP receptor 
pathways, washed platelets release PMV.  Initial data acquired using the Nanosight confirms an 
increase in particles between 100-1000nm in size after platelet activation compared to 
unstimulated controls, however, as this technology does not allow the detection of any surface 
markers it is impossible to tell whether these are microvesicles or exosomes.  Washed isolated 
platelets have been used to prevent contamination from leukocyte microvesicles as without 
markers these cannot be distinguished.  In combination with flow cytometry data showing an 
increase in the platelet specific surface marker, CD42b, following incubation of these PMV with 
monocytes, this suggests that PMV are indeed being generated. 
Data from the Nanosight suggests that TRAP is a weak agonist in terms of stimulating 
PMV production from washed isolated platelets.  Only a small and non-significant increase, in 
the number of PMV generated was observed, compared to the unstimulated control.  In this 
system stimulation with CRP-XL through the platelet GPVI pathway resulted in the largest 
increase in PMV and an increase in the size of the PMV generated.  A combination of CRP-XL and 
thromboxane mimetic (U46619) did not result in an increase in microvesicle production, 
suggesting that the maximum response was seen with CRP-XL alone.  The data from the current 
study is in contrast to a previous study carried out in whole blood and using flow cytometry to 
identify PMV generation where TRAP was found to be the most potent agonist for PMV 
generation (Chow et al., 2000).  However, this study was carried out at a high shear rate (10000s-
1).  It could be that a combination of platelet isolation and lower shear rate results in less PMV 
being produced upon PAR-1 stimulation. 
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Incubation of PMV with isolated monocytes demonstrated that monocyte-PMV 
aggregates are able to form.  With CRP-XL generated microvesicles forming the highest 
percentage of aggregates with monocytes.  This perhaps isn’t surprising as CRP-XL stimulation of 
washed isolated platelets leads to the highest number of microvesicles being generated.  
Previous studies have demonstrated that neutrophils and the monocytic cell line THP-1 cells are 
able to form aggregates with PMV in vitro, the main mechanism for this is thought to be through 
leukocyte PSGL-1 (Forlow et al., 2000; Jy et al., 1995; Nomura et al., 2001).  It is therefore not 
surprising that primary monocytes form aggregates with PMV as they also express high levels of 
PSGL-1. 
The low CD42b MFI observed for these aggregates is nowhere near the CD42b MFI 
observed for a resting platelet in whole blood observed in earlier experiments.  This is further 
evidence to support PMV binding to monocytes in whole blood rather than whole platelets.  The 
percentage ‘MPA’ observed for 30 minutes incubation of monocytes in PBSA is similar to our 
previous data from monocytes incubated for up to 60 minutes under the same shear conditions 
in unstimulated whole blood.  It is possible that these monocyte-PMV aggregates form in the 
circulation and survive the monocyte isolation process. 
Once we had determined that monocyte-PMV aggregates would form these were ready 
to be used in flow assays, however, we observed in early experiments that under low shear 
stress (0.1Pa) monocytes appeared to make transient interactions with vWf, (which we classified 
as rolling) but not with the BSA control.  A previous study has reported that CD170 (Siglec-5) 
expressed by monocytes, neutrophils and B-lymphocytes can interact with vWf under static 
conditions (Pegon et al., 2012).  Another study demonstrated that at room temperature, 
leukocyte PSGL-1 can transiently interact with recombinant vWf and that stable adhesion to vWf 
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can be achieved through β2 integrin (at a shear rate of 50S-1), (Pendu et al., 2006).  However, 
data from our lab suggests that under conditions of higher shear and at 37°C, leukocyte adhesion 
to vWf present on the surface of EC is not significantly increased compared to untreated controls 
(Kuckleburg et al., 2011). 
The vWf used throughout this study has been isolated from human plasma, it is well 
known that soluble P-selectin is also present in the plasma.  As previous data from our lab 
demonstrates that P-selectin can capture leukocytes, allowing them to roll, we decided to 
incubate the vWf coated slides with P-selectin blocking antibody (G1).  This significantly reduced 
monocyte interactions with vWF compared to vWf coated slides incubated with IgG.  This 
suggests that in this instance, the brief interactions detected in this assay were due to monocyte 
interaction with contaminating P-selectin rather than vWf itself.  Further confirmation of the P-
selectin contamination of vWf can be seen from a western blot, where P-selectin is indeed 
detected in the vWf sample. 
Monocyte-PMV aggregates were perfused across vWf coated slides, which had been 
further treated with P-selectin blocking antibody or (non-blocking) IgG control antibody.  The 
data shows no significant increase in monocyte-PMV aggregate capture by either IgG treated or 
anti-P-selectin treated vWf.  This suggests that vWf is unable to support monocyte-PMV 
adhesion in the absence of P-selectin.  However, further experiments need to be carried out to 
confirm this. 
Conclusions 
We have demonstrated that upon activation of washed platelets with an agonist PMV 
are generated.  The most potent agonist in terms of PMV generation was CRP-XL, this also lead 
to larger microvesicles being produced.  PMV were able to aggregate with monocytes, the 
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highest percentage of monocyte-PMV produced was observed after incubation of monocytes 
with CRP-XL microvesicles, these were positive for the CD42b receptor.  When monocyte-PMV 
aggregates (PMV generated from CRP-XL treatment) were perfused across vWf in the presence 
of P-selectin blocking antibody there was no significant increase in transient interactions 
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In this thesis we have demonstrated a role for platelets and platelet microvesicles (PMV) 
in the inflammatory response.  We have shown that in response to inflammatory stimuli (TNFα 
and TGFβ) platelet adhere to GEnC.  Our data also suggests that in response to treatment with 
different platelet agonists, which activate platelets through a variety of different routes, platelet 
microvesicles are generated, these, in turn adhere to leukocytes.  The data suggests that the 
only exception to this was activation of platelets with histones which appears to lead to 
monocytes binding to whole platelets.   
Innate immune cells formed aggregates with platelets (and potentially platelet 
microvesicles) more readily than cells of the acquired immune system, with monocytes 
preferentially forming heterotypic aggregates compared to neutrophils.  Interestingly, 
lymphocytes did not appear to form heterotypic aggregates.  The data also suggests that P-
selectin, which is known to be expressed by both platelets and PMV, is the ligand through which 
aggregates with leukocytes form.  PSGL-1, the ligand with the highest binding affinity for P-
selectin was found to be expressed by all leukocytes, except B-lymphocytes.  The highest levels 
of PSGL-1 expression were found to be expressed by monocytes, suggesting that this may be the 
ligand which P-selectin interacts with (although further work will need to be carried out to 
confirm this). 
Platelet recruitment to EC has been shown to be fundamental at an early stage of 
atherosclerosis disease progression.  Previous data has indicated that in response to activation 
(with TGFβ), HUVEC are able to capture platelets (Tull et al., 2006).  However, before our study 
no one had studied the effect of TGFβ signalling on glomerular endothelial cells and how this 
affects their ability to capture platelets.  Glomerular EC are specialised and line microvascular 
capillary beds, which have a specialised structure, so that a large volume of blood can be filtered 
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as it passes through the glomerulus (Miner, 2011; Passerini et al., 2004; Satchell, 2004; White, 
2012).  This makes GEnC particularly vulnerable to inflammatory disease and platelets may play a 
key role in early disease progression. 
Previous data acquired through the use of a co-culture model has indicated that cross-
talk occurs through secretory phenotype SMC and HUVEC (Tull et al., 2006).  In this instance, 
there is an increase in platelet adhesion to HUVEC in response to TGFβ signalling by SMC (Tull et 
al., 2006).  Cross-talk has been demonstrated to occur between podocytes and GEnC (Satchell, 
2004).  However, no one has yet studied the effect of podocytes on GEnC in the context of 
platelet adhesion.  As primary human GEnC are not readily available, we opted to use a cell line 
GEnC, which had been previously demonstrated to retain EC markers (Satchell et al., 2006).  
However, on completion of the first part of our study, where we demonstrated that GEnC were 
able to adhere to platelets in response to inflammation; new cells were required for 
continuation of the project.  The new batch of cell line GEnC failed to retain EC markers, 
including vWf (a crucial part of the mechanism for platelet capture by EC in our model), this 
meant that the project could not be continued and co-culture studies were not carried out. 
Both platelet microvesicles and leukocyte-platelet aggregates have been shown to be 
increased in inflammatory diseases, of particular interest to us is the increase observed in an 
atherosclerosis disease setting (Burton et al., 2013; Joseph E Italiano Jr, Mairuhu Albert T.A., 
2010; Shantsila et al., 2011).  Previous studies have demonstrated that NPA and MPA (in 
particular) are increased in patients with atherosclerosis or in response to treatment with a 
platelet agonist such as thrombin, TRAP or ADP (Jensen et al., 2001; Klinkhardt et al., 2003; 
Rinder et al., 1991).  However, to our knowledge a thorough screen of so many different platelet 
Chapter-9  General Discussion 
283 
 
agonists and their effect on leukocyte-platelet aggregate formation has not been carried out 
before this study. 
Several different platelet markers have been used to study MPA/NPA including CD61, 
CD62P, CD42b, and CD42a (Keating et al., 2006; Basavaraj et al., 2012; Harding et al., 2004; 
Jensen et al., 2001).  The method for identification of leukocytes from flow cytometry data also 
varies between studies, with some studies using more stringent methods than others (Rinder et 
al., 1991; Shantsila et al., 2011).  The current study adopts a comparatively stringent method for 
identifying NPA and MPA, based on leukocyte markers CD14, CD16 and the platelet marker 
CD42b. Another important difference between studies is the use of different anticoagulants for 
collection of blood samples.  The current study uses CPDA, which although chelating calcium, is 
not efficient, and removes enough to inhibit activation of the coagulation cascade, but leaves 
sufficient in plasma for the function of adhesion receptors.  EDTA is a well known calcium 
chelator. However, it strips all calcium and magnesium for the plasma inhibiting the function of 
adhesion receptors.  This reduces platelet activation and therefore the number of leukocyte-
platelet aggregates (Basavaraj et al., 2012).  Whereas, heparin has been shown to significantly 
increase the numbers of leukocyte-platelet aggregates which form compared to CPDA (Basavaraj 
et al., 2012). 
Although NPA and MPA formation has been well documented, very few studies have 
determined the number of platelets adhering to these leukocytes.  Studies which have indicated 
platelet adhesion to be occurring to monocytes or neutrophils have reported high numbers of 
platelets adhering to these leukocytes (Mickelson et al., 1996; Xiao and Théroux, 2004).  
However, these assays have been carried out under static conditions. In our opinion this 
promotes the interaction for platelets and leukocytes as an artefact of the methodology and  
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gives false indications of the incidence of leukocyte-platelet aggregates, which occur (Mickelson 
et al., 1996; Xiao and Théroux, 2004).  Data from the current study suggests that in the main 
adhesion of platelet derived microvesicles to monocytes and neutrophils occurs upon platelet 
activation, rather than binding of whole platelets. 
Monocytes are known to be a heterogeneous population, which consists of three subsets 
(Shantsila et al., 2011).  Our study also aimed to compare ability of monocyte subsets to form 
aggregates with platelet microvesicles.  Here, we studied two monocyte subsets CD14+CD16- 
and CD14+CD16+.  However, no differences between monocyte subsets adhering to platelet 
microvesicles were detected in the current study.  The only exception to this generalisation was 
the adhesion of whole platelets to the CD14+CD16+ monocyte subset.  This phenomenon 
requires further investigation, as it is unclear why this should be. 
Previous data has indicated that leukocyte-platelet aggregates in whole blood are 
significantly reduced in the presence of P-selectin blocking antibody (Théorêt et al., 2001).  PMV 
are well known to express platelet P-selectin on their surface and are therefore also capable of 
interacting with leukocytes through this mechanism (Joseph E Italiano Jr, Mairuhu Albert T.A., 
2010).  Data from the current study suggests that PMV or platelet adhesion to leukocytes is 
reduced in the presence of P-selectin blocking antibody.  To our knowledge no one to date has 
reported the formation of monocyte-PMV aggregate formation in whole blood in response to 
platelet agonists, or that this interaction is reduced by P-selectin blocking antibody.  Other 
groups have demonstrated, that the presence of PMV is able to increase interactions between 
HL-60, which do not express L-selectin and that P-selectin or PSGL-1 blocking antibody, reduces 
this interaction (Forlow et al., 2000).  This suggests that the interaction between PMV P-selectin 
and leukocyte PSGL-1 is important. 
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Our study indicates that PSGL-1 is expressed on monocytes and neutrophils.  To our 
knowledge this is the only study to date which measures PSGL-1 expression on leukocytes in 
whole blood in response to treatment with known platelet activators TRAP and CRP-XL the data 
reveals that PSGL-1 expression is significantly reduced on both neutrophils and the CD14+CD16- 
monocyte subset, possibly due to the activation of these leukocytes and subsequent shedding of 
the receptor.  Further studies need to be carried out to confirm this. 
The formation of monocyte-PMV aggregates could have a major role in cross-talk during 
inflammatory disease progression.  Atherosclerosis has been shown to be accompanied by high 
levels of platelet surface and soluble P-selectin, TF and high monocyte expression of CD40L and 
MAC-1 (Furman et al., 1998; Shantsila and Lip, 2009).  Monocyte-platelet aggregate formation 
through platelet P-selectin, interacting with monocyte PSGL-1, leads to downstream signalling, 
which results in increased expression of monocyte MAC-1, an inflammatory marker (Evangelista 
et al., 1999).  Importantly, it also results in increased expression of TF by monocytes, this in turn 
triggers the coagulation cascade, which results in thrombin generation and further platelet 
activation (Christersson et al., 2008; Coughlin, 2000).  This demonstrates a role for cross-talk 
between these heterotypic aggregates.  Evidence also suggests a role for signalling through 
microvesicle generation.  TF has been shown to be transferred from activated monocytes to 
platelets (Del Conde et al., 2005) or from activated platelets to monocytes through microvesicle 
generation (Scholz et al., 2002).  This occurs through the parent cell generating microvesicles, 
which contain TF and subsequent adhesion of these vesicles to the recipient cell.  The 
mechanism for delivery of the microvesicle TF cargo is still unknown.  It may be either through 
microvesicle fusion with the recipient cell plasma membrane, or through receptor mediated 
internalisation. 
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The data in this thesis, which suggests PMV adhere to monocytes and neutrophils is 
important.  Although PMV are known to be elevated in inflammatory disease it is not yet known 
how long PMV are stable for, or the mechanism for their clearance.  Rand et al, (2006) 
demonstrated that microvesicles injected into rabbits could not be recovered from the plasma, 
after 10 minutes.  The data from this study implies that the excess microvesicles are cleared 
through an, as yet, unknown mechanism.  The data from the current study suggests that at least 
one mechanism, which could aid in PMV clearance, is through adhesion of PMV to leukocytes 
such as monocytes and neutrophils. 
Our data, and indeed data from others, demonstrates preferential binding of platelets 
(or platelet microvesicles) to monocytes (Jensen et al., 2001; Michelson et al., 2001; Rinder et al., 
1991).  Previous studies in our lab have revealed that activated, adherent, platelets aid in 
recruitment of monocytes to EC (Kuckleburg et al., 2011).  We hypothesised that monocyte-
platelet microvesicle aggregates would have an increased chance of recruitment to EC under 
inflammatory conditions.  As the presence of the platelet receptor CD42b, would allow the 
monocyte-PMV aggregate to adhere to vwf, as well as traditional routes of monocyte capture 
through interactions with EC expressed selectins.  To our knowledge no one has yet studied this.  
However, data from early experiments indicate that at low shear stress monocyte-PMV 
recruitment to vWf is not significantly enhanced.  It is worth noting however, that the responses 
were very variable and only a few experiments were conducted.  A more stringent study of this 
aspect of monocyte-microvesicle aggregates should be conducted to clarify this point. 
In summary, this study suggests that monocyte-PMV aggregates form in whole blood in 
response to platelet activation.  It also suggests that these aggregates do not aid in monocyte 
recruitment to the vessel wall under conditions of low shear.  However, the importance of these 
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monocyte-PMV aggregates should not be under estimated.  The potential for signalling to occur 
between these two cell types and the subsequent downstream effects on inflammatory and 
thrombotic processes could still have a major role in disease progression. 
Further experiments 
The work outlined in this thesis reveals areas that need further investigation.  These are 
listed below; 
 Using CD42a as a marker do monocytes and neutrophils still appear to bind PMV? 
As CD42a is a non sheddable marker this will confirm whether monocytes and neutrophils are 
indeed binding PMV, as this thesis suggests. 
 Is the levels of PSGL-1 found on monocytes, neutrophils and lymphocytes the 
reason why more monocytes form heterotypic aggregates than other leukocytes? 
This thesis demonstrates that monocytes have the highest levels of PSGL-1 and form the most 
aggregates with platelets (or even PMV).  However, further work needs to be done to confirm 
that the levels of PSGL-1 expressed are indeed the reason why more of these aggregates form. 
 How long are MPA, NPA and LPA stable in vivo? 
It is important to clarify that these aggregates are able to form in vivo and that they are stable. It 
is also important to find how long they are stable for.  There presence in vivo may also be an 
indication of how PMV are cleared from the blood plasma. 
 Which receptors are responsible for the stability of MPA and NPA in vitro and in 
vivo? 
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As P-selectin and PSGL-1 are known to only make brief interactions, it is important to determine 
which receptors are able to aid in the stability of heterotypic aggregates. 
 Can monocytes-PMV aggregates be recruited to recombinant vWf at high shear 
stress? 
As platelets are known to aid in leukocyte recruitment and this phenomenon is important at high 
arterial shear stresses, it is important to determine if monocyte-PMV aggregates can be 
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